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Abstract 
Resistance to anti-estrogens (i.e. tamoxifen and fulvestrant) is a major clinical challenge in the treatment 
of estrogen receptor (ER) positive breast cancers. To improve treatment and survival of breast cancer 
patients, the search for new potential targets and biomarkers is crucial. To identify and explore the 
molecular mechanisms driving anti-estrogen resistant cell growth, we have utilized a large kinase 
inhibitor library comprising 195 kinase inhibitors on a unique panel of two fulvestrant and two 
tamoxifen resistant T47D breast cancer cell lines, as well as their parental ER positive anti-estrogen 
responsive T47D cell lines.  
In total, 15 kinase inhibitors were identified to preferentially inhibit growth of fulvestrant resistant T47D 
cell lines compared to growth of parental T47D cell. Moreover, three kinase inhibitors were found to 
preferentially inhibit growth of tamoxifen resistant T47D cell lines, compared to growth of their parental 
cell line. None of the identified inhibitors targeted the human epidermal growth factor receptor (HER) 
family or their downstream signaling molecules, which previously have been shown to be important for 
growth of MCF-7 derived anti-estrogen resistant breast cancer cell lines. Breast cancer is a 
heterogeneous disease and the T47D based model systems could thereby elucidate novel mechanisms 
for anti-estrogen resistant cell growth.  
In the screens, treatment with the highly selective Aurora B inhibitor barasertib was found to 
preferentially inhibit growth of fulvestrant resistant cell lines compared to growth of their parental T47D 
cell line. Subsequently, it was also found that the expression of the activated form of Aurora B is higher 
in the fulvestrant resistant cells compared to parental T47D cells and that treatment with barasertib 
selectively inhibits phosphorylation of the Aurora B kinase. Additional investigations revealed that the 
growth inhibitory effect of barasertib was accomplished through induction of mitotic errors and 
subsequent cell death. These experiments indicate that functional Aurora B kinase may be a driving 
factor for continuous growth of fulvestrant resistant T47D cell lines, and suggests Aurora B inhibition, 
e.g. with the highly selective kinase inhibitor barasertib, as a candidate treatment for breast cancer 
patients with tumors expressing the phosphorylated form of the Aurora B kinase.  
In the screens, treatment with the Src Family Kinase (SFK) inhibitor dasatinib was found to preferentially 
inhibit growth of both fulvestrant and tamoxifen resistant cell lines, compared to growth of their 
 
 
parental cells. Additional experiments showed that treatment with other inhibitors targeting this family 
selectively inhibited growth of resistant cells, and that the protein expression of phosphorylated c-Src, 
which is a SFK, was increased in both fulvestrant and tamoxifen resistant T47D cell lines. This suggests 
that c-Src could be an important kinase for growth of anti-estrogen resistant cells and a treatment target 
in breast cancer patients expressing the active c-Src kinase.  
In conclusion, Aurora B was identified as a novel kinase important for growth of fulvestrant resistant 
T47D cell lines, while c-Src was suggested as a kinase involved in both fulvestrant and tamoxifen 
resistant T47D cell growth.   
 
 
 
Resumé 
I behandlingen af østrogen receptor (ER)-positiv brystkræft er resistens mod antiøstrogenerne 
tamoxifen og fulvestrant en stor klinisk udfordring. Påvisning af nye biomarkører og 
behandlingsmuligheder er derfor essentielt for at forbedre behandlingen og overlevelsesraten for disse 
brystkræftpatienter. For at identificere og undersøge de molekylære mekanismer, som styrer væksten af 
antiøstrogen-resistente celler, har vi udført to store screeningsforsøg. I forsøgene har vi behandlet to 
fulvestrant- og to tamoxifen-resistente T47D brystkræftcellelinjer, samt deres oprindelige (parentale) ER 
positive antiøstrogen-følsomme cellelinjer, med 195 unikke kinasehæmmere, der rammer kendte 
vækstsignaleringsveje i kræftceller.  
I alt identificerede vi 15 kinasehæmmere, som præferentielt inhiberede væksten af T47D cellelinjer 
sammenlignet med væksthæmningen af de parentale T47D celler. Derudover identificerede vi tre 
hæmmere, der præferentielt kunne inhibere væksten af de tamoxifen-resistente T47D cellelinjer 
sammenlignet med væksten af deres parentale cellelinje. Ingen af de identificerede hæmmere var rettet 
mod aktiviteten af human epidermal vækstfaktor receptor (HER) familien eller dens intracellulære 
signaleringsmolekyler, som tidligere er blevet påvist at have en central betydning for væksten af 
antiøstrogen-resistente MCF-7 cellelinjer. Brystkræft er en heterogen sygdom, og modelsystemerne 
med de antiøstrogen-resistente T47D celler er derfor meget værdifulde til at udvide kendskabet til 
mekanismerne bag antiøstrogen-resistent cellevækst.  
I screeningsforsøgene blev Aurora B kinasehæmmeren barasertib identificeret til præferentielt at 
hæmme væksten af de fulvestrant-resistente cellelinjer sammenlignet med væksthæmningen af deres 
parentale T47D celler. Efterfølgende eksperimenter viste, at ekspressionen af den aktiverede form af 
Aurora B var højere i de fulvestrant-resistente cellelinjer sammenlignet med niveauet i de parentale 
celler, og at behandling med barasertib præferentielt kunne hæmme aktiviteten af Aurora B kinasen. 
Yderligere eksperimenter viste, at den væksthæmmende effekt af barasertib blev opnået gennem 
induktion af mitotiske fejl og efterfølgende celledød. Disse resultater indikerer, at funktionel Aurora B 
spiller en rolle for væksten af fulvestrant-resistente T47D celler. Aurora B inhibering, eventuelt med den 
meget selektive kinasehæmmer barasertib, kunne derfor være en behandlingsmulighed for patienter, 
som udtrykker den aktiverede form af Aurora B i deres tumorer. I screeningsforsøgene fandt vi at 
behandling med dasatinib, der hæmmer aktiviteten af kinaserne i Src familien, præferentielt hæmmede 
 
 
væksten af både de fulvestrant- og de tamoxifen-resistente cellelinjer, sammenlignet med 
væksthæmningen af deres parentale T47D celler. Yderligere eksperimenter viste at behandling med 
andre hæmmere, som inhiberede aktiviteten af denne kinasefamilie, også selektivt inhiberede væksten 
af de resistente cellelinjer. Derudover var proteinniveauet af den aktiverede form af c-Src, som er et 
medlem af Src familien, forøget i både de fulvestrant- og tamoxifen-resistente cellelinjer. Disse forsøg 
peger på, at c-Src kan spille en vigtig rolle for væksten af antiøstrogen-resistente celler, og at hæmning 
af kinaseaktiviteten kunne være en behandlingsmulighed for brystkræftpatienter, der udtrykker aktivt c-
Src i deres tumorer.  
Samlet set blev Aurora B identificeret som en ny kinase, hvis aktivitet er væsentlig for vækst af 
fulvestrant-resistente T47D cellelinjer, mens c-Src blev foreslået som en mulig kinase involveret i vækst 
af både fulvestrant- og tamoxifen-resistente T47D cellelinjer. 
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1 Introduction 
The following paragraphs will give a short introduction to breast cancer including epidemiology, 
etiology, and the anatomy of the human breast. This is followed by a description of estrogen dependent 
breast cancer, signal transduction, cell cycle control and apoptosis in normal as well as cancer cells. 
Endocrine treatment and resistance mechanisms will also be elucidated, and finally the cell line model 
systems, used in this study to investigate resistance towards endocrine treatment, will be presented.  
1.1 Breast Cancer in General 
1.1.1 Breast Cancer Epidemiology  
Breast cancer is the most frequent type of cancer and the leading cause of cancer death among females 
(Jemal et al, 2011). In 2011, the Danish incidence was 25.6% resulting in approximately 4600 new 
diagnosed breast cancer cases. Although rare, male breast cancer also occurs, but account for less than 
1% of all breast cancers (SSI, 2012). Breast cancer is more frequently observed in industrialized Western 
countries, but Worldwide almost 460.000 people died of the disease in 2008 (Jemal et al, 2011).  
1.1.2 Breast Cancer Etiology 
Cancer is, in essence, a genetic disease, caused by multiple series of mutations in oncogenes, tumor-
suppressor genes and stability genes (Vogelstein and Kinzler, 2004). Several factors can affect the risk of 
obtaining these alterations, but approximately 5-10% of all breast carcinomas are caused by germline 
mutations, mainly in the breast cancer gene 1 and 2 (BRCA1 and BRCA2). The remaining 90-95% is 
considered sporadic cancers with acquired somatic mutations (Lacroix and Leclercq, 2005). Several life 
style and environmental factors can affect the risk of developing breast cancer; these include alcohol 
consumption, obesity after menopause and physical inactivity (Jemal et al, 2011). The predominant risk 
factor in sporadic breast cancers is, however, hormonal, mainly caused by changes in estrogen levels 
(Brekelmans, 2003). In breast cancer, estrogens act as tumor promotors, since they stimulate 
proliferation of the breast epithelium and have an anti-apoptotic effect. Moreover, the oxidative 
metabolites generated by estrogen metabolism have been shown to induce genotoxic stress (Yager and 
Davidson, 2006). Prolonged endogenous exposure to estrogens caused by early menarche, late 
menopause, late age at first full term pregnancy or nulliparity are all reported to raise the risk of cancer, 
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just as exogenous ovarian hormones, like oral contraceptives or hormone replacement therapy, 
increased the risk (Anderson and Clarke, 2004;Rajkumar et al, 2001). Estrogen dependent breast cancer 
was described as early as in 1896 where it was published that surgical removal of the ovaries decreased 
tumor growth in women with metastatic breast cancer (Beatson, 1896). 
1.1.3 Anatomy of the Mammary Gland 
Mammary gland development is initiated during embryogenesis, thus males and females have the same 
rudimentary mammary gland (Ali and Coombes, 2002). The mammary gland remains quiescent in 
females until puberty where maturation is initiated; however, the gland is not fully developed until first 
full pregnancy (Sternlicht, 2006). The mammary gland is a highly specialized organ comprised of a ductal 
structure lined with a layer of epithelial cells (Figure 1). It contains between 15-20 lobes, each branched 
off in smaller milk producing glands called lobules (Ali and Coombes, 2002). The end bud of the lobules 
matures after menarche to alveoli as a result of increased levels of ovarian and pituitary hormones 
(Clarke et al, 2004;Anderson and Clarke, 2004). The lobes are connected to the nipple by the ducts and 
the entire structure is surrounded by an outer layer of basal myoepithelial cells with contractile 
properties. The gland is embedded in fibroblast stroma, and surrounded by adipose tissue (Ali and 
Coombes, 2002).  
 
Figure 1 - Anatomy and Structure of the Female Breast. Overall structure of the female breast: from the nipple long 
ducts terminate in networks of alveoli called lobes. The ducts and alveoli penetrate the stroma and adipose tissue. The 
illustration includes a magnification of one alveolus visualizing the different cell layers. Shown is also the rib, the muscle 
underlying the breast followed by loose connective tissue. Suspensory ligaments and the skin are indicated as well. 
Modified from (Ali and Coombes, 2002;Sternlicht, 2006).  
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1.2 Estrogen Dependent Breast Cancer 
Breast cancer is a clinically heterogeneous disease, where histologically similar tumors may have 
different prognosis and therapy response. The variation in clinical behavior is due to differences in 
genetic background and in protein expression patterns. Based on gene expression patterns breast 
cancer has been divided in several distinguished subtypes (Sorlie, 2004). Approximately 80% of all 
primary breast cancers are classified as estrogen receptor α (ER) positive, defined by ≥ 1% tumor cells 
with detectable nuclear ER staining in the invasive component of the tumor (DBCG, 2013b). These 
tumors are said to be estrogen dependent, meaning that the cells are dependent on estrogens for 
growth and survival (Ali and Coombes, 2002). The main focus of this thesis will be on ER positive breast 
cancer. However, many breast tumors also exhibit increased expression of the human epidermal growth 
factor receptor 2 (HER2) (Slamon et al, 1987). HER2 positive breast tumors are defined by 
overexpression of HER2 protein and/or HER2 gene amplification (DBCG, 2013b). 10-15% of all breast 
cancers belong to the HER2-enriched subtype, which are HER2 positive and often ER negative (Eroles et 
al, 2012). The prognosis of HER2 positive breast cancer patients is poorer and the HER2 positive disease 
is more aggressive compared to the ER positive (Sorlie et al, 2003).  
Normal breast tissue displays up to 7% ER positive cells, of which 87% are luminal epithelial cells 
(Petersen et al, 1987). The ER positive cells are non-proliferating, but located side by side to estrogen-
stimulated proliferating cells, which are stimulated via paracrine mechanisms during the estrous cycle 
and pubertal growth (Russo et al, 1999). To date it is unknown how the quiescent ER positive cells 
transform into tumorigenic proliferative ER positive cells. 
Breast cancer most frequently arises from the ducts of the breast tissue, and upon carcinogenesis the 
normal structure of the tissue is disrupted (Anderson and Clarke, 2004;Ali and Coombes, 2002). Figure 2 
depicts the histology of normal breast tissue (A) and an ER positive breast tumor (B).  
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Figure 2 - Histological Overview of Normal and Cancerous Breast Tissue. A. Normal breast tissue displays an organized 
structure of epithelial cells, lining the ducts of the lumen. Estrogen receptor α (ER) positive cells stain brown. B. Breast 
cancer tissue displays a disrupted structure and ER is more frequently expressed. Modified from (Ali and Coombes, 
2002).  
1.2.1 Estrogens and Androgens 
Estrogens are steroid hormones synthesized from cholesterol precursors primarily in the ovaries, but 
also in adipose tissue, bone, vascular endothelium and some sites of the brain (Simpson et al, 1999). The 
most abundant form of estrogen is 17β-estradiol, which can be metabolized into estriol and estrone 
(Heldring et al, 2007). Estrogen synthesis is under regulation of the hypothalamic pituitary-gonadal 
(HPG)-axis, where a negative feedback loop causes the level of estrogen to cycle. Upon menopause, 
synthesis of estrogens by the ovaries ceases and eventually terminates (Boron and Boulpaep, 2009). 
Synthesis of estrogens in tissues other than the ovaries depends on the conversion of androgen 
precursors by the enzyme aromatase (Simpson et al, 1999). The aromatase mediated synthesis of 
estrogens continues beyond menopause. Thus, low levels of estrogens are still produced, and the 
amount is sufficient to stimulate growth of an ER positive breast tumor. Besides the involvement of 
estrogens in the menstrual cycle, estrogens also have beneficial effects on bone maintenance and the 
cardiovascular system (Simpson et al, 1999;Heldring et al, 2007). 
1.2.2 The Estrogen Receptor 
Circulating steroid hormones enters the cells by passive diffusion and bind to their receptors, thereby 
affecting cell behavior (Boron and Boulpaep, 2009). The main estrogen action seems to be mediated 
through the two receptors; the classic receptor called ERα and the later identified ERβ (Ali and Coombes, 
2002). The two receptor subtypes both belong to the nuclear receptor (NR) family (Heldring et al, 2007), 
and are very similar in structure and functional organization. The receptors are, however, encoded by 
unique genes and exhibit different tissue distribution of the breast. The ERα is only present in the nuclei 
of epithelial cells lining the ducts and lobules, while the ERβ is present in the nuclei of both epithelial 
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and myoepithelial cells (Speirs et al, 2002). ERα appears to be the predominant regulator of estrogen-
regulated genes in breast cancer, while ERβ only seems to exhibit insignificant impact (Palmieri et al, 
2002;Fuqua et al, 2003). Therefore, the focus in this study will be on ERα, which henceforth will be 
denoted as ER. 
ER consists of six functional domains designated A-F (Kumar and Chambon, 1988), see Figure 3. The A/B 
domain in the N-terminus modulates transcription of estrogen regulated genes through the ligand 
independent transactivation domain, activation function 1 (AF-1) (Tzukerman et al, 1994). The C domain 
recognizes and binds to the estrogen-response element (ERE) on the DNA and is therefore called the 
DNA binding domain (DBD). The D domain is a hinge region between C and E, and this region is believed 
to be important for binding of co-regulative proteins (Kumar et al, 1987;Barone et al, 2010). The ligand 
binding domain (LBD) as well as the ligand-dependent transactivation domain, activation function 2 (AF-
2), is located in the E domain (Tzukerman et al, 1994;Kumar et al, 1987). The F domain is situated in the 
C-terminus, and has a specific modulatory function. This affects the agonist/antagonist effectiveness of 
anti-estrogens and the transcriptional activity of the ligand bound ER in the cells (Montano et al, 1995). 
 
Figure 3 - The Estrogen Receptor α Protein. From the N-terminal is the A/B domain containing the ligand independent 
activation function 1 (AF-1) domain. The A/B domain is followed by the C domain containing the DNA binding domain 
(DBD). Domain D functions as a flexible hinge. Domain E contains both the ligand binding domain (LBD) as well as the 
ligand dependent transactivation domain AF-2. Lastly, at the C-terminal is the F domain. Based on (Kumar and Chambon, 
1988;Barone et al, 2010). 
1.3 Signal Transduction in Breast Cancer 
Normal cell utilize signal transduction in varies essential cellular functions; cell differentiation, 
homeostasis, cell survival, controlled proliferation and cell death. Carcinogenic cells alter and exploit 
these signal transduction pathways in order to achieve malignant growth (Hanahan and Weinberg, 
2000). The following paragraphs give a general insight to signal transduction in breast cancer. The 
pathways are initiated by ligand binding and can be regulated through phosphorylation or de-
phosphorylation, of scaffolding as well as adaptor molecules.  
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1.3.1 Estrogen Receptor Signaling 
The majority of breast cancers are dependent on activation of the ER, and subsequent transcription of  
target genes, which are important for growth, proliferation and survival (Musgrove and Sutherland, 
2009).  
Regulation of gene expression as a consequence of ER activation is obtained through various genomic 
and non-genomic actions; see Figure 4. Classical ER signaling is activated by ligand binding and 
subsequent conformational changes and dimerization of ER (Ali and Coombes, 2002). The ER dimer, in 
complex with various co-regulators, directly binds to specific EREs on the DNA to either activate or 
repress expression of ER regulated target genes (Figure 4A). A second genomic pathway is termed the 
ERE-independent or the non-classical, since the ER does not bind directly to the DNA (Musgrove and 
Sutherland, 2009;Barone et al, 2010). In this pathway the ligand activated ER is dependent on 
interaction with other transcription factors, particularly members of the family of activating protein 1 
(AP-1), specificity protein 1 (Sp1), and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) (Figure 4B) (Barone et al, 2010). The third genomic pathway does not require estrogen binding, 
and is therefore termed ligand-independent. Activation of ER is a result of phosphorylation of AF-1, DBD, 
and the hinge domains caused by second messengers downstream of activated receptor tyrosine 
kinases (RTKs) (described in paragraph 1.3.2 and Figure 4C) (Barone et al, 2010;Musgrove and 
Sutherland, 2009). The last known type of ER signaling pathway is nongenomic. Here ER is activated 
upon binding of the ligand to a cytoplasmic or membrane-associated ER receptor. Ligand binding 
induces assembly of functional protein complexes, consisting of e.g. the kinase c-Src, which 
subsequently activates intracellular signaling cascades. This in turn activates various transcription 
factors which can affect the gene expression of proteins implicated in growth, proliferation and survival 
(Figure 4D) (Musgrove and Sutherland, 2009). Many factors have been found to regulate ER mediated 
transcription both in the presence and absence of estrogen, e.g. cyclin D which activates ER mediated 
transcription in the absence of estrogen and enhances transcription in its presence (Zwijsen et al, 1997). 
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Figure 4 - Illustration of Estrogen Receptor Signaling. A. Classical activation of the estrogen receptor (ER) by ligand binding 
and subsequent dimerization and binding to the estrogen response elements (EREs). B. The non-classical pathway: ER 
binds and regulates gene transcription of ER regulated genes via various transcription factors (TFs). C. The ligand-
independent pathway: ER is activated by phosphorylation, caused by protein-kinase-cascades downstream of the 
activated receptor tyrosine kinases (RTKs). D. The nongenomic pathway is activated upon binding of the ligand to a 
cytoplasmic or membrane-associated ER receptor. This initiates intracellular signaling cascades activating various TFs 
capable of affecting gene expression. Based on (Bjornstrom and Sjoberg, 2005). 
1.3.2 Receptor Tyrosine Kinase Signaling 
Estrogen target genes can be expressed in the absence of estrogen through the activation of second 
messengers downstream of the RTKs (Figure 4C and D). The RTKs are one of the most important families 
mediating transmembrane signaling and are essential in the regulation of numerous physiological 
activities. RTKs include the HER family, vascular endothelial growth factor receptor (VEGFR), fibroblast 
growth factor receptor (FGFR), and the platelet-derived growth factor receptor (PDGFR) (Schlessinger, 
2000). Especially the HER family, comprising HER1-4, is of interest in connection with breast cancer, 
since its members are implicated in the development and progression of the disease (Baselga and Swain, 
2009). Crosstalk between ER and RTK are of great importance in the regulation of ER signaling, but RTK 
activation and subsequent intracellular signaling also affect a range of other cellular processes, as can be 
seen for the HER receptors in Figure 5. 
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1.3.2.1 Human Epidermal Growth Factor Receptor 
The HER family consists of four members: epidermal growth factor receptor (EGFR) (also termed HER1 
or ErbB1), HER2 (ErbB2 or Neu), HER3 (ErbB3), and HER4 (ErbB4) (Graus-Porta et al, 1997). Each of the 
receptors consists of an extracellular ligand binding domain, an α-helical transmembrane segment and 
an intracellular protein tyrosine kinase domain (Baselga and Swain, 2009). EGFR, HER3 and HER4 have 
several ligands referred to as the EGF-related peptide growth factors (Olayioye et al, 2000). HER2 does 
not bind a specific ligand, but serves as a co-receptor and dimerization partner, and is indirectly 
activated in a ligand-dependent manner, when it dimerizes with the other activated receptors of the 
HER family (Zahnow, 2006). Monomers of EGFR, HER3 and HER4 are inactive, but ligand binding induces 
a conformational rearrangement allowing for receptor dimerization and subsequent initiation of 
intrinsic tyrosine kinase activity (Baselga and Swain, 2009;Ferguson et al, 2003). HER3 only forms 
heterodimers, since it has an inactive kinase domain and therefore must associate with another HER 
receptor to initiate intracellular signaling (Berger et al, 2004).  
Intrinsic tyrosine kinase activation triggers auto-phosphorylation of specific tyrosine residues within the 
cytoplasmic domain. The phosphorylated residues serve as scaffolds; mediating interaction of 
cytoplasmic proteins involved in subsequent intracellular signaling cascades (Olayioye et al, 2000). Two 
major pathways are activated upon HER signaling, namely the mitogen activated protein (MAP) kinase 
pathway and the phosphoinositide 3-kinase (PI3K)/Akt pathway (Olayioye et al, 2000;Baselga and Swain, 
2009) which are described below and shown in Figure 5. 
The HER receptors exist as homo- or heterodimeric complexes, and it is the combination and thereby 
the pattern of the C-tail phosphorylation’s which determines the signaling properties and subsequent 
effects on cell survival, proliferation, and migration (Graus-Porta et al, 1997;Olayioye et al, 2000). HER2 
is the preferred heterodimerization partner and it favors interaction with HER3 (Tzahar et al, 1996). 
Homodimers of HER2 are also observed, especially in cancerous cells where they form spontaneously if 
HER2 is overexpressed. This leads to excessive HER2-mediated signaling, which drives oncogenic cell 
survival and proliferation (Baselga and Swain, 2009). It has been shown that expression of EGFR, HER2 
and HER3 in breast tumors is associated with poor prognosis, while HER4 expression is linked to better 
survival (Witton et al, 2003). 
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Figure 5 - Signaling Downstream of the Human Epidermal Growth Factor Receptors (HERs). The mitogen activated 
protein (MAP) kinase pathway signals through the kinases rat sarcoma (Ras), rapidly accelerated fibrosarcoma (Raf), 
mitogen activated protein kinase (MEK) and the extracellular signal regulated kinase (ERK) and stimulates proliferation, 
cell cycle control and angiogenesis. The phosphoinositide 3-kinase (PI3K)-Akt pathway stimulates cell cycle control, 
survival and anti-apoptosis through PI3K and Akt and their downstream transcription factors, e.g. the protein complex 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). c-Src affects the phosphorylation of HER dimers 
and the activation of PI3K and phosphatase and tensin homolog (PTEN). Based on (Baselga and Swain, 2009;Guarino, 
2010).  
1.3.2.2 Mitogen Activated Protein Kinase Pathway 
The MAP kinase pathway may be initiated by phosphorylation of tyrosine residues at the C terminal tail 
of HER dimers or other RTKs. However, the pathway can also be activated upon ligand binding to plasma 
membrane localized ER as described for the nongenomic pathway (Figure 4D) (Marino et al, 2006). The 
phosphotyrosine on HER serves as docking site for c-Src, which further phosphorylates the C terminal 
tail creating more Src homology 2 (SH2)-binding sites, where the SH2 domain containing protein (Shc) 
can bind. The adaptor protein growth factor receptor binding protein 2 (GRB2) subsequently binds to 
Shc and the complex can then recruit the guanine nucleotide exchange factor son of sevenless (SOS). 
SOS activates the small G-protein Rat sarcoma (Ras) to exchange guanosine diphosphate (GDP) for 
guanosine triphosphate (GTP). Ras bound to GTP can activate Rapidly accelerated fibrosarcoma (Raf), a 
MAP kinase kinase kinase (MAPKKK), by phosphorylation which in turn phosphorylates and thereby 
activates the mitogen activated protein kinase 1/2 (MEK 1/2, henceforth MEK), which is a MAPKK 
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(Zahnow, 2006;Schlessinger, 2000). Activated MEK next phosphorylates the MAPK extracellular signal 
protein kinase 1/2 (ERK 1/2, henceforth ERK), which may translocate to the nucleus and implicate 
transcription of genes driving cellular migration, differentiation and angiogenesis. Activation of the MAP 
kinase pathway also causes expression of the transcription factor c-Myc, thus increasing the expression 
of cyclin D which in turn promote progression through the cell cycle and thereby proliferation (Alberts et 
al, 2008;Baselga and Swain, 2009).   
1.3.2.3 Phosphoinositol 3 Kinase/Akt Pathway  
Activation of the HER receptors can also entail binding and subsequent activation of PI3K through the 
SH2 domain in its regulatory 85 kDa subunit (p85) (Zahnow, 2006). PI3K can be further activated by c-Src 
through phosphorylation of the p85-subunit (Cuevas et al, 2001). Following activation, the catalytic 110 
kDa subunit (p110) mediates the conversion of the membrane lipid phosphatidylinositol 3,4-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3), which functions as a secondary 
messenger. PIP3 recruits the 3-phosphoinositide-dependent kinase 1 (PDK1), which is involved in the 
phosphorylation of Akt (also termed protein kinase B (PKB)) (Zahnow, 2006). The active Akt 
subsequently phosphorylates several target proteins, such as Glycogen synthase kinase 3 beta (GSK3β), 
NFκB, and p27, which are involved in the regulation of cell proliferation and survival (Kane et al, 
1999;Baselga and Swain, 2009). Akt may also act on anti-apoptotic molecules such as the B-cell 
lymphoma 2 (Bcl-2) proteins, which inhibits cell induced apoptosis (Datta et al, 1997). Decreased 
expression of the tumor suppressor phosphatase and tensin homolog (PTEN) indirectly stimulates PI3K 
activity, since it dephosphorylates PIP3 and thus prevents the activation of Akt (Brugge et al, 2007). The 
PI3K/Akt pathway has also been found to be activated through plasma membrane localized ER in the 
nongenomic pathway (Marino et al, 2006). 
1.3.2.4 c-Src 
c-Src is a membrane-associated non-receptor tyrosine kinase and the first identified proto-oncogene. 
The kinase belongs to the Src family of protein kinases (SFKs) which constitute nine members; Blk, Fgr, 
Hck, Lck, Lyn, Fyn, Src, Yes and Yrk. The four latter being ubiquitously expressed. The family exhibits a 
conserved domain organization including a SH2 and SH3 domain as well as a tyrosine kinase domain 
(Parsons and Parsons, 2004). c-Src integrates and regulates signaling from various RTKs, such as EGFR, 
HER2, HER3, PDGFR, and FGFR, and is thereby involved in several important signal transduction 
pathways (Muthuswamy et al, 1994;Bromann et al, 2004;Ishizawar et al, 2007). The regulation causes 
activation of intracellular target proteins, including PI3K, but has also been found to reverse the activity 
of PTEN (Lu et al, 2003;Guarino, 2010). c-Src seems to be important for HER2:HER3 heterodimer 
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formation and is implicated in the transduction of intracellular signaling upon activation of ER in the 
nongenomic pathway (Figure 4D) (Varricchio et al, 2007;Ishizawar et al, 2007). c-Src is also important for 
regulation of cell motility, adhesion, and invasion, among others due to its interactions with the focal 
adhesion kinase (FAK) and the transmembrane adhesion receptors, the integrines (Guarino, 2010).  
c-Src has been found to be overexpressed in various cancers including pancreatic, colon, lung, ovarian 
and gastric cancer (Irby and Yeatman, 2000). Several studies have also shown an elevated activity of the 
kinase in breast cancer and the expression of c-Src is associated with reduced overall survival (Elsberger 
et al, 2010;Verbeek et al, 1996;Morgan et al, 2009). The majority of breast cancers with overexpressed 
or activated c-Src also overexpress one of the HER receptors (Biscardi et al, 1998;Belsches-Jablonski et 
al, 2001;Wilson et al, 2006). Additionally, studies have shown that dual targeting of c-Src and ER resulted 
in synergistic growth inhibition of breast cancer cell both in vivo and in vitro and the treatment 
completely prevented the development of treatment resistant cell lines (Hiscox et al, 2009;Anbalagan et 
al, 2012). 
Given its overexpression in various cancers and the implication in essential signal transduction 
pathways, several c-Src inhibitors have been developed. One of the best studied is dasatinib (BMS-
354825), which is a highly potent ATP competitive inhibitor of SFKs and Brc-Abl kinases (Lombardo et al, 
2004). Dasatinib was the first dual inhibitor of SFKs and Abl approved by the United States Food and 
Drug Administration (FDA) in the treatment of chronic myeloid leukemia and Philadelphia chromosome-
positive acute lymphoblastic leukemia (Zhang and Yu, 2012). Several clinical trials investigating dasatinib 
as a mono- or combinational therapy in breast cancer patients have been initiated. However, 
monotherapy with dasatinib has only shown modest clinical activity (Finn et al, 2011;Herold et al, 
2011;Mayer et al, 2011). In one phase II clinical trial, including both ER positive and/or HER2 positive 
patients, an overall clinical benefit rate of 13% was observed. Interestingly, all benefit was seen in 
patients with ER positive tumors (Mayer et al, 2011).  
Several other SFK inhibitors are currently in clinical trials for the treatment of solid tumors, including the 
highly selective KX2-391, which is the only SFK inhibitor targeting the peptide binding site of the SFKs 
(Anbalagan et al, 2012).  
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1.4 Cell Cycle Control and Cancer 
Cells are reproduced by a cycle of organized events where cell content is duplicated and the cell is 
divided into two daughter cells. Controlled progression through the cell cycle ensures maintenance of 
homeostasis and survival of the organism. Cancer cells often lack some of these control mechanisms 
allowing for uncontrolled cell duplication (Vermeulen et al, 2003b).  
The cell cycle comprises the interphase and the mitotic (M) phase. The interphase is further subdivided 
into gap phase 1 (G1) and gap phase 2 (G2), which allow time for growth, and the DNA synthesis (S) 
phase, where the chromosomes duplicate. Cell division occurs in M phase, which is divided into nuclear 
division (mitosis) and cytoplasmic division (cytokinesis). Mitosis is further subdivided into five stages: 
prophase, prometaphase, metaphase, anaphase, and telophase, see Figure 6. The cell cycle is tightly 
regulated by various cell cycle control systems and progression through the cell cycle is especially 
controlled at three major transition points, also called checkpoints (Alberts et al, 2008). The checkpoints 
are distributed throughout the cell cycle enabling the control system to arrest the cell at the given cell 
phase, until proper conditions for cell cycle progression is met (Chin and Yeong, 2010). The restriction 
point in G1 (start) is referred to as point of no return, since passing commits the cell to go through the 
cell cycle. At this transition the cells monitor the internal and external environment to ensure proper 
conditions for entry into S phase and progression through cell division. The transition from G2 to M is 
also strictly monitored. At this transition the control system ensures that the DNA is correctly replicated 
and that the internal and external environment is suitable for mitosis to proceed. The G2/M checkpoint 
triggers early mitotic events leading to chromosome alignment on the spindle in metaphase. Prior to 
cytokinesis the cells pass the metaphase-to-anaphase transition, consisting of the spindle-assembly 
checkpoint, at this point the cell monitors whether all chromosomes are correctly attached to the 
mitotic spindle to ensure that cytokinesis results in two identical daughter cells (Figure 6) (Alberts et al, 
2008).  
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Figure 6 - The Cell Cycle. A schematic overview of the cell cycle phases. Chromosome duplication takes place during  
interphase (grey), which consists of gap phase 1 (G1), DNA synthesis (S) phase, and the gap phase 2 (G2). The cell is 
divided during the Mitotic (M) phase. Green arrows indicate important cell cycle transitions. Modified from (Alberts et al, 
2008).  
The cell cycle control system contain various proteins, but most important are the cyclin-dependent 
kinases (CDKs) which are activated by the cyclins and regulate the checkpoints in G1 and G2/M. CDKs 
generally remain at constant levels throughout the cell cycle, while binding partners, such as cyclins and 
posttranslational modifiers, undergo periodic fluctuations to regulate the cell cycle progression. Cyclin 
D1-3 are the most important cyclins in G1, while cyclin E is important for the transition from G1 to S. 
Cyclin A is important in S and the transition from G2 into M phase, while cyclin B are active in M phase 
(Caldon et al, 2006;Vermeulen et al, 2003b).  
An important regulator of cell cycle progression is tumor protein 53 (p53). Mutations in the tumor 
suppressor gene TP53, encoding the p53 protein, are the most common genetic change identified in 
human cancers (Vogelstein et al, 2000). In breast cancer, p53 mutation is associated with more 
aggressive disease and decreased overall survival. The frequencies of p53 mutations are, however, lower 
in breast cancer than in other solid tumors (Pharoah et al, 1999;Alsner et al, 2000). p53 is activated upon 
cell stress or damage and is important for cell cycle arrest and induction of cell death (Vogelstein et al, 
2000). p53 exerts its inhibition on cell cycle through various factors. In G1 activated p53 induces 
transcription of the CDK inhibitor cyclin dependent kinase inhibitor 1 (p21) and thereby inhibits 
proliferation of abnormal cells (Sherr and McCormick, 2002). p53 can also inhibit the progression from 
G2 to M, since activated p53 can stimulate expression of the protein 14-3-3σ, which sequesters cyclin 
B/CDK in the cytoplasm, thus arresting the cells in G2 (Chan et al, 1999).  
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1.4.1 Cell Cycle Control during Interphase  
Initiation of cell cycle progression is dependent on an active cyclin D/CDK complex. Cyclin D is regulated 
by a number of mitogenic factors, acting on its transcription and translation as well as its stability (Sherr 
and McCormick, 2002). Activation of the PI3K/Akt and MAP kinase pathways by growth factors is 
thereby also implicated in cyclin D regulation: an activated MAP kinase pathway induces transcription of 
c-Myc, which in turn entails transcription of cyclin D (Alberts et al, 2008). Active Akt induces 
phosphorylation, and thus inactivation, of GSK3β, which in its active form induces degradation of cyclin 
D. Akt also directly phosphorylates the CDK inhibitors p21 and p27. The phosphorylation results in a 
relocation of the proteins, thus preventing inactivation of the cyclin D/CDK complex. p27 is also 
degraded by an active MAP kinase pathway. The active cyclin D/CDK complex in G1 causes 
phosphorylation of retinoblastoma protein (Rb), introducing a conformational change which releases 
E2F protein from Rb. E2F functions as a transcription factor and mediates transcription of proteins 
required for S phase entry, including cyclin A (Sherr and McCormick, 2002). Expression of cyclin D is 
transcriptionally regulated by ER which directly binds and activate the cyclin D promoter (Sabbah et al, 
1999). Cyclin D is highly expressed in many breast cancers and studies have shown that high levels of 
cyclin D correlates with development of resistance against treatment with the anti-estrogen tamoxifen 
(Wilcken et al, 1997;Hui et al, 2002).  
1.4.2 Cell Cycle Control during Mitosis 
Activation of the cyclin B/CDK complex in late G2 triggers the entry into mitosis (Alberts et al, 2008). 
Cyclin B/CDK activity is the driving force that promotes mitotic entry and progression, but another 
protein family, namely the Aurora kinase family, is essential in the regulation of correct progression 
through mitosis and cytokinesis.The Aurora family constitutes three serine-threonine kinases denoted 
Aurora A, Aurora B, and Aurora C (Vader and Lens, 2008;Katayama and Sen, 2010). The Aurora kinases 
exhibit a similar sequence within their catalytic domain, but have very distinct localization and function 
throughout the cell cycle (Carmena and Earnshaw, 2003), see Figure 7.   
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Figure 7 - Localization of Aurora A and Aurora B in mitotic cells. The level of Aurora kinases fluctuates throughout the 
cell cycle and is highest in G2/M and substantially reduced in G1 cells. In prophase, Aurora A (green boxes) is 
concentrated around the centrosomes, whereas Aurora B (red circles) is localized in the nucleus. In metaphase, Aurora A 
concentrates to the microtubules near the spindle poles and Aurora B is located in the inner centromere. In anaphase, 
most of the Aurora A proteins localize to the polar microtubules, but some might also be located in the spindle midzone. 
Aurora B is concentrated in the spindle midzone and at the cell cortex at the site of cleavage-furrow ingression. In 
cytokinesis, both kinases are concentrated in the midbody. The inset boxes illustrate that the kinases are dynamic until 
anaphase where Aurora B becomes immobile when targeted to the spindle midzone. From (Carmena and Earnshaw, 
2003). 
The gene transcription of Aurora A and Aurora B is cell cycle regulated and affected by transcription 
factors, such as the E2F family (Tanaka et al, 2002;Kimura et al, 2004). Aurora protein levels peaks 
during M phase and their activity is terminated when the kinases are degraded by the proteasome, as a 
consequence of ubiquitylation by the anaphase-promoting complex/cyclosome (APC/C), in late mitosis 
(Stewart and Fang, 2005;Honda et al, 2000).  Aurora C is the least studied of the three kinases and little 
is known of its functions and its role in cell cycle control. However, studies have shown that Aurora C 
plays an important role during spermatogenesis and that Aurora C can complement Aurora B in mitotic 
cells (Sasai et al, 2004;Dieterich et al, 2007;Kimmins et al, 2007). 
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1.4.2.1 Aurora A 
Aurora A is important for maturation of the centrosomes in the G2 phase and the subsequent 
centrosome separation and assembly of the bipolar spindle in mitosis. Aurora A has also been shown to 
play an important role in the timing of mitotic entry, since it recruit the cyclin B/CDK complex to the 
centrosomes prior to its activation (Vader and Lens, 2008;Hirota et al, 2003). The Aurora A encoding 
gene maps to the chromosome 20q13 region, which is frequently amplified in many human cancers 
(Katayama et al, 2003). Aurora A has especially been shown to be amplified or overexpressed in bladder, 
colon, ovarian, pancreatic and breast cancer (Katayama et al, 2003;Tanaka et al, 1999). In breast cancer, 
overexpression of the kinase was reported to correlate with invasive disease and chromosomal 
instability (CIN) (Tanaka et al, 1999;Miyoshi et al, 2001). Overexpression of Aurora A is thought to 
contribute to the development of CIN by hyperactivation of the centrosomes and assembly of multipolar 
spindles (Katayama and Sen, 2010;Zhou et al, 1998). RNA interference experiments in HeLa cells have 
also shown that loss of Aurora A leads to incorrect centrosome duplication and misalignment of the 
chromosomes during metaphase (Marumoto et al, 2003). Perturbation of Aurora A expression in 
pancreatic cell lines also induced delayed mitotic entry and cell cycle arrest at the G2/M checkpoint 
(Rojanala et al, 2004).  
1.4.2.2 Aurora B 
Aurora B is the catalytic component of the chromosomal passenger complex (CPC), which also consist of 
the three regulatory and targeting components; inner centromere protein (INCENP), survivin and 
borealin. Aurora B activation is a complex, multistep process. Aurora B initially binds to INCENP, which 
activates low levels of kinase activity. This enables Aurora B to phosphorylate INCENP and Thr232 of its 
own kinase domain, resulting in further activation of Aurora B. Other kinases also regulate Aurora B 
activity and full activation requires phosphorylation of Ser311 by checkpoint kinase 1 (Chk1). The activity 
of INCENP is regulated by the cyclin B/CDK complex (Carmena et al, 2012). CPC is important in 
chromosome condensation, correction of erroneous kinetochore-microtubule attachments, activation of 
the spindle-assembly checkpoint and cytokinesis, as described below (Carmena et al, 2012).  
Chromosome condensation is driven by the action of condensin complexes and is essential for error-free 
sister chromatid separation. CPC is proposed to regulate the binding between the condensin I complex 
and the chromosomes, and thereby contributes to proper condensation of the chromosomes (Vader 
and Lens, 2008;Carmena et al, 2012).  
The sister chromatids are separated between metaphase and anaphase and correct chromosome 
distribution is dependent on bi-oriented chromosome attachments to the microtubule. The spindle-
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assembly checkpoint is activated upon mitotic entry, due to unattached or tensionless kinetochores, and 
inactivation is required to progress through the metaphase to anaphase transition, see Figure 8 
(Carmena et al, 2012). CPC promotes activation of the spindle-assembly checkpoint, by specifically 
destabilizing the binding of erroneous microtubules-kinetochores attachments. Unattached 
kinetochores serve as a platform for the generation of the mitotic checkpoint complex (MCC), which 
prevents the activation of APC/C (van der Waal et al, 2012). The spindle-assembly checkpoint is silenced 
once all the kinetochores establish correct bi-oriented attachments to the microtubules, which ceases 
the generation of the MCC and thereby allow activation of APC/C. APC/C-dependent degradation of 
securin and cyclin B, subsequently causes sister chromatid separation and inactivation of CDK, which 
promotes anaphase onset (Yu, 2007).  
 
Figure 8 - Principles of the Spindle Assemply Checkpoint. During prometaphase, unattached kinetochores catalyze the 
formation of the mitotic checkpoint complex (MCC), leading to inhibition of the anaphase-promoting complex/cyclosome 
(APC/C). Once all the chromosomes are aligned with their kinetochores attached to the spindle (metaphase), generation 
of the MCC ceases, allowing Cdc20 to activate the APC/C, leading to the ubiquitylation and degradation of securin and 
cyclin B1. Degradation of securin liberates separase which in turn cleaves the kleisin subunit of the cohesin ring 
structure; this opens the ring, allowing sister chromatids to separate (anaphase). Meanwhile, degradation of cyclin B1 
inactivates CDK1, leading to mitotic exit. From (Lara-Gonzalez et al, 2012). 
The drop in Cyclin B/CDK activity in anaphase is an important trigger of the translocation of the CPC 
from centromeres to the central spindle prior to cytokinesis (van der Waal et al, 2012). The timing of 
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cytokinesis has to be closely coordinated with chromosome segregation to allow accurate partitioning of 
the genome and formation of the two daughter cells. CPC has an important role in this coordination, and 
abrogation of functional Aurora B results in polyploidy due to cytokinetic failure (Carmena et al, 
2012;Boss et al, 2009).  
The human gene encoding Aurora B is located on chromosome 17p13. This region is not commonly 
amplified in human tumors, but overexpression of the Aurora B gene is evident in a range of primary 
cancers, such as prostate, head and neck, colon, and thyroid cancers and its overexpression has been 
correlated with clinical aggressiveness (Boss et al, 2009;Gautschi et al, 2008). Increased Aurora B 
expression has also been found in breast cancer, but the increased expression also correlated with 
increased cell proliferation, and could therefore just be a result of a function specific increase during the 
G2/M phase (Hegyi et al, 2012). A polymorphism in the Aurora kinase B gene that predisposes for breast 
cancer has also been reported in one study (Tchatchou et al, 2007). Overexpression of Aurora B 
interferes with chromosome bi-orientation and the spindle-assembly checkpoint due to enhanced 
disruption of kinetochore-microtubule attachments and sister chromatid cohesion. Overexpression also 
causes an abnormal cytokinesis resulting in chromosome segregation errors (Katayama and Sen, 2010).  
It has been found that perturbations in Aurora A and Aurora B expression preferentially induce 
apoptosis in cancer cell lines compared to the normal mammary ductal epithelial cell line MCF10A 
(Warner et al, 2006) and overexpression of Aurora B in chinese hamster embryonic diploid fibroblasts 
have been found to induce aneuploid cells capable of forming aggressive tumors in nude mice (Ota et al, 
2002). 
1.4.3 Aurora Inhibition in Cancer Treatment 
Aurora proteins are expressed at abnormal high levels in various tumors compared to normal cells, and 
have therefore been suggested as therapeutic targets. Subsequently, several anti-cancer drugs targeting 
this family have been developed, including the pan-CDK and Aurora inhibitor JNJ-7706621 and the highly 
selective Aurora B inhibitor barasertib (AZD1152-HQPA) (Katayama and Sen, 2010).  
In a preclinical study it was shown that treatment with JNJ-7706621 preferentially blocks proliferation of 
tumor cell lines, including the breast cancer cell line MDA-MB-231. Promising anti-tumor effects were 
also found when the drug was administered in a human tumor xenograft model (Emanuel et al, 2005). 
Barasertib is a reversible selective ATP-competitive inhibitor of the Aurora B kinase. The drug is 
administered as a prodrug, which is rapidly converted to its active moiety in plasma (Mortlock et al, 
2007;Jung et al, 2006). Treatment with barasertib in hematologic cells lines leads to induction of 
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polyploidy and subsequent cell death, which is consistent with phenotypes induced by loss of Aurora B 
kinase activity (Oke et al, 2009). Administration of barasertib has also been shown to potently inhibit the 
growth of human colon, lung, hematologic and breast tumor xenografts as well as a panel of human 
breast cancer cell lines (Wilkinson et al, 2007;Oke et al, 2009;Gully et al, 2010). Moreover, barasertib 
was found to induce degradation of the Aurora B protein (Gully et al, 2010). In two phase I studies, 
administration of barasertib to patients with advanced solid tumors was generally well tolerated. 
Although, no objective tumor response was observed in any of the patients, 23-25% of the barasertib 
treated patients achieved prolonged disease stabilization (Boss et al, 2011;Schwartz et al, 2013). 
Barasertib was also well tolerated in patients with acute myeloid leukemia enrolled in a phase I and a I/II 
study. These trials showed an overall response rate of 19-25% (Tsuboi et al, 2011;Lowenberg et al, 
2011). 
1.5 Mechanisms of Cell Death  
Programmed cell death (PCD) plays an important role during tissue development and maintenance of 
cellular homeostasis. Cell death and proliferation are intimately coupled and some cell cycle regulators, 
such as p53, can influence both cell division and programmed cell death (Vermeulen et al, 2003a). PCD is 
subdivided, based on the nuclear morphology of the dying cell; apoptotic PCD is characterized by severe 
chromatin condension (described below), apoptosis-like PCD exhibit less compact and irregular 
chromatin masses, and necrosis-like PCD occurs either in complete absence of chromatin condensation 
or with chromatin clustering forming loose speckles (Leist and Jäättelä, 2001). Cells can also die in 
response to an acute insult such as trauma or lack of blood supply. Cells usually do so by a process called 
necrosis which causes the cells to swell and burst, thus spilling their contents and eliciting an 
inflammatory response. Necrosis can also occur if the PCD fails. Most cancer therapies, e.g. 
chemotherapy, function by inducing cell death (Alberts et al, 2008). 
1.5.1 Apoptosis  
Apoptosis is important in development, aging, and homeostasis, but also occurs as a defense mechanism 
in immune responses or when cells are damaged by disease or cytotoxic agents (Norbury and Hickson, 
2001;Kerr et al, 1972). Apoptotic cells shrink and condense, the cytoskeleton collapses, the nuclear 
envelope disassembles and the nuclear chromatin condenses and breaks into fragments. During PCD the 
dying cell is engulfed by neighboring cells or macrophages to counteract loss of cell contents and 
thereby avoid a damaging inflammatory response (Kerr et al, 1972;Kurosaka et al, 2003). The 
intracellular machinery responsible for apoptosis depends on a family of cysteine aspartyl proteases 
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(caspases) (Cohen, 1997). Caspases induce apoptosis by the cleavage of several key proteins required for 
cellular functioning and survival. One of these proteins is the poly ADP ribose polymerase (PARP), which 
is involved in the repair of single-strand DNA breaks (Boulares et al, 1999). 
The most abundant form of PCD is apoptosis, but a single stimulus often triggers several distinct death 
programs concurrently. Normally, only the fastest and most effective death pathway is evident, but the 
cell can also display characteristics of several death programs simultaneously (Jäättelä, 2004).  
Evasion of PCD is a hallmark of cancer, and cancer cells are often protected from cell death by harboring 
mutations in pro-apoptotic proteins (e.g. p53) and overexpression of anti-apoptotic proteins (e.g. Akt 
and inhibitors of apoptotic proteins) (Jäättelä, 2004;Hanahan and Weinberg, 2000).  
1.6 Breast Cancer Treatment 
At time of diagnosis, 85-90 % of women with breast cancer have localized disease with no indications of 
metastasis or spread to the draining lymph nodes. These patients will be offered a curative intended 
operation, either a lumpectomy or a mastectomy, and the majortity will also receive adjuvant therapy. 
The remaining 10-15% will be offered a systemic treatment as the primary treatment, to e.g. downstage 
the disease allowing a following operation (Sundhedsstyrelsen, 2012).  
1.6.1 Adjuvant Endocrine Therapy 
The main purpose of adjuvant treatment is to control undetected remaining deposits of breast cancer 
cells to reduce the recurrence rate and improve long term survival (EBCTCG, 2005). The choice of 
secondary adjuvant therapy is dependent on the histological classification of the cancer cells, the extent 
of the disease and the age of the patient (DBCG, 2013a). It is often a combination of radiation therapy 
and systemic treatment with cytotoxic and/or endocrine therapy (Sundhedsstyrelsen, 2012). After 
surgery, more than 90% of the patients will be treated with systemic agents. In Denmark, all women 
under 60 years, and women above 60 with ER negative or HER2 positive breast cancer, will be given 
cytotoxic therapy. HER2 positive patients will concurrently receive targeted treatment against HER2 i.e. 
the anti-HER2 agent trastuzumab (Herceptin®). ER positive patients will receive endocrine therapy 
(DBCG, 2013a).  
ER is a valuable biomarker in breast cancer treatment, since it serves as a predictive marker for response 
to endocrine therapy and a prognostic marker as it correlates with a good prognosis. HER2 is also used 
as a biomarker in breast cancer; expression predicts response to targeted treatment against HER2 
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(Duffy, 2005). However, HER2 is also a prognostic marker since overexpression of the protein or 
amplification of the gene correlate with a poor prognosis (Rasmussen et al, 2008). These biomarkers do 
not fully represent the heterogeneity of the disease, and can thereby not reliably predict the therapeutic 
response of all breast cancer patients (Bertos and Park, 2011). However, the expression of ER and HER2, 
are the best predictive markers identified for breast cancer treatment, and the only biomarkers 
recommended to be used in the clinic (DBCG, 2013a). 
Endocrine therapies affect the estrogen production or inhibit the activation of the receptor. The classes 
of endocrine therapy include selective estrogen receptor modulators (SERMs), selective estrogen 
receptor downregulators (SERDs) and aromatase inhibitors (AIs) (Giuliano et al, 2011). Postmenopausal 
women are recommended 5 years treatment with AIs, while premenopausal women are treated for 5 
years with SERMs (Sundhedsstyrelsen, 2012).  
1.6.1.1 The Selective Estrogen Receptor Modulator Tamoxifen 
The predominant choice of SERM is tamoxifen (ICI 46,474), which is administered orally in daily doses 
(DBCG, 2013a). Tamoxifen was discovered in the 1970s and was the first endocrine agent approved for 
breast cancer treatment (Jordan, 2006;Harper and Walpole, 1967;Jensen and Jordan, 2003). Adjuvant 
therapy with tamoxifen has revolutionized the treatment of ER positive breast cancer. In the past two 
decades the rate of recurrences has been halved and the mortality rate has been reduced by 25-30 % 
(EBCTCG, 2005).  
Tamoxifen is a non-steroidal compound, which upon binding to ER may exhibit agonistic or antagonistic 
effects depending on the celltype. In breast cancer, tamoxifen acts as an antagonist, since it blocks the 
transactivating AF-2 site of ER. This inhibits the association of transcriptional co-activators to this site, 
causing transcription or regulation of ER target genes to be impaired. However, ER bound to tamoxifen 
is still able to dimerize, translocate to the nucleus and bind to EREs, and the AF-1 site is not blocked 
upon tamoxifen binding. The agonist actions of tamoxifen are therefore proposed to be mediated 
through AF-1 induced transcription (Howell et al, 2000;Howell, 2006). The main activation of ER in bones 
and uterus occurs through the AF-1 site, and consequently tamoxifen exhibits an agonistic effect in 
these tissues (Ali and Coombes, 2002;Jensen and Jordan, 2003). The chemical structure of tamoxifen can 
be seen in Figure 9. 
1.6.1.2 The Selective Estrogen Receptor Downregulator Fulvestrant 
The SERD fulvestrant (ICI 182,780 or Faslodex) is a steroidal 7α-alkylsulfinyl analogue of estradiol, which 
is structurally different from tamoxifen (Figure 9) (Howell et al, 1995). The compound is a pure estrogen 
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antagonist, exerting only anti-estrogenic effects by inhibiting the binding of estrogen (Nicholson and 
Johnston, 2005). The relative in vitro binding affinity of fulvestrant is 0.89 compared with that of 
estradiol (1.0) (Wakeling et al, 1991). By contrast, the affinity of tamoxifen is only 0.025 (Wakeling and 
Bowler, 1987). Initially, the steroidal SERD ICI 164,384, which is a 7α-alkylamide analog of estradiol, was 
introduced, however the compound never made it to the clinic, due to poor potency in animal 
experiments (Wakeling et al, 1991).  
Binding of fulvestrant to ER blocks nuclear localization of the receptor  and impairs receptor 
dimerization by means of the 7α-alkylsulfinyl side-chain (Parker, 1993;Dauvois et al, 1993). The ER-
fulvestrant complex is also unstable, resulting in increased degradation of the ER protein (Nicholson et 
al, 1995). Tamoxifen only blocks the AF-2 transactivation domain of ER (Jensen and Jordan, 2003) and it 
has been shown that the AF-1 activity play an important role for tumor growth (Ali and Coombes, 
2002;Thrane et al, 2013). Fulvestrant, which inactivates both AF-1 and AF-2, can therefore be effective 
as second line treatment (Osborne et al, 2004). The potential of steroidal anti-estrogens as second line 
therapy for tamoxifen resistant breast cencer was first shown in our model systems with the tamoxifen 
resistant MCF-7 breast cancer cell line MCF-7/TamR-1 (also called AL-1), which were growth inhibited by 
ICI 164,384 (Lykkesfeldt and Sorensen, 1992). This observation was confirmed by Howell et al. (1995), 
who in a small initial clinical study, showed that 69% of tamoxifen resistant patients responded to 
fulvestrant treatment. Downregulation of ER by fulvestrant results in a reduced cross-talk between the 
ER and other growth pathways, such as the MAP kinase pathway (Scott et al, 2011).  
Fulvestrant is administered to patients as an intramuscular injection once a month and was approved by 
the FDA for treatment of postmenopausal ER positive metastatic breast cancer patients in 2002 and by 
the European Commission in 2010. It has been discussed whether premenopausal women would benefit 
from treatment with fulvestrant, but the high ovary production of estrogen in these patients suggests 
that higher doses of fulvestrant would be required to prevent the estrogenic actions (Scott et al, 2011).  
 
Figure 9 - Chemical Structure of Estradiol, Tamoxifen and Fulvestrant. Modified from (Nicholson and Johnston, 2005). 
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1.6.1.3 Aromatase Inhibitors 
In postmenopausal breast cancer patients, most estrogen is synthesized from androgens by the enzyme 
aromatase in the cancer cells as well as adipose tissue and muscles (Manni, 1993;Lykkesfeldt et al, 
2009). Therefore, postmenopausal women benefit by AI treatment, which reduces the level of 
circulating estrogen by 90-99% (Giuliano et al, 2011). Three aromatase inhibitors are approved for 
treatment by the FDA; anastrozole, exemestane, and letrozole (Chen et al, 2007). 
1.7 Endocrine Resistance 
Adjuvant therapy has reduced the mortality rate by 25-30% in the past two decades (EBCTCG, 2005). In 
spite of this progress many patients experience resistance to the treatment and subsequent recurrence 
of the disease. Resistance can either be present from the beginning of the treatment, called de novo 
resistance, or be acquired following treatment. De novo resistance is dependent on inherent breast 
cancer characteristics, which is present before treatment is initiated (Nicholson and Johnston, 2005). 
Almost half of the patients with metastatic disease experience de novo resistance and do not respond to 
first line treatment with tamoxifen (Giuliano et al, 2011). Acquired resistance occurs in patients, who 
after initial response develop recurrent disease during treatment and the resistance is assumed to result 
from induced or acquired changes in breast cancer cell characteristics (Nicholson and Johnston, 2005). 
In a 15 year period one third of the patient treated with tamoxifen for 5 years will experience 
recurrence, and will subsequently require additional treatment (EBCTCG, 2005). Following relapse, many 
patients benefit from treatment with fulvestrant. But despite the initial response almost all patients 
with advanced disease will eventually develop resistance against the anti-estrogenic therapy (Osborne 
et al, 1995;Howell et al, 1995;Musgrove and Sutherland, 2009). Understanding the mechanisms of 
resistance is therefore of great importance in the search for new targets for treatments.  
1.7.1 Tamoxifen Resistance 
To date, the mechanisms of acquired resistance towards tamoxifen are not fully elucidated, but several 
mechanisms have been outlined. These include ER status, growth factor receptor signaling and ER co-
regulator status (Zilli et al, 2009).  
Expression of ER is the main predictor of response to endocrine therapy and lack of ER is the most 
common cause of de novo resistance to endocrine therapy (Zilli et al, 2009). A minor fraction (20-40%) of 
ER positive patients treated with tamoxifen has been found to lose the expression of ER at time of 
relapse (Johnston et al, 1995). Thus, loss of ER expression is a mechanism of acquired resistance and the 
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ER negativity may be induced by epigenetic changes (Yang et al, 2000). Most recurrent tumors have 
decreased ER expression (Johnston et al, 1995) and in these tumors, upregulation of alternative growth 
promoting signaling, such as activation of the MAP kinase and/or PI3K/Akt pathways, may have occured. 
This has been found in breast cancer cell lines where the level of EGFR and ERK signaling were increased 
upon acquiring tamoxifen resistance (Thrane et al, 2013). Overexpression of HER2 has also been shown 
to arise during breast cancer progression, thus abrogating the need for estrogen signaling (Meng et al, 
2004;Gutierrez et al, 2005). Gene amplification or protein overexpression of HER2 is the only known 
biomarker available to identify ER positive patients which will experience reduced response to 
tamoxifen treatment (Rasmussen et al, 2008). Tamoxifen only inhibit the AF-2 site of ER. Crosstalk from 
HER signaling can thus regulate the activity of ER through AF-1 and thereby promote growth inspite of 
tamoxifen treatment (Howell, 2006). It has also been shown that tamoxifen can induce growth 
stimulation in tamoxifen resistant cell lines, indicating that these cells utilize agonistic ER stimulation by 
tamoxifen for growth (Thrane et al, 2013). In line with this, evidence also indicates that changes in the 
levels of ER co-repressors and co-activators, directly influence the balance of agonistic versus 
antagonistic effect of tamoxifen, as well as the ligand-independent activity of the AF-1 domain. The co-
regulators thereby regulate ER transcription, which are critical in determining the endocrine sensitivity 
(Girault et al, 2003;Lavinsky et al, 1998).  
1.7.2 Fulvestrant Resistance 
Anti-estrogen resistance has mainly been investigated in regards to the widely used tamoxifen. In spite 
of similarities in the resistance mechanisms, tamoxifen and fulvestrant resistance cannot be considered 
completely equivalent (Musgrove and Sutherland, 2009;Zilli et al, 2009) and many tamoxifen resistant 
tumors do not experience cross-resistance when treated with fulvestrant (Howell et al, 1995;Osborne et 
al, 2004).  
Cell lines with acquired resistance towards the anti-estrogen fulvestrant exhibit complete loss or severe 
downregulation of the ER (Lykkesfeldt et al, 1995;Larsen et al, 1997;McClelland et al, 2001;Sommer et 
al, 2003) and (Kirkegaard, unpublished data). Cross-activation between ER and HER signaling, which is 
found in tamoxifen resistance, is therefore not considered a major mechanism utilized in fulvestrant 
resistant cell growth. To circumvent the fulvestrant induced growth inhibition, the cancer cells seem to 
utilize alternative growth stimulating pathways which are estrogen independent (Musgrove and 
Sutherland, 2009;Frogne et al, 2009a;Osborne et al, 2004). This may be accomplished through altered 
signaling in growth factor activated pathways, since acquired fulvestrant resistance has been found to 
be associated with changed HER signaling. Expression of the HER receptor is not uniform, but upon 
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acquisition of fulvestrant resistance, the cells generally exhibit increased levels of EGFR, HER2 and HER3, 
while HER4 expression is severely downregulated (Lykkesfeldt et al, 1995;Larsen et al, 1997;McClelland 
et al, 2001;Sommer et al, 2003) and (Kirkegaard, unpublished data). Expression of HER ligands has also 
been found to be increased in fulvestrant resistant cell lines as well as activation of downstream effector 
proteins in the MAP kinase and PI3K/Akt pathway (Frogne et al, 2009a;McClelland et al, 2001;Frogne et 
al, 2005). Moreover, Increased NFκB signaling has been implicated in the ability of breast cancer cells to 
survive treatment with tamoxifen and fulvestrant (Yde et al, 2012). 
1.8 In vitro Models of Anti-Estrogen Resistance 
Breast cancer cell lines are widely used as model systems to mimic the clinical situation in patients. The 
cell lines are derived from patients and thus function as in vitro models. Model systems do not 
necessarily mimic the actual mechanisms occurring in the patients since breast cancer is a 
heterogeneous disease as shown in a recent paper which identified ten different breast cancer subtypes 
(Curtis et al, 2012). Therefore, results from in vitro breast cancer cell models should be taken with great 
caution and be tested in translational research to disclose the clinical relevance. Nevertheless, cell line 
models have disclosed important concepts and hypotheses regarding anti-estrogen resistance 
(Musgrove and Sutherland, 2009). 
1.8.1 Estrogen Dependent Breast Cancer Models 
MCF-7 is one of the most investigated ER positive breast cancer cell lines, but other breast cancer cell 
lines, such as T47D, are also used as model systems for breast cancer. MCF-7 and T47D derive from 
pleural effusions from two different female patients with metastatic breast cancer (Soule et al, 
1973;Keydar et al, 1979). Both cell lines exhibit an aneuploidy karyotype, are ER positive and HER2 
negative, and display estrogen responsive cell growth (Briand and Lykkesfeldt, 1984;Lykkesfeldt and 
Briand, 1986) and (Kirkegaard, unpublished data). The cell lines can either be grown in vitro in cell 
cultures, or as xenotransplants in athymic nude mice (Lykkesfeldt et al, 1994;Schafer et al, 2000) and 
(Kirkegaard, unpublished data). The cell lines differ in expression of several proteins and T47D has also 
been found to harbor a mutation in p53, while MCF-7 express wild type p53 (O'Connor et al, 1997;Aka 
and Lin, 2012).  
1.8.1.1 Anti-Estrogen Resistant Breast Cancer Models  
To investigate the mechanisms of acquired resistance, several tamoxifen and fulvestrant resistant cell 
lines have been established. The in vitro model systems for fulvestrant and tamoxifen resistance used in 
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this study were developed by the Breast Cancer Group at the Danish Cancer Society Research Center 
from the estrogen responsive breast cancer cell lines T47D and MCF-7. Panels of four tamoxifen 
resistant and seven fulvestrant resistant MCF-7 cell lines are available in our laboratory, as well as two 
tamoxifen and two fulvestrant resistant T47D cell lines (Lykkesfeldt et al, 1994;Lykkesfeldt et al, 
1995;Madsen et al, 1997) and (Lykkesfeldt and Kirkegaard, unpublished data). The anti-estrogen 
resistant cell lines were established by long-term treatment of the parental T47D or MCF-7 cell lines 
with either 100 nM fulvestrant/ICI 164,340 or 1 μM tamoxifen, corresponding to the plasma 
concentration in anti-estrogen treated breast cancer patients (DeFriend et al, 1994;Daniel et al, 1981). 
Treatment of the cell lines should thereby mimic the clinical development of anti-estrogen resistance.  
The anti-estrogen resistant cell lines used in this thesis were established by slightly different methods, as 
depicted in Appendix II , but most stages were comparable, and all cell lines were established as single-
cell colonies from the parental cell line by long-term treatment with the anti-estrogen. Initially, most of 
the parental cells died as a consequence of the anti-estrogen treatment. However, few cells were able 
to survive and small colonies of slowly proliferating cells eventually emerged. The colonies were isolated 
and allowed to grow and the cells slowly increased their growth rate. Following various time frames (4-
21 month) from the first treatment, the cell lines could be split weekly with a split ratio resembling the 
parental cell lines and the clonally derived anti-estrogen resistant cell lines were thereby established 
(Lykkesfeldt et al, 1995). The development of resistance involved both the initial survival from treatment 
and the slow gain of growth promoting activity. Thus, the initial survival may be due to de novo 
resistance, whereas the increased growth rate is an acquired condition. We believe the model systems 
are mimicking acquired resistance in patients.  
In our cell lines, development of resistance to anti-estrogens is associated with reduced or lost 
expression of the ER and changes in HER expression levels (Lykkesfeldt et al, 1995;Frogne et al, 
2009a;Thrane et al, 2013) and (Kirkegaard and Yde, unpublished data). 
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2 Aim 
The aim of this Master Thesis was to identify and explore the molecular mechanisms driving growth of 
newly established T47D breast cancer cell lines resistant to the anti-estrogen fulvestrant.  
More specifically, the goals were:  
- To identify kinase inhibitors that preferentially target growth of the anti-estrogen resistant cell 
lines compared to the anti-estrogen sensitive parental T47D cell line.  
- To validate the growth inhibitory effect of selected kinase inhibitors identified in the screen. 
- To select kinase inhibitors for further investigation and determine the protein expression of 
these kinase inhibitor target(s). 
- To identify mechanisms of growth inhibition induced by the kinase inhibitors. 
- To discuss the potential of the identified inhibitor(s) as a treatment option and asses the value 
of the target(s) as biomarker. 
The initially aim was to characterize two new fulvestrant resistant T47D cell lines, and this will be the 
main focus of this thesis. However, investigations utilizing T47D cell lines resistant to the anti-estrogen 
tamoxifen were also made possible during my study, and were therefore included. 
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3 Materials and Methods 
3.1 Cell Lines and Cell Culturing 
In this master thesis nine different cell lines have been utilized. In the following paragraph the growth 
conditions of the cell lines will be elucidated and summarized in Table 1. The fulvestrant resistant T47D 
cell lines as well as the parental anti-estrogen sensitive T47D cell line were investigated in the majority 
of the experiments.  
3.1.1 T47D and Cell Culturing 
The T47D cell line was originally obtained from the Human Cell Culture Bank (Mason Research Institute, 
Rockville, MD, USA). The cells were routinely propagated in in 5 mL phenol-red free Roswell Park 
Memorial Institute (RPMI 1640) medium (Gibco, Invitrogen, CA, USA). Phenol-red was omitted, owing to 
its potential estrogenic effect (Berthois et al, 1986). RPMI 1640 was supplemented with 5% (v/v) heat-
inactivated fetal bovine serum (FBS) (Batch no. 140; Perbio, ThermoFisher Scientific, Dharmacon Inc. 
Waltham, MA, USA), 2.0 mM GlutaMAXTM (Gibco Invitrogen) and 8 µg/mL insulin (Sigma-Aldrich, 
Copenhagen, Denmark) making up the standard growth medium for the T47D cell line. The standard 
growth medium was renewed every second to third day. In all experiments penicillin 2.5×10-4 U/L and 
streptomycin 2.5×10-4 μg/mL (P/S) (Gibco, Invitrogen) were added to the standard growth medium. 
Passage of the cell lines was performed once a week by washing the cells twice in trypsin (Gibco, 
Invitrogen) followed by incubation for 7 min at 37 °C. Cells were resuspended in 5-7 ml standard growth 
medium and cell number was determined by manually counting the cells in a Bürker-Türk chamber. Cells 
were seeded at densities ranging from 3.5-5×105 in T25 NunclonTM Δ flasks (Nunc, Thermo Fisher 
Scientific Roskilde, Denmark) to ensure a confluence of 80 % when the cells were split. During 
propagation the cells were kept at 37 °C in a humid air incubator with 5% CO2. 
3.1.1.1 Fulvestrant Resistant T47D Cell Lines 
The fulvestrant resistant cell lines: T47D/182R-1 and T47D/182R-2, referred to as 182R-1 and 182R-2, 
were established from T47D by Tove Kirkegaard as described in section 1.8.1.1 and Appendix II . The 
fulvestrant resistant cells were propagated in standard growth medium supplemented with 100 nM 
fulvestrant (TOCRIS Biosciences, Avonmouth, Bristol, England), which is equivalent to the plasma 
concentration measured in patients treated with fulvestrant (DeFriend et al, 1994). Stock solutions of 
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10-3 M fulvestrant were dissolved in 96 % ethanol (EtOH). The fulvestrant resistant cells were 
propagated and kept as described above for T47D cells. 
3.1.1.2 T47D subline 2 
To enable estrogen receptor-mediated growth inhibition by tamoxifen (Briand and Lykkesfeldt, 1984), 
the T47D cell line was adapted to grow in standard growth medium supplemented with only 2% FBS. 
This parental cell line was established by Anne E. Lykkesfeldt as described in Briand and Lykkesfeldt 
(1984) and will be referred to as T47D subline 2 (T47D/S2). The cell line was propagated as described for 
T47D, apart from the lower serum concentration. 
3.1.1.3 Tamoxifen Resistant T47D Cell Lines 
The tamoxifen resistant cell lines: T47D/TR-1 and T47D/TR-2, referred to as TR-1 and TR-2, were 
established from T47D/S2 by Anne E. Lykkesfeldt as described in section 1.8.1.1 and Appendix II . The 
tamoxifen resistant cells were propagated in standard growth medium supplemented with 1 µM 
tamoxifen (Sigma-Aldrich), which is equivalent to the plasma concentration measured in patients 
treated with tamoxifen (Daniel et al, 1981). Stock solutions of 10-2 M tamoxifen were dissolved in 96 % 
EtOH. The tamoxifen resistant cells were propagated and kept as described above for the T47D/S2 cells. 
3.1.2 MCF-7 and Cell Culturing 
The MCF-7 cell line was originally obtained from the Human Cell Culture Bank (Mason Research 
Institute), but have been gradually adapted to grow at a low serum concentration, which mimic the 
serum condition in postmenopausal women (Briand and Lykkesfeldt, 1984). The low serum MCF-7 cells 
(MCF-7/S0.5) were routinely propagated in 5 ml phenol-red free Dulbecco’s Modified Eagles 
Medium/Ham’s F12 (DMEM/F12) (Gibco, Invitrogen). The DMEM/F12 was supplemented with 1% (v/v) 
heat inactivated FBS (Batch no. 140) (Perbio, ThermoFisher Scientific), 2.0 mM GlutaMAXTM (Gibco, 
Invitrogen) and 6 ng/ml insulin (Sigma-Aldrich, St. Louis, MO, USA) making up the standard growth 
medium for the MCF-7/S0.5 cell line. The standard growth medium was renewed every second to third 
day. In all experiments P/S (Gibco, Invitrogen) were added to the standard growth medium. Passage of 
the cell lines was performed once a week by washing the cells twice in trypsin (Gibco, Invitrogen) and 
incubating for 6 min at 37 °C. Cells were resuspended in 5 ml standard growth medium and the cell 
number was determined by manually counting the cells in a Bürker-Türk chamber. Cells were seeded at 
densities ranging from 0.8-1.2×105 in T25 flasks (Nunc). During propagation the cells were kept at 37 °C 
in a humid air incubator with 5% CO2. 
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3.1.2.1 Fulvestrant Resistant MCF-7 Cell Lines 
Several cell lines with acquired anti-estrogen resistance derived from the MCF-7/S0.5 cell line have been 
established by Anne E. Lykkesfeldt as described in Lykkesfeldt et al. (1995), paragraph 1.8.1.1 and 
Appendix II . In this thesis, two fulvestrant resistant cell lines were selected for in vitro studies: MCF-
7/S0.5/182R-6 established by fulvestrant (ICI 182,780) treatment and MCF-7/S0.5/164R-7 established by 
ICI 164,384 treatment. The MCF-7/S0.5/164R-7 cell line was demonstrated to be cross resistant to 
fulvestrant and is therefore also classified as fulvestrant resistant (Lykkesfeldt et al, 1995). The 
fulvestrant resistant cell lines MCF-7/S0.5/182R-6 and MCF-7/S0.5/164R-7 were grown in MCF-7/S0.5 
standard growth media supplemented with 100 nM fulvestrant (TOCRIS Bioscience) and this will be 
referred to as the standard growth medium for these cell lines. The cell lines were routinely propagated 
as described for MCF-7/S0.5. 
Table 1 - Standard Growth Medium for Cell Lines Utilized in Experiments. Cell lines used in the experiments, 
where they derived from and the content of their standard growth medium. Fetal bovine serum (FBS) 
Cell Line  
Derived 
From 
STANDARD GROWTH MEDIUM 
Growth 
Medium 
FBS Insulin Glutamax Fulvestrant Tamoxifen 
T47D
a 
 RPMI-1640 5 % 8 µg/mL 2.0 mM   
T47D/182
R
-1 T47D RPMI-1640 5 % 8 µg/mL 2.0 mM 100 nM  
T47D/182
R
-2 T47D RPMI-1640 5 % 8 µg/mL 2.0 mM 100 nM  
T47D/S2 T47D RPMI-1640 2 % 8 µg/mL 2.0 mM   
T47D/TR-1 T47D/S2 RPMI-1640 2 % 8 µg/mL 2.0 mM  1 µM 
T47D/TR-2 T47D/S2 RPMI-1640 2 % 8 µg/mL 2.0 mM  1 µM 
MCF-7/S0.5 MCF-7
a 
DMEM/F12 1 % 6 ng/ml 2.0 mM   
MCF-7/164
R
-7 MCF-7/S0.5 DMEM/F12 1 % 6 ng/ml 2.0 mM 100 nM  
MCF-7/182
R
-6 MCF-7/S0.5 DMEM/F12 1 % 6 ng/ml 2.0 mM 100 nM  
a Purchased from Human Cell Culture Bank (Mason Research Institute, Rockville, MD, USA). 
3.2 Doubling time 
To determine the doubling time of parental and fulvestrant resistant T47D cell lines, 3×104 cells/well 
were seeded in 24-well plates (Falkon, Becton Dickinson, NJ, USA) in their standard growth medium and 
allowed to adhere for one day. At selected time points (day 1-12), cells from 3 wells were trypsinized 
and cell number determined by manually counting the cells in a Bürker-Türk chamber. Growth medium 
was renewed every 2-3 day in the remaining wells. The doubling time was calculated from the 
exponential part of the growth curve. 
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3.3 Cell Morphology 
3.3.1 Cell Culturing 
To visualize changes in cell morphology upon acquisition of fulvestrant resistance the cells were seeded 
in SlideFlask Chambers (Nunc) with cell densities ranging from 1.3-1.6×105 cells/flask. The cells were 
seeded in 3 mL standard growth media and allowed to grow for 5 days prior to staining. The standard 
growth medium was renewed twice during the growth period. 
3.3.2 Fixation, Hematoxylin and Eosin Staining and Phase Contrast Microscopy 
Cells grown in SlideFlask Champers for 5 days were washed in Dulbecco’s Phosphate-Buffer Saline 
(DPBS) (Gibco, Invitrogen) and fixed with 4% formaldehyde (VWR, Leuven, Belgium) (20 min, room 
temperature (RT)). The cells were subsequently permeabilized for 10 min with 0.5% triton X-100 (Sigma-
Aldrich) in Tris-Buffered Saline (TBS) consisting of 5 mM Tris-HCL (Applichem, Darmstadt, Germany), 27 
mM potassium chloride (Merck), and 138 mM sodium chloride (J.T. Baker, Deventer, The Netherlands). 
This was followed by a wash in TBS, rinsing in running tap water (5 min) and subsequently nuclei staining 
by Hematoxylin (Tissue-Tek, Sakura Fenetek, Alphen ann den Rijn, The Netherlands) for 5 min. The cells 
were then rinsed in running tap water (5 min) and for cytoplasmic staining the cells were dyed (2 min) 
with 0,2% Eosin solution (Tissue-Tek). The slides were subsequently dipped 2 times 10 in 70% EtOH and 
immersed in water until the surface did not repel water. The slides were mounted in ready-to use 
Faramount Aqueous Mounting medium (Dako) and covered by coverslips (VWR). 
The cells were visualized by phase contrast microscopy at a 40x magnification using an Olympus IX71 
(Olympus, Tokyo, Japan), data was photographed using an Olympus DP72 camera (Olympus) and CellP 
software (Olympus). 
3.4 Functional Kinase Inhibitor Screen 
To identify kinases driving growth of anti-estrogen resistance T47D cell lines (TR-1, TR-2, 182R-1 and 
182R-2) the Selleck Chemicals Kinase Inhibitor Screening Library (96-well) (Selleck Chemicals) was 
applied to the parental cell lines (T47D and T47D/S2) as well as the resistant cell lines. The 195 kinase 
inhibitors were purchased pre-dissolved in DMSO at a concentration of 10 mM and prior screening; all 
inhibitors were diluted to 1 mM. The kinase inhibitors are listed in Appendix IV and screen setup is 
illustrated in Appendix V . 
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3.4.1 Cell Culturing and Treatment 
2000 cells/well were seeded in 100 μL of their standard growth medium in 96-well white plates (nunc). 
The cells were allowed to adhere for two days before additional 100 μL experimental medium 
containing the kinase inhibitors was added resulting in a final concentration of 1 µM for each of the 
kinase inhibitors. The samples treated with inhibitors were distributed over three 96-plates for each cell 
line and all plates contained 6-10 internal control samples treated with vehicle (0.1% DMSO). On day 3 
of the treatment, 100 μL experimental medium was renewed.  
3.4.2 Cell Viability Assay 
Following 5 days of treatment with the kinase inhibitors, cell number was measured utilizing CellTiter-
Glo® Reagent (CTGR) (Promega Corporation, Madison, WI, USA). 100 μL experimental medium was 
removed and replaced by 50 μL CTGR and the signal was allowed to settle for 10 min. CTGR is a 1:1 
blend of CellTiter-Glo® Buffer (Promega) and lyophilized CellTiter-Glo® substrate (Promega). Ultra-GloTM 
Recombinant Luciferase present in the CTGR catalyzes the mono-oxygenation of Beetle luciferin to 
oxyluciferin in the presence of magnesium and adenosintriphosphate (ATP). CTGR also induce cell lysis 
and the luminescent end product oxyluciferin can thus be recorded by a luminometer. The cell number 
can be deduced, since the amount of ATP generated by the cells is proportional to cell number when 
investigating up to 50,000 cells/well (Promega, 2011). The luminescent signal was measured on a 
Varioskan Flash platereader (Thermo Electron Coorporation, Waltham, MA, USA). The growth inhibitory 
effect of the individual kinase inhibitors was calculated relative to the internal control samples on each 
plate, followed by a calculation of the fold change relative to the growth of the parental cell line. 
3.5 Cell Growth Assays 
To verify the results from the kinase inhibitor screens, dose-response growth assays were performed 
followed by a crystal violet colometric assay to determine cell number. In the dose-response growth 
experiments a reduction in cell number following treatment could be due to both cell death, cell cycle 
arrest and inhibition of cell growth. 
3.5.1 Cell Culturing and Treatment 
Growth experiments were performed in 96-well plates (Nunc). Cells were seeded at densities between 
2000-2500 cells per well in 100 µL of their standard growth medium. The cell lines differed in plating 
efficiency and growth characteristics and the seeding densities were therefore adjusted to obtain similar 
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cell densities at the time of treatment, aiming at a maximum of 80% confluence in the control culture at 
the end of the experiment. Cells were allowed to plate for 2 days before 100 μL experimental medium 
was added to each well. All growth assays included control samples treated with vehicle (0.1% DMSO). 
After 3 days of treatment, 100 μL experimental medium was renewed and following 5 days of 
treatment, the cells were stained with crystal violet (see below). Compounds applied for treatment in 
growth assays are listed in Table 2. 
Table 2 - Cell lines, compound and concentrations utilized in varies growth assays. All growth assays included 
control samples treated with vehicle (0.1% DMSO) and all compounds were purchased from Selleck and diluted in 
dimethyl sulfoxide (DMSO) (w/v) (Sigma-Aldrich). 
Compound Cell lines Concentrations 
AZD7762 T47D, 182
R
-1, 182
R
-2 0.25, 0.5 or 1.0 µM 
Barasertib T47D, 182
R
-1, 182
R
-2 
0.25, 0.5 or 1.0 µM 
5, 10, 15, 20, 25, 30, 35, 40 or 50 nM 
Barasertib T47D/S2, TR-1, TR-2 5, 10, 25 or 50 nM 
Barasertib 
MCF-7/S0.5, MCF-7/S0.5/182R-6, MCF-
7/S0.5/164R-7 
5, 10, 25 or 50 nM 
JNJ-7706621 T47D, 182
R
-1, 182
R
-2 0.5, 1.0 or 1.5 µM 
JNJ-7706621 T47D/S2, TR-1, TR-2 0.5, 1.0 or 1.5 µM 
KX2-391 T47D, 182
R
-1, 182
R
-2 10, 25, 50, 75 or 100 nM 
Nintedanib T47D, 182
R
-1, 182
R
-2 0.5, 1.0 or 1.5 µM 
PF-562271 T47D, 182
R
-1, 182
R
-2 0.25, 0.5 or 1.0 µM 
TG100-115 T47D, 182
R
-1, 182
R
-2 0.25, 0.5 or 1.0 µM 
3.5.2 Crystal Violet Colorimetric Assay 
Following 5 days of treatment a crystal violet colometric assay were performed. Crystal violet is a 
cationic dye which binds DNA and negatively charged proteins. In this thesis, it was used in a 
colorimetric assay based on a linear correlation between staining intensity and cell number (Bonnekoh 
et al, 1989). The crystal violet staining could thereby be used as a measurement of the number of 
remaining living cells after treatment. The reduction of cell number can be due to inhibition of cell 
growth, cell cycle arrest as well as cell death.  
The growth medium was gently removed by pipetting and the cells were stained with 100 μL 0.5% 
crystal violet solution (w/v) (Sigma-Aldrich) (10 min, RT). Excess dye was gently removed and the plate 
was rinsed twice in tap water. The wells were allowed to dry completely before the crystal violet was 
dissolved in 125 μL citrate buffer/well with shaking (30 min, RT). The citrate buffer was made of 0.1 M 
sodium citrate-dihydrate (Sigma-Aldrich) in solution with 50% EtOH. The color density was measured 
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spectrophotometrically at 570 nm on a Multiscan Ex Platereader (Thermo Electron Coorporation, 
Waltham, MA, USA) giving optical density (OD) values. Cell growth was expressed as percent of growth 
compared to vehicle (0.1% DMSO) treated control and statistical analyses were performed on all results 
as described in section 3.10. 
3.6 Western Analysis 
Western blot analysis is a semiquantitative method to determine the protein content in cell lysates. 
Proteins can be separated on a gel according to molecular weight utilizing SDS-PAGE and transferred to 
a membrane from which immunological tests can be performed to detect individual proteins. 
3.6.1 Cell Culturing, Treatment, and Harvesting 
The cells were seeded in 6-well plates (Nunc) at varies densities aiming at a confluence of maximum 80% 
at the end of the experiment. Control cells and cells treated for 4 and 24 hours were seeded in densities 
ranging from 1.2-1.7×105 cells/well and cells treated for 96 hours were seeded at densities ranging from 
2.0-2.6×105 cells/well. The cells were cultured in their standard growth medium, which were renewed 
on day 3 and 5 days. Prior to harvest, the cells were treated for 96, 24 or 4 hours with 50 nM barasertib 
and control samples were treated with vehicle (0.1 % DMSO). After treatment, the cells were washed 
with DPBS and lysed in 45-100 μL radioimmunoprecipitation buffer (RIPA buffer) on ice (10 min). The 
volume of RIPA buffer was adjusted according to the confluence of the cells. RIPA buffer contained 100 
mM sodium chloride (J.T. Baker), 20 mM Tris-HCL (pH 8.0) (Applichem) 1% (v/v) Triton X-100 (Sigma-
Aldrich), 0.5% (w/v) sodium dodecyl sulphate (SDS) (Sigma-Aldrich) and 1 mM (w/v) ethylene diamine 
tetraacetic acid (EDTA) (Merck, Darmstadt, Germany). Prior to use, the RIPA buffer was supplemented 
with 1 nM dithiothreitol (DTT) (Sigma-Aldrich), 1 mM sodium fluoride (Sigma-Aldrich), 100 μM sodium 
orthovanadate (Sigma-Aldrich), 150 μM phenylmethylsulphonyl fluoride (PMSF) (Sigma-Aldrich) and 1 
pill/10 mL Complete Mini Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA). Cell lysates were 
transferred to eppendorf tubes (Almeco cm-lab A/S, Esbjerg, Denmark), centrifuged (30 min, 15,000 g, 4 
°C) and supernatants were collected. During protein measurement and sample preparation lysates were 
kept on ice.   
3.6.2 Measurement of Protein Concentration in Cell Lysates 
The lysates were diluted 1:10 or 1:20 depending on protein quantity and total protein concentrations 
were determined using a Bio-Rad Protein Assay (Bio-Rad Laboratories, Munich, Germany) according to 
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the manufacturer's instructions. The assay utilizes the principle of the Bradford protein assay to 
measure the concentration of soluble proteins by addition of the dye coomassie brilliant blue, which 
binds to aromatic amino acid residues of the proteins. This results in a shift in the absorbance from 465 
nm to 595 nm and the protein concentration can thereby be determined spectrophotometrically at 595 
nm (Compton and Jones, 1985). For each experiment protein standards (25, 50, 100, 200, 300, 400, 800 
μg/mL Bovine Serum Albumin, purity ≥ 96%) (Sigma Aldrich) were measured and a standard curve was 
made to determine the protein concentrations of the lysates. 
3.6.3 Sample Preparation 
Samples were prepared with cell lysate equivalent to 20-40 μg total protein depending on the 
experiment. All samples were adjusted to the same volume with RIPA buffer and XT sample buffer (Bio-
Rad Laboratories) corresponding to one third of the total sample volume was added. The samples were 
either used at once or stored (overnight (ON), -80 °C). 
3.6.4 SDS-PAGE 
Samples were heated (2 min, 96 °C), spun down and loaded on a 3-8% Criterion™ XT Tris-acetate precast 
polyacrylamide gel (Bio-Rad Laboratories) together with the molecular weight protein markers; 
HiMark™ Pre-stained HMW Protein Standard (Invitrogen) and PageRuler™ Unstained Protein Ladder 
(Fermentas Life Sciences, Burlington, Canada). To separate the proteins by their molecular weight the 
gel was run at 150 volt (60 min) in XT BioRad tricine running buffer (Bio-Rad Laboratories) diluted 1:20 in 
milli-Q water.  
3.6.5 Wet Electroblotting 
Proteins separated on the 3-8% gel were transferred onto a polyvinylidene fluoride Immunobilon-P 
membrane (Millipore, Bedford, MA, USA) using wet electroblotting. Prior to use the membrane was 
soaked in 96% EtOH (2 min) and equilibrated in transfer buffer. The transfer buffer contained 15.2 g/L 
tris-base (VWR), 72 g/L glycine (Merck), and 20% EtOH. Criterion™ Blotter Filter Paper (Bio-Rad 
Laboratories) was used for transfer. While soaking in wet transfer buffer, the transfer stack was 
arranged in the following order from cathode to anode: sponge, filter paper, gel, membrane, filter 
paper, sponge. Wet blotting was performed in cold transfer buffer at 30 volt (60 minutes). Following 
transfer, the membrane were dyed in 0.1% (w/v) Ponceau S solution (Sigma-Aldrich) (15 min), 
decolorized 2 times 5 min in 5% (v/v) acetic acid solution (Sigma-Aldrich) and left to dry. 
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3.6.6 Antigen Detection 
The membrane was activated in 96% EtOH (10 sec) and washed twice in TBS for 10 min at RT. 
Subsequently unspecific binding was blocked in blocking buffer (2-3 hours, RT). Blocking buffer consisted 
of 5% (w/v) non-fat dried milk (Irma), 5% FBS and 0.2% (v/v) Tween 20 (Merck) in TBS. Hereafter, the 
membrane was incubated with primary antibody diluted in blocking buffer on a shaking table (ON, 4 °C). 
Table 3 lists detailed antibody information.  
Table 3 - Primary Antibodies used for Western Analysis. Antibodies utilized for western analysis listed in 
alphabetical order. Molecular weight (MW). 
Antigen MW (kDa) Antibody Dilution Source Catalog # 
Aurora A 48 Monoclonal, rabbit IgG 1:1000 CST
a 
4718P 
Aurora B 40 Monoclonal, rabbit IgG 1:1000 CST
a 
3094P 
p
 Thr288
-Aurora A/  
p
 Thr232
-Aurora B/ 
p
 Thr198
-Aurora C 
48/ 
40/ 
35 
Monoclonal, rabbit IgG 1:1000 CST
a 
2914P 
p
 Tyr416
-c-Src 60 Polyclonal, rabbit 1:1000 CST
a 
2101 
c-Src 60 Monoclonal, rabbit IgG 1:1000 CST
a 
2109 
Hsp70 70 Monoclonal, mouse 1:500,000 Neomarkers
b 
MS-482-PO 
PARP 116+85 Monoclonal,  mouse IgG1 1:1400 BD Bioscience
c 
511024 
aCell Signaling Technology, Danvers, MA, USA, bNeomarkers, Fremont, CA, USA and cBD Biosciences, San Jose, CA, USA. 
Following incubation, the membrane was washed four times 15 min at RT with 0.1% Tween 20 in TBS 
(TBS-tween), and incubated with horse radish peroxidase (HRP) conjugated secondary antibody diluted 
in blocking buffer (1 hour, RT). Washing was performed five times 10 min at RT with TBS-tween. The 
secondary antibodies used were polyclonal rabbit anti-mouse HRP linked immunoglobulins diluted 
1:2000 (Dako, Cat #P026, Glostrup, Denmark) and polyclonal goat anti-rabbit HRP linked 
immunoglobulins diluted 1:2000 (Dako, Cat #P0448). The investigated proteins were visualized by 
incubating the membranes in the chemiluminescent HRP substrate ECLPLUS (GE healthcare, Waukesha, 
WI, USA) (2 min, RT), followed by detection by the Image Reader LAS-1000 (Fuji Film, San Jose, CA, USA). 
Subsequently, signals were handled in Image Gauge V2.2 software (Fuji Film). If more than one protein 
had to be detected, the membrane was washed with TBS-tween and incubated with Re-blot Plus, Mild 
Stripping Solution (Millipore, Cat #: 2504) (10 min, RT) according to manufactures instructions. After 
stripping, the membrane was washed twice in blocking buffer for 5 min at RT followed by incubation of 
primary antibody (ON, 4 °C). The membrane was then treated as described from the top of this section.  
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3.7 Transient Knockdown utilizing Short Interference RNA 
To investigate the effect of the Aurora A and B proteins on growth, the proteins were knocked down 
utilizing small interfering RNAs (siRNAs). siRNA were transferred to the cells by nucleofection, which is a 
nonviral method to transfer substrates, such as siRNA, into mammalian cells. Nucleofection utilizes 
electroporation where an electric pulse generates areas of cell membrane break down by which siRNA 
can enter the cytoplasm and nucleus (Gresch et al, 2004). 
3.7.1 Nucleofection  
Single and double knockdown of Aurora A and B was performed with the parental T47D cell line and the 
fulvestrant resistant 182R-1 and 182R-2 cell lines. The cells were seeded in T75 flasks (nunc) at a density 
of 1.6×106 cells per flask and grown in their standard growth medium. Following 5 days of growth the 
cells were detached with 4 ml AccuMax solution (PAA Laboratories GmbH, Pasching, Austria) diluted 1:5 
in DPBS (10-15 min, 37 °C), and resuspended in 4 ml growth medium without anti-estrogen. Cell number 
was determined utilizing a Bürker-Türk chamber and cell suspensions equaling 1×106 cells were 
transferred to eppendorf tubes (Almeco cm-lab A/S), centrifuged (2 min, 200 g, RT) and supernatants 
were discarded. Pellets were resuspended in 100 μL Cell Line Nucleofector Solution V (Amaxa, Lonza, 
Cologne, Germany) and siRNAs were added. A pool of two different Aurora A-targeting siRNAs (Sigma-
Aldrich, cat. #SASI_Hs01_00076963 and #SASI_Hs01_00079241), one Aurora B siRNA (Sigma-Aldrich, 
SASI_Hs01_00076963) and scrambled sequence (non-targeting) control pool siRNA (ThermoFisher 
Scientific, cat. #D-001810-10-05) were used. Cells were transfected with 400 nM total siRNA in the single 
knockdown experiments, and with 200 Aurora A mix and 200 nM Aurora B siRNA in the experiments 
were both Aurora A and B where knocked down. The cells were transferred to an electroporation 
cuvette (Sigma-Aldrich) and nucleofected on the Nucleofector II Device (Amaxa) according to the 
manufacturer’s instructions. Following nucleofection, the cuvette was flushed in growth medium 
without anti-estrogen and the solution was transferred to 3.5 mL growth medium without anti-estrogen 
in a 13 mL tube (SARSTEDT, Nümbrecht, Germany).  
Transfected cells were seeded in 6- and 96-well plates (nunc) to measure protein expression and cell 
growth, respectively. Medium was replaced at day 1 with the cell line specific standard growth medium. 
Three days after transfection, cells grown in 6-well plates were harvested in RIPA buffer and subjected 
to western analysis, as described in paragraph 3.6, to investigate the protein expression of Aurora A and 
B. Cells grown in 96-well plates were stained with crystal violet on day 7, as described in section 3.5.2, to 
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deduce cell number. Cell growth was expressed as percent of growth relative to cells transfected with 
scramble siRNA (control).  
3.8 Fluorescence Imaging  
3.8.1 Cell Culturing and Treatment 
To investigate the impact of the Aurora B kinase inhibitor barasertib on chromosome segregation the 
cells were seeded in SlideFlask Chambers (Nunc) in cell densities ranging from 0.9-1.3×105 cells/flask. 
The cells were seeded in 3 mL standard growth medium and allowed to grow for 5 days prior to 
treatment with vehicle (0.1% DMSO) or 50 nM Barasertib for 42 hours. The standard growth medium 
was renewed twice during the growth period. 
3.8.2 Fixation, Permeabilization, Hoechst Staining and Mounting 
Cells grown in SlideFlask Champers for 7 days were washed in DPBS and fixed with 4% formaldehyde 
(VWR) (10 min, RT). The cells were then washed twice in DPBS, permeabilized with 0.2% trixon X-100 
(Sigma-Aldrich) in DPBS (2 min) and washed twice in DPBS for 5 min. Subsequently, the cells were 
stained with Hoechst 33342 (gift from Elisabeth Corcelle-Termeau) 1:40,000 diluted in DPBS (3 min) 
followed by two washes in DPBS. Hoechst is a nucleic acid stain emitting a blue fluorescence when 
bound to double stranded DNA, wich can be detected by fluorescence microscopy. Next, the slides were 
mounted using Fluorescence mounting medium (Dako) and covered by coverslips (VWR). 
3.8.3 Fluorescence Microscopy 
The fluorescence microscopy was carried out at a magnification of 40x on an Olympus IX71 (Olympus, 
Tokyo, Japan) and data was photographed using an Olympus DP72 camera (Olympus) and CellP software 
(Olympus). 
3.9 Flow Cytometric Analysis 
Flow cytometry can be used to measure and quantify cellular characteristics, organelles or structural 
components. In the flow cytometer the cell passes through a chamber as single cells while they are 
excited by the beam of at least one laser. The resulting light scatter and emitted fluorescent light can 
thereby be measured individually for each cell and the signal can be collected for analysis (Nunez, 
2001b).   
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3.9.1 Cell Cycle Analysis 
The distribution of the cells in the different cell cycle phases can be determined by measuring the 
amount of DNA in each cell. The DNA content of a cell duplicates during the S phase and measurements 
of the DNA contents in a cell can thereby determine its position in the cell cycle. The DNA can be stained 
by the nucleic acid dye propidium iodide (PI), and the DNA content for each individual cell can thus be 
measured by the flow cytometer (Nunez, 2001a). Cell cycle analysis can also be used to detect induction 
of cell death, since the DNA of dying cells is fractionated, allowing for these cells to be distinguished in a 
Sub-G1 phase (Kajstura et al, 2007). To investigate the cell cycle distribution of the cell lines upon 
treatment with barasertib the cells were seeded in 6-well plates (nunc). Cell densities were ranging from 
0.7-1.1×105 cells/well for control samples and samples treated for 24 and 48 hours, and 1.1-1.4×105 
cells/well for the samples treated for 72 and 96 hours. All samples were seeded in their standard growth 
medium and allowed to adhere and grow for at least 5 days prior to treatment. For each cell line a 
sample was treated with 50 nM barasertib for 24, 48, 72 and 96 hours and with vehicle (0.1% DMSO) for 
96 hours, prior to cell analysis. Following treatment the medium was transferred to tubes, and the cells 
were washed in 1 ml DPBS, which was collected together with the growth medium. To obtain single cells 
the cells were trypsinated by addition of 300 μL trypsin (Gibco, Invitrogen) (10 min, 37 °C), transferred to 
their respective tubes and spun down (5 min, 200 g). Pellets were resuspended in 1 ml ice cold EtOH to 
permeabilize the cells, and kept in -20 °C ON. The next day cells where spun down and pellet was 
resuspended in 400 μL DPBS containing 20 μg/ml PI (Sigma-Aldrich) and 40 μg/ml RNaseA (Roche) and 
incubated in the dark (30 min, RT). RNaseA was added to remove RNA from the cells and thereby 
prevent RNA staining and subsequent artifacts (Nunez, 2001a). Cell cycle distribution was analyzed on a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and the phase fractions were measured 
with CellQuest Pro software (BD Biosciences). The flourochrome components from PI were excited at 
536 nm and the emission along with the light scatter could thus be recorded at 517 nm. 10,000 cells 
were analyzed per sample. 
3.9.2 Cell Death Analysis by SYTOX Green Staining 
To determine if barasertib induced cell death, cells were seeded in 6-well plates (nunc) with 1.2-1.5×105 
cells/well for the control, and 2.5-3.0 for the barasertib and cisplatin treated samples in their standard 
growth medium. Cells were allowed to plate for two days prior to addition of experimental medium 
containing vehicle (0.1% DMSO) or 50 nM barasertib. 20 μM cisplatin (Sigma-Aldrich) was included as a 
positive control. The cells were photographed on day 2 by an Olympus DP72 camera (Olympus) using 
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CellP software (Olympus) and a Olympus IX71 (Olympus) microscope. After four days of treatment SYTOX 
green (Invitrogen) was added directly to the cell media in a 1:10,000 dilution and the cells were 
incubated in the dark (15 min, 37 °C). The SYTOX green nucleic acid stain (Invitrogen) penetrates and dye 
the membrane of comprised cells and excites flourochrome components at 504 nm, while cells with 
intact membranes will remain unstained (Yde et al, 2007). Dead cells were subsequently visualized by 
fluorescence microscopy, as described above for phase-contrast pictures on day 2. Cell medium were 
then transferred to tubes and kept on ice while the attached cells were washed with 1 ml DPBS, which 
was collected together with the cell medium. To detach and obtain single cells, 300 μL AccuMax (PAA 
Laboratories GmbH, Pasching, Austria) 1:5 dilution in DPBS was added (10-15 min, 37 °C). The detached 
cells were transferred to respective tubes and spun down (5 min, 200 g) and pellets were resuspended 
in 300 μL DPBS. The samples were analyzed on a FACSCalibur (BD Biosciences) flow cytometer, recording 
the emission at 523 nm. The stained cells were recorded with CellQuest Pro software (BD Biosciences) 
and 10,000 cells were analyzed per sample. 
3.10 Statistical Analysis 
Statistical analyses were performed on results from the cell growth assays in order to determine 
significant growth inhibition differences between parental and anti-estrogen resistant cell lines, upon 
treatment with a kinase inhibitor. Data is expressed as mean ± standard deviation (SD) as a percentage 
of vehicle (0.1% DMSO) treated controls ± SD. Hereafter, a two-tailed Student’s T-test was applied 
followed by Bonferroni’s correction.  
The inhibitory effect of each inhibitor in the kinase inhibitor screens was calculated by comparing 
growth of treated cells with the average growth of the vehicle (0.1% DMSO) treated control cells. One-
tailed Student’s T-test was performed on triplicate values comparing effect in parental and resistant cell 
lines. Fold changes were calculated by comparing mean inhibitory effects on resistant cell lines to the 
mean inhibitory effect on the parental cell line. A volcano plot was generated plotting -log10(p-value) 
against log2(fold change) visualizing the data generated.  
All statistics were performed using Excel (Microsoft, Seattle, CA, USA) and the level of statistical 
significance was set to p<0.05, indicated by one asterisks (*). 
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4 Results 
The aim of this thesis was to identify and explore the molecular mechanisms driving growth of newly 
established anti-estrogen resistant T47D breast cancer cell lines. Fulvestrant resistance was the main 
focus, but investigations utilizing tamoxifen resistant T47D cell lines, were also included. To identify 
kinases driving growth of anti-estrogen resistant T47D cell lines (TR-1, TR-2, 182R-1 and 182R-2), a kinase 
inhibitor library comprising 195 different kinase inhibitors was applied to the parental cell lines (T47D 
and T47D/S2) as well as the resistant cell lines. The screens identified several kinase inhibitors, which 
exhibited a preferential growth inhibition of the resistant cell lines, and some of these kinase inhibitors 
were selected for validation studies. One of the identified hits, the Aurora B inhibitor barasertib was 
chosen for more thorough investigations, with respect to effect on cell cycle distribution and cell death 
upon treatment with this inhibitor. The project also included a general characterization of morphology 
and doubling time of the fulvestrant resistant T47D cell lines. The results of these investigations will be 
described in the following paragraphs.  
4.1 Morphology of Fulvestrant Resistant T47D Cell Lines 
To elucidate the morphological changes upon acquiring resistance to fulvestrant, the parental T47D as 
well as the fulvestrant resistant 182R-1 and 182R-2 cells were stained with hematoxylin and eosin (HE). 
The experiment was performed twice, and representative images are shown in Figure 10. This illustrates 
that the resistant cells exhibit a larger volume and a more irregular cell shape (Figure 10B and C) when 
compared to parental T47D cells (Figure 10A). Especially the nuclei of the resistant cells are irregular and 
multinucleated cells are present. 
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Figure 10 - Hematoxylin and Eosin (HE) Stained Samples of Parental and Fulvestrant Resistant T47D Cell Lines. Cells 
were seeded in SlideFlask Champers and allowed to grow for 5 days. Subsequently the cells were fixed, permeabilized 
and stained with HE. The cells were investigated via an Olympus IX71 microscope and the experiment was repeated 
twice. A. T47D. B. 182R-1. C. 182R-2. Resistant cells showed multinucleation (arrow).  
4.2 Doubling Time and Plating Efficiency of Fulvestrant Resistant T47D Cell Lines 
To determine the doubling time of the parental and fulvestrant resistant T47D cells, a growth 
experiment was performed. Cell number was determined every 2-3 days as indicated in Figure 11. 
Doubling time was calculated from the exponential part of the growth curve (days 2-7) and was found to 
be 36 hours for the parental T47D cells and slightly increased to 38 and 39 hours for 182R-1 and 182R-2, 
respectively. Noteworthy, the cell number at day 1 for the resistant cells was lower than the number of 
cells seeded (day 0), demonstrating that the plating efficiency of the resistant cells was lower than the 
parental cells (Figure 11). 
 
Figure 11 - Doubling Time for T47D, 182R-1 and 182R-2. T47D and the fulvestrant resistant cell lines 182R-1 and 182R-2 
cells were seeded in 24-well dishes in their standard growth medium. Cell number at day 0 is the number of cells seeded. 
At each indicated time points (day 1-12), cells from 3 wells were counted in a Bürker-Türk chamber. The values are 
pooled data from two independent experiments and show the average cell number/well  SD as a function of time. 
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4.3 Kinase Inhibitor Screen with Fulvestrant Resistant T47D Cell Lines 
It has previously been shown that growth of fulvestrant resistant MCF-7-based cell lines switches from 
being driven by ER to be mediated by the HER receptors upon acquisition of fulvestrant resistance 
(Pancholi et al, 2008;Frogne et al, 2009a;Sonne-Hansen et al, 2010). We have shown that expression of 
the HER receptors also changes upon acquiring fulvestrant resistance in the T47D model system. 
However, the cell lines could not be preferentially growth inhibited by knockdown of HER2, which is 
overexpressed, or by inhibition of the HER receptor activity (Kirkegaard, unpublished data). Experiments 
confirming these findings can be seen in Appendix III , where expression of the HER receptors and 
downstream molecules as well as a growth experiment with the pan-HER inhibitor CI-1033 is presented.  
Several protein kinases have been suggested to play a crucial role in development of cancer and drug 
resistance (Witsch et al, 2010). There are over 520 different protein kinases, but especially molecules 
implicated in cellular growth and differentiation are of interest in connection with carcinogenesis 
(Blume-Jensen and Hunter, 2001). To identify kinases causally involved in fulvestrant resistance, the 
parental T47D cell line as well as the fulvestrant resistant cell lines (182R-1 and 182R-2) were exposed to 
a large kinase inhibitor screen, comprising 195 different kinase inhibitors. The kinase inhibitors are listed 
in Appendix IV and an illustration of the screen setup can seen in Appendix V . The screen was 
performed with triplicate samples and the cells were treated with 1 µM of the inhibitors. For statistical 
analysis Student’s T-test was applied.  
In the kinase screen, an inhibitor was designated as a hit if treatment entailed a twofold preferential 
growth inhibition of the fulvestrant resistant cells compared to the anti-estrogen sensitive parental cell 
line. In order to select hits, we calculated fold change in growth inhibition in resistant 182R-1 and 182R-2 
cells relative to growth inhibition of parental T47D cells (relative grow inhibition). Moreover, to ensure 
that the results were statistically significant, we selected inhibitors with a p-value below 0.05. Figure 12 
visualizes a volcano plot of the generated data. In the volcano plot, the y-axis gives the –log10 to the 
statistical significance of the relative growth inhibition of resistant 182R-1 and 182R-2 cells versus 
parental T47D cells. The x-axis gives log2 to the relative growth inhibition of the resistant 182R-1 and 
182R-2 cells versus parental T47D cells. In Figure 12, the blue box includes the hits of the kinase inhibitor 
screen, e.g. the kinases which exerted a more than twofold greater inhibition of the resistant cells 
compared to the parental T47D cells (p<0.05). 
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Figure 12 - Results from the Kinase Inhibitor Screen Visualized in a Volcano Plot. Data obtained from the kinase 
inhibitor screen plottet –log10(p-value) against log2(fold change) result in a volcano plot. The blue box includes the 
kinases (hits) which exerted a more than twofold greater inhibition of the fulvestrant resistant cells (182R-1 and 182R-2) 
compared to the parental T47D cells (p<0.05). The hits barasertib, dasatinib and JNJ-7706621 are indicated.  
In total, 16 hits were identified for 182R-1, while 23 inhibitors exhibited a preferential growth inhibition 
of 182R-2. 15 of these inhibitors were common hits in the two the fulvestrant resistant cell lines. The 
inhibition effect as well as the target(s) of the 15 inhibitors is listed in Table 1 and a histogram of the 
growth effect of each of the 15 inhibitors identified as common hits can be seen in Figure 13. All results 
from the kinase inhibitor screen can be found in Appendix VI . 
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Table 4 - Data for the Common Hits Identified in the Kinase Inhibitor Screen. Triplicate samples of parental T47D 
and fulvestrant resistant 182R-1 and 182R-2 cells were treated with 1.0 µM of the indicated kinase inhibitors for 5 
days. Cell number was determined by a cell viability assay. Inhibitory effect  standard deviation (SD) and targets 
of the kinase inhibitors are shown. Abbreviations: Abelson (Abl), Casein kinase (CK), checkpoint kinase (Chk), 
cyclin-dependent kinases (CDK), fibroblast growth factor receptor (FGFR), Fms-like Tyrosine Kinase (Flt), focal 
adhesion kinase (FAK), janus kinase (JAK), platelet-derived growth factor receptor (PDGFR), proline-rich tyrosine 
kinase (Pyk), Src Family kinases (SFKs), vascular endothelial growth factor receptor (VEGFR), and phosphoinositide 
3-kinase (PI3K).  
Inhibitor 
Inhibitory Effect ± SD (%) 
      T47D                      182
R
-1                     182
R
-2 
Target(s) 
Barasertib 28.2 ± 1.7 58.9 ± 2.2 59.9 ± 2.1 Aurora B 
PHA-680632 23.5 ± 7.4 62.8 ± 2.7 56.1 ± 5.0 Aurora A/B/C 
SNS-314 Mesylate 19.4 ± 1.5 47.0 ± 2.6 52.8 ± 5.1 Aurora A/B/C 
ZM-447439 24.2 ± 6.1 57.7 ± 1.8 65.6 ± 1.5 Aurora A/B/C 
CCT129202 20.1 ± 13.2 44.5 ± 4.8 48.8 ± 4.3 Aurora A/B/C 
AMG 900 25.3 ± 3.0 55.8 ± 4.5 55.5 ± 0.6 Aurora A/B/C 
JNJ-7706621 1.7 ± 5.7 27.5 ± 4.9 33.4 ± 4.8 
Aurora A/B, cyclin A/CDK2, 
cyclin E/CDK2, cyclin B/CDK1  
AT9283 6.2 ± 3.6 46.4 ± 2.5 52.6 ± 2.1 Aurora A/B, JAK2/3 and Abl 
ENMD-2076 24.3 ± 16.5 61.8 ± 2.8 65.7 ± 1.5 
Aurora A/B, Flt3/4, SFKs and 
VEGFR2 
AZD7762 8.6 ± 10.3 30.3 ± 1.1 33.8 ± 2.8 Chk1/2 
CX-4945 8.2 ± 2.1 27.9 ± 1.7 21.8 ± 1.7 CK2 
PF-562271 1.4 ± 4.5 19.0 ± 3.5 14.8 ± 2.5 FAK and Pyk2 
Nintedanib 11.8 ± 3.0 42.2 ± 3.5 33.9 ± 6.2 FGFR, VEGFR, PDGRF and SFKs 
Dasatinib 18.0 ± 3.5 47.1 ± 2.7 37.0 ± 3.4 SFKs, Abl and c-Kit 
TG100-115 5.0 ± 1.5 12.9 ± 2.3 13.2 ± 5.3 PI3Kγ/δ 
 
The majortity of the identified hits targeted proteins involved in cell cycle regulation (Aurora, CDK, 
Chk1/2 and CK2) and especially the Aurora proteins were targeted by the identified inhibitors. The rest 
of the hits targeted receptors (VEGFR, FGFR and PDGFR, c-Kit) or downstream signaling molecules (PI3K, 
SFKs, FAK, Abl, Pyk2), as depicted in   
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Table 4. The average growth inhibition for the inhibitors which only target the Aurora family was 
calculated to 23% for the parental T47D cell line and 54% and 56% for the resistant cell lines (182R-1 and 
182R-2). When the Aurora family was not targeted, the greatest growth inhibition was obtained with 
nintedanib and dasatinib, which both targets SFKs. Nintedanib and dasatinib inhibited growth of the 
parental T47D cell line with less than 18% and the resistant cell lines more than 33%. Noteworthy, JNJ-
7706621 and PF-562271 had no effect on growth of the parental T47D cells, but exerted a significant 
growth inhibition of the resistant cell lines, 33% and 15%, respectively. The hits JNJ-7706621, barasertib, 
AZD7762, dasatinib, nintedanib, PF-562271 and TG100-115 (indicated in bold in Figure 13) were selected 
for validation studies, and will be examined in paragraph 0.  
The majority of the investigated kinase inhibitors (110 out of 195) exerted a growth inhibition of 20% or 
less on the parental T47D at the chosen concentration (1 µM) and only 14, 23 and 14 of the 195 kinase 
inhibitors had standard deviations over 10% in the parental, 182R-1 and 182R-2, respectively. 
 
 
Figure 13 - Histogram for the Common Hits Identified in the Kinase Inhibitor Screen. Triplicate samples of parental 
T47D and fulvestrant resistant 182R-1 and 182R-2 cells were treated with vehicle (0.1% DMSO) or 1.0 µM of the indicated 
kinase inhibitors for 5 days. Cell number was determined by a cell viability assay. Mean cell numbers in percentage of 
vehicle treated control  SD are shown. Asterisks (*) indicate statistically significant difference from the parental T47D 
cell line when treated with the indicated inhibitor. Inhibitors in bold were subjected to further validation. 
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4.4 Kinase Inhibitor Screen with Tamoxifen Resistant T47D Cell Lines 
To identify kinases causally involved in tamoxifen resistance, the parental T47D/S2 cell line as well as the 
tamoxifen resistant cell lines (TR-1 and TR-2) were exposed to the kinase inhibitor screen, as described 
for the fulvestrant resistant T47D cell lines (paragraph 4.3). In the kinase screen an inhibitor was 
designated as a hit if treatment entailed a twofold preferential growth inhibition of the tamoxifen 
resistant cells (TR-1 and TR-2) compared to the parental cell line (T47D/S2). In order to select hits, we 
calculated fold change in growth inhibition in resistant TR-1 and TR-2 cells relative to growth inhibition 
of parental T47D/S2 cells. Figure 14 visualizes a volcano plot of the generated data. In Figure 14, the 
blue box includes the hits of the kinase inhibitor screen, e.g. the kinases which exerted a more than 
twofold greater inhibition of the resistant cells compared to the parental T47D/S2 cells (p<0.05). 
 
 
Figure 14 - Results from the Kinase Inhibitor Screen Visualized in a Volcano Plot. Data obtained from the kinase 
inhibitor screen plottet –log10(p-value) against log2(fold change) result in a volcano plot. The blue box includes the 
kinases (hits) which exerted a more than twofold greater inhibition of the tamoxifen resistant cells (TR-1 and TR-2) 
compared to the parental T47D/S2 cells (p<0.05). The hits dasatinib and JNJ-7706621 are indicated. 
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The hits from the upper right corner were identified; three of the inhibitors were common hits in both of 
the tamoxifen resistant cell lines, and three hits were only a hit in one of the cell lines. Table 5 outlines 
all of the identified hits as well as their target(s) and a histogram of the results for the identified hits can 
be seen in Figure 15. All results from the kinase inhibitor screen can be found in Appendix VII . 
Table 5 - Data for the Hits Identified in the Kinase Inhibitor Screen. Triplicate samples of parental T47D/S2 and 
tamoxifen resistant TR-1 and TR-2 cells were treated with 1.0 µM of the indicated kinase inhibitors for 5 days. Cell 
number was determined by a cell viability assay. Inhibitory effect  standard deviation (SD) and targets of the 
kinase inhibitors are shown. Inhibitors indicated in bold were common hits in both of the tamoxifen resistant cell 
lines. Abbreviations: Abelson (Abl), cyclin-dependent kinases (CDK), janus kinase (JAK), Src Family Kinases (SFKs), 
and phosphoinositide 3-kinase (PI3K). 
Inhibitor 
Inhibitory effect ± SD (%) 
      T47D/S2                      TR-1                           TR-2                
Target(s) 
JNJ-7706621 0.6 ± 1.7 20.2 ± 2.1 17.2 ± 2.7 
Aurora A/B, CDK2/cyclin A, 
CDK2/cyclin E, CDK1/cyclin B 
Dasatinib 23.3 ± 0.9 49.6 ± 1.7 51.5 ± 2.9 SFKs, Abl and c-Kit 
AZD5438 3.6 ± 4.9 14.5 ± 1.3 10.1 ± 1.4 CDK1/2/9 
DCC-2036 14.4 ± 7.5 38.1 ± 1.1 27.0 ± 14.2 SFKs and Bcr-Abl 
AZD1480 2.2 ± 3.9 7.7 ± 1.4 4.6 ± 1.6 Jak1/2 
TG100-115 0.9 ± 2.2 0.6 ± 0.2 8.7 ± 3.9 PI3Kγ/δ 
 
JNJ-7706621 and dasatinib were found to be common hits in both the fulvestrant and the tamoxifen 
resistant T47D cell lines (Figure 13 and Figure 15). In the tamoxifen resistant cell lines (TR-1 and TR-2), 
dasatinib exerted a growth inhibition of approximately 50%, while the parental cell line was inhibited by 
23%. The growth inhibition was slightly greater than in the fulvestrant resistant cell lines, where growth 
were inhibited by 37 and 47%, respectively. JNJ-7706621 did not inhibit growth of the parental T47D/S2 
cell line, but growth was inhibited by 17% and 20% in TR-1 and TR-2, respectively, compared to 
approximately 30% growth inhibition of fulvestrant resistant cell lines. Both of these inhibitors were 
selected for further validation.  
About half of the inhibitors (91 out of 195) exerted a growth inhibition of 20% or less on the parental 
T47D/S2 at the chosen concentration (1 µM) and only 14, 13 and 16 of the 195 kinase inhibitors had 
standard deviations over 10% in T47D/S2, TR-1 and TR-2, respectively. 
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Figure 15 - Histogram for the Hits Identified in the Kinase Inhibitor Screen. Triplicate samples of parental T47D/S2 and 
tamoxifen resistant TR-1 and TR-2 cells were treated with vehicle (0.1% DMSO) or 1.0 µM of the indicated kinase 
inhibitors for 5 days. Cell number was determined by a cell viability assay. Mean cell numbers in percentage of vehicle 
treated control  SD are shown. Asterisks (*) indicate statistically significant difference from the parental T47D/S2 cell 
line when treated with the indicated inhibitor. Inhibitors in bold were subjected to further validation. 
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4.5 Validation of Selected Hits 
Among the 15 inhibitors identified as common hits in the fulvestrant resistant cell lines, seven inhibitors 
(indicated in bold in Figure 13) were selected for validation studies. All validation studies were 
performed as dose-response growth experiments comparing growth of the parental T47D cell line with 
growth of 182R-1 and 182R-2. Two of the identified common hits in the tamoxifen resistant cell lines 
were also validated (indicated in bold in Figure 14). In these dose-response growth experiments growth 
of TR-1 and TR-2 were compared to growth of the parental T47D/S2 cell line.  
4.5.1 Validation of JNJ-7706621  
The pan-Aurora and CDK inhibitor JNJ-7706621 was a common hit in both the fulvestrant and tamoxifen 
resistant cell lines and was therefore validated in dose-response growth experiments, at concentrations 
from 0.5-1.5 µM. Three dose-response growth expreriments were conducted treating the fulvestrant 
resistant T47D cell lines and their parental T47D cells with JNJ-7706621. The results varied, one 
experiment showed no preferential inhibition between parental and fulvestrant resistant cells, one 
showed significantly greater inhibition at 0.5 and 1.0 µM, while the third experiment only resulted in a 
preferential inhibition at 1 µM. The third experiment is shown in Figure 16A. In the shown experiment 
the parental cell line was inhibited by 23% compared to untreated control and the fulvestrant resistant 
cell lines were growth inhibited by 34-42%. In contrast, treatment with JNJ-7706621 induced a 
preferential growth inhibition of the tamoxifen resistant cell compared to parental T47D/S2 at all 
investigated concentrations (Figure 16B). Growth of the parental T47D/S2 cells was inhibited by 
approximately 30% compared to untreated control, whereas growth of the tamoxifen resistant cell lines 
was inhibited by 45% at a concentration of 1 µM. These data did not confirm the finding in the kinase 
inhibitor screen, where treatment with JNJ-7706621 showed no growth inhibitory effect on parental cell 
lines. However, we could confirm a statistically greater growth inhibition of both fulvestrant and 
tamoxifen resistant cell lines compared to their parental cell lines, at a concentration of 1 µM. The 
growth inhibitory effects of JNJ-7706621 will not be investigated further in this project. 
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Figure 16 - Validation of JNJ-7706621. Cells were seeded in 96-weel plates and experimental medium containing vehicle 
(0.1 % DMSO) or JNJ-7706621 in the indicated concentrations was added on day 2 and renewed on day 5. Cell number 
was determined by a crystal violet colometric assay on day 7. Mean cell numbers in percentage of vehicle treated control 
 SD are shown. Asterisks (*) indicate statistically significant difference from the parental cell line at the investigated 
concentration (p<0.05). A. T47D, 182R-1 and 182R-2. The experiment was performed trice with 8 sample replicates, one 
experiment is shown. B. T47D/S2, TR-1 and TR-2. The experiment was performed twice with 8 sample replicates, 
representative experiment is shown. 
4.5.2 Validation of Barasertib 
In the kinase screen with the fulvestrant resistant cell lines, nine of the 15 identified kinase inhibitors 
targeted the Aurora proteins (Table 4). Eight of these kinase inhibitors were pan-Aurora inhibitors, 
whereas barasertib was the only inhibitor, which selectively targeted one of the Aurora proteins at the 
chosen concentration. Another Aurora B inhibitor, hesperadin, was also found to preferentially inhibit 
the resistant cell lines in the kinase inhibitor screen (Appendix VI ). Treatment with hesperadin growth 
inhibited the parental T47D cell line by 22%, while 182R-1 and 182R-2 were inhibited by 44 and 40%, 
respectively. Thus, hesperadin did not fulfill the criteria of a hit and was precluded as a common hit for 
the fulvestrant resistant cell lines. Aurora A inhibitor I, which selectively targets Aurora A at the chosen 
concentration, was also included in the kinase inhibitor screen (Appendix VI ). This inhibitor did not 
exhibit a preferential growth inhibition of the fulvestrant resistant cells compared to the parental T47D 
cells. Both T47D, 182R-1 and 182R-2 were growth inhibited by 42-49% when treated with 1 µM 
concentrations of Aurora A inhibitor I. Thus, since we found that selective targeting of the Aurora B 
kinase, but not Aurora A, induced a preferential growth inhibition of the fulvestrant resistant cell lines, 
the highly selective Aurora B inhibitor barasertib was chosen to be validated as a hit in a dose-response 
growth experiment (Figure 17A). A statistically significant growth inhibition was obtained with 
concentrations of barasertib from 0.25-1.0 μM for both of the fulvestrant resistant cell lines. However, 
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as also observed in the kinase screen, the parental T47D cell line was not unaffected. Noteworthy, 
maximal growth inhibition of the fulvestrant resistant cell lines was seen with the lowest tested 
concentration of 0.25 µM (Figure 17A). Therefore, a dose-response growth experiment was performed 
with lower concentrations of barasertib (10-50 nM) (Figure 17B). Figure 17B shows that maximal growth 
inhibition of fulvestrant resistant cell lines as well as the parental cell line was obtained with as low a 
concentration of barasertib as 10 nM. The maximal growth inhibition of parental cells were 30 %, while 
the parental cell were growth inhibited by 65%. Barasertib could thereby be validated as a hit and based 
on clinical relevance, novelty value, and mechanisms of its target Aurora B, barasertib was chosen as the 
primary kinase inhibitor for further investigation (see paragraph 4.7-4.13). 
 
Figure 17 - Validation of Barasertib. T47D, 182R-1 and 182R-2 were seeded in 96-well plates. Experimental medium 
containing vehicle (0.1 % DMSO) or barasertib in the indicated concentrations was added on day 2 and renewed on day 
5. Cell number was determined by a crystal violet colometric assay on day 7. The experiments were performed with 4 
sample replicates in A and 8 sample replikates in B. Mean cell numbers in percentage of vehicle treated control  SD are 
shown. Asterisks (*) indicate statistically significant difference from the parental T47D cell line at the investigated 
concentration (p<0.05).  
4.5.3 Validation of AZD7762 
To investigate whether other kinases involved in the cell cycle control system were important for growth 
of the fulvestrant resistant cell lines, the Chk1/2 inhibitor AZD7762 was chosen to be validated in a dose-
response growth experiment. Treatment with increasing concentrations (0.25-1 µM) of AZD7762 
exhibited a preferential growth inhibition of the resistant cell lines at a concentration of 1 µM. Growth 
of the parental T47D cells was inhibited by 20%, whereas growth of the resistant 182R-1 was inhibited by 
30% and 182R-2 by 55%, compared to the untreated control (Figure 18). Compared to growth of the 
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parental T47D cell line, only 182R-2 cells displayed a statistical significantly greater growth inhibition 
when treated with 1 µM AZD7762 (Figure 18). The Chk1/2 inhibitor AZD7762, will not be investigated 
further in this project. 
 
Figure 18 - Validation of AZD7762. T47D, 182R-1 and 182R-2 cells were seeded in 96-well plates. Experimental medium 
containing vehicle (0.1 % DMSO) or AZD7762 in the indicated concentrations was added on day 2 and renewed on day 5. 
Cell number was determined by a crystal violet colometric assay on day 7. Mean cell numbers in percentage of vehicle 
treated control  SD are shown. The experiment was performed with quadruplicate samples and asterisks (*) indicate 
statistically significant difference from the parental T47D cell line at the investigated concentration (p<0.05).  
4.5.4 Validation of Dasatinib, Nintedanib and PF-562271  
The SFK, Abl and c-Kit inhibitor dasatinib was identified as a common hit in both kinase inhibitor screens. 
Dasatinib was therefore chosen to be validated in dose-response growth experiments with both 
fulvestrant and tamoxifen resistant T47D cell lines. The experiments were performed by Tove Kirkegaard 
and the results can be found in Appendix VIII . The dose-response growth experiments showed that 
treatment with increasing concentrations of dasatinib (0.05-1.0 µM) in the fulvestrant resistant cell lines 
resulted in a 40% growth inhibition compared to untreated control. The parental T47D cell lines were 
only inhibited by 15%. Treatment with dasatinib in the tamoxifen resistant cell lines (0.05-1.0 µM) 
resulted in a 60% growth inhibition compared to untreated control. The inhibition of parental T47D/S2 
were slightly higher than for T47D, since this cell line were inhibited by 20% compared to untreated 
T47D/S2 cells. The experiments could thereby confirm that treatment with dasatinib resulted in a 
statistically significant greater growth inhibition of both fulvestrant and tamoxifen resistant cell lines 
compared to their parental cell lines. 
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Another SFK inhibitor, nintendanib, was also found to preferentially inhibit growth of the fulvestrant 
resistant cells in the screen. Nintedanib wich both inhibit RTKs (FGFR, VEGFR and PDGFR) and SFKs (Lck, 
Lyn and c-Src) was also validated in a dose-response growth experiment, which showed that treatment 
with (0.5-1.5 µM), resulted in a preferential growth inhibition of the fulvestrant resistant cell lines 
compared to the parental T47D cells (Figure 19A). Growth of resistant cell lines were reduced by 25-35% 
compared to the untreated control at a concentration of 1 µM nintedanib. In contrast, growth of the 
parental T47D cells was not affected. In the kinase screen none of the other inhibitors targeting VEGFR, 
FGFR or PDGFR were identified as a hit (except the multi targeting ENMD-2076), and treatment with 
some of the inhibitors actually increased the growth of the fulvestrant resistant cells compared to the 
untreated control, see Appendix VI . The average growth inhibition, when the cells were treated with a 
kinase inhibitor targeting VEGFR, FGFR or PDGFR, was calculated to 13-16% for all cell lines. 
 
Figure 19 - Validation of Nintedanib and PF-562271. T47D, 182R-1 and 182R-2 cells were seeded in 96-well plates. 
Experimental medium containing vehicle (0.1 % DMSO) or inhibitor in the indicated concentrations was added on day 2 
and renewed on day 5. Cell number was determined by a crystal violet colometric assay on day 7. Mean cell numbers in 
percentage of vehicle treated control  SD are shown. The experiments were performed with quadruplicate samples and 
asterisks (*) indicate statistically significant difference from the parental T47D cell line at the investigated concentration 
(p<0.05). A. Dose-response growth experiment with nintedanib. B. Dose-response growth experiment with PF-562271. 
The FAK and Pyk2 inhibitor PF-562271 were also identified as a hit in the kinase inhibitor screen with the 
fulvestrant resistant cells. FAK interact with c-Src in the regulation of cell motility, adhesion, and 
invasion (Guarino, 2010) and PF-562271 was therefore chosen to be validated as a hit. Treatment with 
increasing concentrations (0.25-1 µM) of the FAK and Pyk2 inhibitor PF-562271 resulted in a preferential 
growth inhibition of the resistant cell lines (Figure 19B). A concentration of 1 µM inhibited the resistant 
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cell lines by 20-30%, in contrast, there was no effect when the parental T47D cells were treated (Figure 
18A). Thus, compared to the parental T47D cells, treatment with PF-562271 resulted in a statistically 
significant growth inhibition of both 182R-1 and 182R-2 at 1 µM, the same concentration used in the 
kinase screen experiment. 
The kinase inhibitor screen included 11 inhibitors which targeted SFKs, see Appendix VI . The average 
growth inhibition, when the cells were treated with a kinase inhibitor targeting this kinase family, was 
calculated to be 17% for the parental T47D cells and 32% for the fulvestrant resistant cell lines. The 
results indicate that SFKs are important for growth of anti-estrogen resistant cell lines and additional 
investigations were therefore performed to further elucidate the involment the kinase family for 
acquiring resistance (see paragraph 0). 
4.5.5 Validation of TG100-115 
In the kinase screen experiment treatment with the PI3Kγ/δ inhibitor TG100-115 resulted in a 
preferential growth inhibition of the fulvestrant resistant cell lines compared to parental T47D cells. 
Previous experiments have shown that HER signaling trough the PI3K/Akt pathway is not important for 
growth of the fulvestrant resistant T47D cell lines (Kirkegaard, unpublished data). Thus, a dose-response 
growth experiment was performed to determine whether the inhibitor was a true hit and to verify that 
the PI3K/Akt pathway is not important for growth of the fulvestrant resistant T47D cell lines 
The preferential growth inhibitory effect of TG100-115 on fulvestrant resistant cell lines in the kinase 
screen experiment could not be confirmed in a dose-response growth experiment. Treatment with 
increasing concentrations of TG110-115 (0.25-1 µM) reduced growth of both the parental and the 
resistant cells with 10-15% compared to the untreated control (Figure 20). Thus, TG100-115 could not 
be validated as a true hit from the kinase inhibitor screen and will not be investigated further in this 
study. 
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Figure 20 - Validation of TG100-115. T47D, 182R-1 and 182R-2 cells were seeded in 96-well plates. Experimental medium 
containing vehicle (0.1 % DMSO) or TG100-115 in the indicated concentrations was added on day 2 and renewed on day 
5. Cell number was determined by a crystal violet colometric assay on day 7. Mean cell numbers in percentage of vehicle 
treated control  SD are shown. The experiment was performed with quadruplicate samples and asterisks (*) indicate 
statistically significant difference from the parental T47D cell line at the investigated concentration (p<0.05). 
 
Collectively, these dose-response growth experiments confirmed that JNJ-7706621 and dasatinib were 
true hits in both kinase inhibitor screens, while AZD7762, barasertib and nintedatib, but not TG100-115, 
were true hits from the kinase inhibitor screen with the fulvestrant resistant cell lines.  
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4.6 Protein Expression of c-Src and Dose-Response Growth Experiment with KX2-391 
To further investigate importance of SFKs for growth of anti-estrogen resistant cell lines, the fulvestrant 
resistant cell lines were treated with the highly selective SFK inhibitor KX2-391. In the kinase inhibitor 
screen, KX2-391 inhibited growth of the parental T47D cell line by 54% (see Appendix VI ). Since this 
level of inhibition precluded a twofold higher inhibition of the resistant cell lines, KX2-391 was not 
identified as a hit. However, treatment with the inhibitor still entailed a preferentially growth inhibition; 
182R-1 was inhibited by 91%, while 182R-2 was inhibited by 85%. To facilitate a reduced growth 
inhibition, a dose-response growth experiment with lower concentrations (10-100 nM) was performed. 
Unexpectedly, the lowest concentration of 10 nM was as efficient as 100 nM and 1 µM with respect to 
exerting about 60% growth inhibition of parental cells, compared to untreated control. However, growth 
of 182R-1 and 182R-2 was still significantly more inhibited when compared with the parental cell line 
grown at concentrations from 25-100 nM (Figure 21A).  
 
Figure 21 – Growth Effect of Treatment with the SFK Inhibitor KX2-391 and Expression of c-Src Detected by Western 
Analysis. A. Dose-response growth experiment with KX2-391. T47D, 182R-1 and 182R-2 were seeded in 96-well plates. 
Experimental medium containing vehicle (0.1 % DMSO) or KX2-391 in the indicated concentrations were added on day 2 
and renewed on day 5. Cell number was determined by a crystal violet colometric assay on day 7. Mean cell numbers in 
percentage of vehicle treated control  SD are shown. The experiment was performed with 4 sample replicates and 
asterisks (*) indicate statistically significant difference from the parental T47D cell line at the investigated concentration 
(p<0.05). B. Western blots showing total and phosphorylated (p) form of c-Src (Tyr416) in lysates from T47D, 182R-1 and 
182R-2 grown in standard growth medium. Cells were seeded in 6-well plates and medium was renewed on day 2 and 
day 5. Cells were harvested for western analysis on day 6. 40 µg total protein were loaded in each lane and heat shock 
protein 70 (Hsp70) was used as loading control. 
 
  
  RESULTS 
 
  59 
 
Since inhibition of SFKs preferentially affected growth of the anti-estrogen resistant cell lines, total and 
phosphorylated protein level of one of the SKFs, c-Src, were investigated utilizing western blot analysis. 
The level of total, as well as phosphorylated c-Src, was found to be increased in both 182R-1 and 182R-2. 
Increased levels of phosphorylated c-Src were also found for the tamoxifen resistant cell lines, compared 
to parental T47D/S2, in a western blot experiment performed by Tove Kirkegaard (Appendix VIII ). The 
role of c-Src in anti-estrogen resistant growth was not investigated further in this project. 
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4.7 Effect of Barasertib in other Anti-Estrogen Resistant Model Systems 
To investigate whether the selective Aurura B inhibitor barasertib could exhibit a preferential growth 
inhibition in other anti-estrogen resistant model systems, cell lines from the tamoxifen resistant T47D 
model system and the fulvestrant resistant MCF-7 model system were treated with the inhibitor in dose-
response growth experiments. 
4.7.1 Effect of Barasertib in Tamoxifen Resistant T47D Cell Lines 
Barasertib was not found to be a hit in the kinase inhibitor screen performed with the tamoxifen 
resistant T47D cell lines (Table 5). In the kinase screen, T47D/S2, TR-1 and TR-2 were all growth inhibited 
by 20-23% when treated with barasertib (Appendix VII ). To validate this result, a dose-response growth 
experiment was performed (Figure 22). Treatment with increasing concentrations of barasertib (5-50 
nM) growth inhibited the parental T47D/S2 by 30% compared to untreated control and a 40% growth 
inhibition was seen in tamoxifen resistant cell lines. The growth inhibitory effect of barasertib at 10 and 
25 nM for TR-1 and at 10 and 50 nM for TR-2 was significantly greater than the growth inhibition of the 
parental cell line.   
 
Figure 22 - Dose-response Growth Experiment with Barasertib in Tamoxifen Resistant Cell Lines. T47D/S2, TR-1 and TR-
2 were seeded in 96-well plates. Experimental medium containing vehicle (0.1 % DMSO) or barasertib in the indicated 
concentrations was added on day 2 and renewed on day 5. Cell number was determined by a crystal violet colometric 
assay on day 7. Mean cell numbers in percentage of vehicle treated control  SD are shown. The experiment was 
performed with 8 sample replicates and asterisks (*) indicate statistically significant difference from the parental 
T47D/S2 cell line at the investigated concentration (p<0.05). 
4.7.2 Effect of Barasertib in Fulvestrant Resistant MCF-7 Cell Lines  
To investigate the effect of barasertib in fulvestrant resistant cells derived from another breast cancer 
cell line, the MCF-7 cell line, dose-response growth experiments with the parental MCF-7/S0.5 and the 
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fulvestrant resistant MCF-7/S0.5/164R-7 and MCF-7/S0.5/182R-6 was performed. Parental MCF-7/S0.5 
and MCF-7/S0.5/182R-6 cells displayed a similar dose-dependent growth inhibition, whereas the MCF-
7/S0.5/164R-7 cell line was significantly less sensitive to treatment with 25 and 50 nM concentrations of 
barasertib (Figure 23). In agreement with these results, growth of MCF-7, MCF-7/S0.5/164R-7 and MCF-
7/S0.5/182R-6 were found to be inhibited by 57, 45 and 44%, respectively, when these cells were 
subjected to a kinase inhibitor screen preformed in our laboratory (Thrane, unpublished data).  
 
Figure 23 - Dose-response Growth Experiment with Barasertib in Fulvestrant Resistant MCF-7 Cell Lines. MCF-7/S0.5, 
MCF-7/S0.5/164R-7 and MCF-7/S0.5/182R-6 were seeded in 96-well plates. Experimental medium containing vehicle (0.1 
% DMSO) or barasertib in the indicated concentrations was added on day 2 and renewed on day 5. Cell number was 
determined by a crystal violet colometric assay on day 7.  Mean cell numbers in percentage of vehicle treated control  
SD are shown. The experiment was performed with 6 sample replicates and asterisks (*) indicate statistically significant 
difference from the parental MCF-7 cell line at the investigated concentration (p<0.05). 
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4.8 Protein Expression of Aurora Kinases   
The majority if the identified hits in the kinase inhibitor screen with the fulvestrant resistant cell lines 
targeted the Aurora family of protein kinases. Therefore, western blot analysis was performed to 
investigate the basal level of total and phosphorylated Aurora proteins. When measuring the protein 
expression of Aurora B in the untreated cells, comparable levels were detected (Figure 24A). In contrast, 
the phosphorylated forms of both Aurora A and B were increased in the fulvestrant resistant cell lines 
compared to the parental T47D cells. The selective Aurora B inhibitor barasertib was identified to induce 
a preferential growth inhibition of fulvestrant resistant cell lines compared to parental T47D cells (Figure 
17). To investigate the effect of barasertib on the protein expression of the Aurora family, T47D, 182R-1 
and 182R-2 cells were treated with 50 nM barasertib in increasing time periods (4-96 hours). Treatment 
with barasertib for 4 hours reduced the level of phosphorylated Aurora B, but had no effect on the level 
of phosphorylated Aurora A in both parental and resistant cell lines. Following 96 hours of barasertib 
treatment the expression of total Aurora B was reduced to nearby an undetectable level in all cell lines 
(Figure 24B).  
 
Figure 24 - Expression of Aurora Proteins Detected by Western Analysis. Western blots showing total and 
phosphorylated (p) form of Aurora B (Thr232) and phosphorylated form of Aurora A (Thr288) in lysates from T47D, 182R-1 
and 182R-2. Cells were seeded in 6-well multi dishes in their standard growth medium and allowed to plate for 2 days 
before treatment with vehicle (0.1% DMSO) or 50 nM barasertib for 4, 24 or 96  hours. Cells were harvested for western 
analysis on day 6. 40 µg total protein were loaded in each lane and heat shock protein 70 (Hsp70) was used as loading 
control. A. Basal protein expression. B. Protein expression upon treatment with barasertib. 
4.9 Growth Effect of Aurora A and B Knockdown by siRNA  
The above-shown increased level of phosphorylated Aurora A and Aurora B in fulvestrant resistant T47D 
cell lines and the preferential growth inhibition of the fulvestrant resistant cells when they were treated 
with the Aurora B specific kinase inhibitor barasertib, indicate that the Aurora proteins could be 
important for fulvestrant resistent T47D cell growth. To further elucidate the importance of the Aurora 
proteins for fulvestrant resistance, siRNA-mediated knockdown of the Aurora proteins was performed. 
Western blot analysis was conducted to measure knockdown efficiency and showed almost complete 
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knockdown of Aurora A in all cell lines (Figure 25A). In contrast, only a minor reduction in Aurora B 
protein expression was observed for the parental cell line and efficient knockdown of Aurora B was only 
detected in 182R-2 cells, at the investigated siRNA concentrations (Figure 25A). The reduced level of 
Aurora A protein entailed a 20% statistically significant preferential growth inhibition of both of the 
resistant cell lines, when compared to parental T47D cells (Figure 25B). Knockdown of Aurora B also 
entailed a statistically significant preferential growth inhibition (20%), but only for 182R-2 where the 
knockdown was efficient (Figure 25B). No statistically significant preferential growth inhibition was 
observed when the cells were nucleofected with a combination of Aurora A and B siRNA (Figure 25B).  
 
Figure 25 - Knockdown of the Aurora Proteins. T47D, 182R-1 and 182R-2 cells were nucleofected with 400 nM scramble 
siRNA (control), Aurora B siRNA or Aurora A siRNA. Double knockdown was performed with 200 nM of each of the 
Aurora siRNAs. A. Western blot analysis to determine the efficiency of siRNA-mediated knockdown of Aurora proteins. 
Following nucleofection the cells were seeded in 6-well plates and harvested in RIPA on day 3. 33 µg total protein were 
loaded in each lane for Western analysis and heat shock protein 70 (Hsp70) was used as loading control. B. Growth 
experiment with nucleofected T47D cell lines. Following nucleofection, the cells were seeded in 96-well plates in 
standard growth medium without anti-estrogens. Cell number was determined by a crystal violet colometric assay on 
day 7. Mean cell numbers in percentage of scrample siRNA transfected control  SD are shown. The experiment was 
performed with 8 sample replicates and asterisks (*) indicate statistically significant difference from the parental T47D 
cell line transfected with the indicated siRNA (p<0.05). 
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4.10 Cell Cycle Distribution in Barasertib Treated T47D Cell Lines 
Aurora B is important for correct cell cycle progression and plays a key role in the maintenance of 
normal ploidy during cell division (Carmena and Earnshaw, 2003). Cell cycle analysis was therefore 
performed to investigate the effect of treatment with the Aurora B targeting kinase inhibitor barasertib 
on cell cycle distribution of T47D, 182R-1 and 182R-2. The cells were treated with vehicle (0.1% DMSO) or 
barasertib (50 nM) for 24, 48, 72 or 96 hours prior to addition of the nucleic acid dye propidium iodide 
(PI). Thus, flow cytometry was used to measure the DNA contents, and thereby determine the 
distribution of cells in the different cell cycle phases. A graphic presentation of cell cycle phase 
distribution following treatment with barasertib is shown in Figure 26A, where the cell cycle phases are 
indicated. Figure 26B shows a quantification of the phase fractions seen in Figure 26A i.e. the 
percentage of the cells in each cell cycle phase. Treatment with barasertib introduced a shift in cell cycle 
distribution for all investigated cell lines (Figure 26A). For the parental T47D cell line, 15% of the cells 
were in G2/M phase in the untreated control, while 77% were in G1 (Figure 26B). 24 hours of treatment 
with 50 nM barasertib increased the fraction of cells in G2/M phase to 65%. Upon 48 hours of treatment, 
74% of the cells where in G2/M phase, while only 17% were in G1. The percentage of G1 phase cells 
continued to decrease in cells treated for 72 and 96 hours. Following 96 hours of treatment, cell cycle 
analysis revealed a decrease in G2/M phase cells, while a concurrent increase in cells with DNA content 
above 4N was detected (Figure 26B). For the fulvestrant resistant cell lines, the same shift in cell cycle 
phase distribution was observed following 24 and 48 hours of treatment. However, prolonged treatment 
did not result in further accumulation in G2/M nor in formation of polyploid cells. Treatment with 
barasertib did not entail a change in the fraction of cells in Sub-G1 for the parental call lines. In contrast, 
an increase from approximately 3% in untreated control to 17% in cells treated for 96 hours was 
observed for both of the resistant cell lines.  
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Figure 26 - Cell Cycle Phase Distribution Following Barasertib Treatment. Cells were seeded in 6-well plates in their 
standard growth medium and allowed to plate for 2 days before treatment with vehicle (0.1% DMSO) or barasertib (50 
nM) for 24, 48, 72 or 96  hours. Cells were harvested for cell cycle analysis and stained with propidium iodide on day 6. 
A. Cell cycle analysis by flow cytometry of T47D, 182R-1 and 182R-2 cells treated as described above. The histograms 
depict the cell cycle phase distribution in the following phases: G1 phase (the first peak), S phase (area between the two 
first peaks), G2/M phase (second peak), SubG1 (area before first peak) and polyploid cells (area after second peak).  
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B. Histogram showing percent distribution of cells in G2/M, S, G1 and SubG1 as well as cells with DNA content above 4N. 
The histograms are based on data in A and duration of barasertib treatment is indicated. Two individual experiments 
were performed and representative results are shown. 
4.11 Cell Division in Barasertib Treated T47D Cell Lines 
Since treatment with barasertib induced polyploid cells, cell nuclei were stained with Hoechst to 
investigate whether treatment with the inhibitor had an impact on chromosome segregation and cell 
division. Control samples of both parental and resistant cells treated with vehicle (0.1% DMSO) were 
able to enter mitosis and successfully undergo cytokinesis (Figure 27). In the barasertib treated samples, 
only few dividing cells could be observed, especially in the resistant cell lines. T47D cells treated with 
barasertib were unable to correctly align the chromosomes on the mitotic metaphase plane and proper 
division of sister chromatids in anaphase also seemed to be affected. Dividing 182R-1 consistently 
aligned the chromosomes in a shape of a Y, while the chromosome alignment of 182R-2 was shaped like 
an S. No divisions of sister chromatids were observed in either of the resistant cell lines. An estimated 
two third of the 182R-1 cells seemed to be affected by treatment, resulting in multinucleated cells and 
cells with micronuclei. 182R-2 cells were also strongly affected, however to a little less extent. A small 
fraction of necrotic cells were observed in all cell lines (not shown). 
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Figure 27 - Visualisation of Cell Nuclei after Treatment with Barasertib. T47D, 182R-1 and 182R-2 were seeded in 
SlideFlask Champers and allowed to grow for 5 days prior to treatment with vehicle (0.1% DMSO) or 50 nM barasertib for 
42 hours. Subsequently the cells were fixed, permeabilized and stained with Hoechst. The cells were investigated via an 
Olympus IX71 microscope at a magnification of 40x and the experiment was repeated twice.  
4.12 Morphological Changes in Barasertib Treated T47D Cell Lines 
To determine if treatment with barasertib induced morphological changes, T47D, 182R-1 and 182R-2 cells 
were studied under a microscope. Visual inspections of the cells following 48 hours of barasertib 
treatment revealed that both the parental and resistant cells increased in size, however, substantial 
morphological differences between the parental and fulvestrant resistant cell were observed. Following 
48 hours of treatment the parental T47D cells remained firmly attached to the surface. In contrast, the 
resistant cells began to detach and especially 182R-2 emitted spikes (Figure 28). Treating T47D, 182R-1 
and 182R-2 with a concentration of 10 nM barasertib in a period of 1 month resulted in increased 
surface detachment and severe cell death in all cell lines. While only few of the resistant cells survived, 
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the parental cells were approximately 50% confluent, however, exhibited clear morphological changes 
compared to untreated cells (data not shown).  
 
Figure 28 - Cell Pictures after Treatment with Barasertib. T47D, 182R-1 and 182R-2 were seeded in 6-well plates for 2 
days prior to treatment with vehicle (0.1% DMSO) or 50 nM Barasertib for 48 hours. Pictures were taken with an 
Olympus IX71 microscope at a magnification of 40x. 
4.13 Cell Death in Barasertib Treated T47D Cell Lines 
Visual inspection and an increased proportion of cells in SubG1 cell cycle analysis indicated increased 
induction of cell death upon treatment with barasertib, especially in the resistant cell lines.  
4.13.1 Cell Death Detected by PARP Cleavage 
To examine whether apoptosis takes place in response to treatment with barasertib, the apoptotic 
indicator PARP cleavage was studied by western blot analysis. The cells were treated with barasertib (50 
nM) for 4, 24 or 96 hours. The experiment showed presence of cleaved PARP (85 kDa) in the resistant 
cells following 96 hours of treatment. The parental T47D cells only expressed full length PARP (116 kDa) 
(Figure 29).  
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Figure 29 - Western Analysis of PARP Cleavage after Barasertib Treatment. Western blots showing total and cleaved 
form of PARP in lysates from T47D, 182R-1 and 182R-2. Cells were seeded in 6-well plates in their standard growth 
medium and allowed to plate for 2 days before treatment with vehicle (0.1% DMSO) or 50 nM barasertib for 4, 24 or 96  
hours. Cells were harvested for western analysis on day 6. 40 µg total protein were loaded in each lane and heat shock 
protein 70 (Hsp70) was used as loading control and. The experiment was performed twice and a representative result is 
shown. 
4.13.2 Cell Death Detected by SYTOX Green Staining 
To further examine the induction of cell death in T47D, 182R-1 and 182R-2 upon treatment with 
barasertib, a SYTOX green assay was performed. SYTOX green is able to penetrate disrupted cell 
membrane and thereby detect dead cells. The cells were treated with vehicle (0.1% DMSO) or 50 nM 
barasertib for four days. Cisplatin was used as a positive control. Prior to harvest, SYTOX green was 
added to the medium and the number of SYTOX positive cells (dead cells) could thereby be measured by 
flow cytometry. A graphic presentation is shown in Figure 30 where bold numbers indicate the 
percentage of dead cells in each sample. The percentage of dead cells in the untreated control samples 
were higher for both of the resistant cell lines compared to the parental cell line. Less than 5% of 
parental T47D cells were dead while 9.82 and 15.85% of the 182R-1 and 182R-2 cells were dead, 
respectively.  Treatment with barasertib clearly induced more cell death in the fulvestrant resistant cell 
lines when compared to T47D. A small increase from 4.75 to 9.61% dead cells was detected in the 
parental cell line upon treatment, while 40.14 and 53.74% of the resistant 182R-1 and 182R-2 cells were 
dead. Cisplatin also induced cell death in all three cell lines and treatment with cisplatin showed an 
increased percentage of dead cells in the fulvestrant resistant cell lines when compared to T47D (Figure 
30).  
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Figure 30 – Flow Cytometric Determination of SYTOX Green Stained Cells. Cells were seeded in 6-well plates in their 
standard growth medium and allowed to plate for 2 days before treatment with vehicle (1.0% DMSO) or 50 nM 
barasertib for 96 hours (h). Cisplatin was used as a positive control. Cells were harvested for SYTOX green staining on day 
6. SYTOX green positive cells (dead cells) were identified by flow cytometry and percentage of dead cells are indicated in 
bold. Two individual experiments were done and data from one representative experiment are shown.  
Before the cells were harvested for flow cytometric analysis, the cells were photographed using a 
fluorescence microscope to visualize dead cells, which were SYTOX green positive (Figure 31).  The 
images show that the number of SYTOX green positive cell in cultures grown in their standard growth 
medium were slightly higher in the resistant cell lines compared parental cell line. Moreover, compared 
to parental cells, the number of SYTOX green positive cells was strongly increased when the fulvestrant 
resistant cells were treated with barasertib or cisplatin for 96 hours. Thus, the pictures confirmed the 
results from the flow cytometric analysis (Figure 30) showing that barasertib-induced cell death was 
more prominent in the two fulvestrant resistant cells lines when compared to T47D.  
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Figure 31 - Cell Pictures Following SYTOX Green Staining. Cells were seeded in 6-well multi dishes in their standard 
growth medium and allowed to seed for 2 days before treatment with vehicle (1.0% DMSO) or 50 nM barasertib. 
Cisplatin was used as a positive control. Cells were stained with SYTOX green to identify cell dead (green cells) on day 6. 
Flourescence images were obtained with an Olympus IX71 microscope at a magnification of 20x. 
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5 Discussion 
Breast cancer is the most frequent cancer among women in Denmark (SSI, 2012). With the discovery of 
endocrine therapy during the 1970th the mortality rate for breast cancer patients has improved greatly. 
However, acquired resistance to treatment occurs both in patients, who have received adjuvant 
endocrine therapy and in patients receiving endocrine therapy for advanced disease. Upon relapse, 
patient may benefit from second line treatment with e.g. the anti-estrogen fulvestrant, but almost all 
patients with advanced breast cancer eventually acquire resistance against this treatment as well 
(Osborne et al, 1995;Howell et al, 1995;Musgrove and Sutherland, 2009). It is therefore of great 
importance to elucidate the molecular mechanisms driving growth of endocrine resistant breast cancer 
cells. 
5.1 HER Signaling is Not the Driving Mechanism of Fulvestrant Resistant T47D Cell 
Growth 
Previous findings in our laboratory have shown that fulvestrant resistant MCF-7 cell lines utilize HER 
signaling for growth and that treatment targeting the HER receptors and their downstream signaling 
molecules preferentially inhibited growth of the fulvestrant resistant cell lines compared to parental 
MCF-7 cells (Frogne et al, 2005;Frogne et al, 2009a;Sonne-Hansen et al, 2010). Additional preclinical 
studies have also shown that upon development of fulvestrant resistance, the breast cancer cells can 
switch from ER driven growth to growth stimulated by HER signaling (McClelland et al, 2001;Sommer et 
al, 2003;Massarweh et al, 2006) and clinical data have shown that some patients, who originally were 
HER2 negative, had HER2 positiv metastasis (Gutierrez et al, 2005). Moreover, data from our laboratory 
have shown that breast cancer patients receiving adjuvant tamoxifen therapy more frequently develop 
advanced disease, if their primary tumor expresses the activated forms of HER1-3 (Frogne et al, 2009b). 
These findings have led to the suggestion that patients could benefit from a combined treatment with 
anti-estrogens and HER receptor inhibition (Sonne-Hansen et al, 2010). 
Most cell line models for anti-estrogen resistance are based on the ER positive MCF-7 cell line. Breast 
cancer is a heterogeneous disease, and it would therefore be favorable to investigate the development 
of anti-estrogen resistance in other cell line model systems to elucidate, whether the switch to HER-
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driven cell growth is a general mechanism for ER positive breast cancer cells upon acquiring resistance 
to anti-estrogens.  
We have therefore established fulvestrant resistant breast cancer cell lines derived from the ER positive 
breast cancer cell line T47D. In agreement with the finding in the MCF-7 based resistant cell lines, the 
T47D based fulvestrant resistant cell lines also displayed changes in the expression of the HER receptors, 
compared to the parental T47D cell line. HER2 was overexpressed, whereas the expression of EGFR, 
HER3 and HER 4 was unchanged or reduced (Appendix III and Kirkegaard, unpublished data). However, a 
preferential growth inhibition of the resistant cell lines could not be detected when the cells were 
treated with a panel of HER inhibitors or an inhibitor of the downstream signaling molecule PI3K (Figure 
18, Appendix III and Kirkegaard, unpublished data). Combined with data showing that knockdown of 
HER2 in the resistant cell lines had no growth inhibiting effects (Kirkegaard, unpublished data) these 
findings demonstrate that HER signaling is not the driving mechanism for growth of the fulvestrant 
resistant T47D derived cell lines. Additionally, the fulvestrant resistant T47D cell lines were found to be 
ER negative, in contrast to the fulvestrant resistant MCF-7 cells, which only exhibit redused levels of ER 
compared to their parental MCF-7 cells (Lykkesfeldt et al, 1995) and (Kirkegaard, unpublished). Thus, the 
resistance mechanisms are different in the fulvestrant resistant T47D and the fulvestrant resistant MCF-
7 based model systems. Moreover, preliminary data have shown that the expression of the HER 
receptors in our tamoxifen resistant T47D cell lines is unchanged or slightly reduced compared with the 
expression in the parental T47D cells (Yde, unpublished data). These T47D derived data also differ from 
MCF-7 derived data, as growth of tamoxifen resistant MCF-7 cells, at least partially, depends on HER 
signaling (Thrane et al, 2013). These differences could mimic the diversity in clinical breast cancer and 
could thereby represent two distinct patient groups. Therefore, to identify novel mechanisms utilized for 
growth of anti-estrogen resistant T47D cell lines, a functional kinase inhibitor screen were applied to the 
resistant cell lines as well as their parental cell lines.  
5.2 Functional Kinase Inhibitor Screen 
Two kinase inhibitor screens were performed to identify mechanisms utilized for growth of anti-
estrogen resistant T47D cell lines. In the first screen, growth of fulvestrant resistant T47D cells were 
compared to growth of parental T47D cells upon treatment with 195 kinase inhibitors. The second 
screen compared growth of tamoxifen resistant T47D cell lines with the parental T47D/S2 cell line 
following treatment with the inhibitors. The screen with the fulvestrant resistant cell lines identified 15 
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inhibitors which preferentially inhibited growth of fulvestrant resistant T47D cell lines, while the second 
screen identified three inhibitors which preferentially growth inhibited the two tamoxifen resistant T47D 
cell lines compared to the parental cells. 
The screens were only performed with one concentration of the inhibitors (1 µM) which potentially is a 
toxic concentration of some of the compounds. Many of the compounds also inhibit additional targets 
at the investigated concentration, meaning that the resulting growth reduction not necessarily reflects 
inhibition of the main inhibitor target. 
The kinase inhibitor screen performed with tamoxifen resistant cell lines, only resulted in three common 
hits. The sparse number of inhibitors identified to exhibit a twofold preferential growth inhibition of the 
resistant cells may indicate that none of the kinases targeted in this screen are the driving factor for 
tamoxifen resistant cell growth. The screen included 195 kinase inhibitors, but many of them targeted 
the same kinases. Thus, the resistant cells may utilize mechanisms besides the ones tested in this screen. 
However, the limited number of hits could also be a result of non-obtimal conduction of the experiment, 
since the control samples were more than 80% confluent at the end of this experiment. This could 
exclude some inhibitors from being identified as a hit, since space limitations would prevent the cells 
from additional growth and reduce the response to treatment. 
In both kinase inhibitor screen, very low standard deviations were obtained and most of the result could 
be confirmed in dose-response growth experiments. This demonstrates the credibility of the 
experimental results obtained with the kinase inhibitor screen. However, some variations between 
validation and screen results were observed e.g. when parental cell lines (T47D and T47D/S2) were 
treated with JNJ-7706621. The parental cell lines were growth inhibited in both validation studies, but 
not in the kinase screens. In the validation studies the cells were treated with a fresh stock of JNJ-
7706621 and this could possibly explain the variation between the assay results.  
Similar kinase inhibitor screens in MCF-7 based cell lines have confirmed that anti-estrogen resistant 
cells in this model system depend on the HER receptors for signaling, since inhibitors targeting HER and 
their downstream signaling molecules, e.g. Akt and MEK, exhibited a preferential growth inhibition of 
the anti-estrogen resistant MCF-7 cell lines (Thrane anf Thomsen, unpublished data). The validity of the 
screen assay was thereby confirmed, since these screens identified the already known important 
signaling pathways of the MCF-7 based cell lines (Frogne et al, 2005;Frogne et al, 2009a;Thrane et al, 
2013). Kinase inhibitors targeting HER or their downstream signaling molecules where not identified as 
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hits in the screens with either the fulvestrant resistant nor the tamoxifen resistant T47D cell lines, 
substantiating that the T47D and MCF-7 model systems differ from one another. 
5.3 Cell Cycle Proteins are Important for Growth of Anti-Estrogen Resistant T47D Cells 
The kinase inhibitor screen with the fulvestrant resistant T47D cell lines identified 15 kinase inhibitors 
which exited a more than twofold growth inhibition of the resistant cell lines (182R-1 and 182R-2), 
compared to the parental T47D cell line. The majority of these inhibitors targeted kinases important for 
cell cycle signaling, especially inhibition of the Aurora kinase protein family resulted in a preferential 
growth inhibition, but inhibitors targeting CDKs, Chk1/2 and CK2 were also identified as hits. Several 
studies have shown that the Aurora proteins are overexpressed in a broad range of cancer, including 
breast cancer, and since the Aurora protein family plays a critical role in the regulation of key cell cycle 
processes, it has been subject of many resent investigations (Katayama and Sen, 2010;Gautschi et al, 
2008). Two inhibitors targeting the Aurora family were chosen for validation studies, namely the pan-
Aurora and CDK inhibitor JNJ-7706621 and the selective Aurora B inhibitor barasertib.  
5.3.1 JNJ-7706621 Preferentially Inhibits Growth of Tamoxifen Resistant T47D Cell Lines 
In the kinase screen, JNJ-7706621 was identified as a hit in both the fulvestrant resistant and tamoxifen 
resistant T47D cell lines (Table 4 and Table 5). Moreover, it has been found in two additional kinase 
inhibitor screens performed in our laboratory, that JNJ-7706621 preferentially inhibited growth of 
tamoxifen resistant MCF-7 cell lines compared to parental MCF-7/S0.5 cells, whereas no preferential 
growth inhibition was seen in fulvestrant resistant MCF-7 breast cancer cell lines compared to MCF-
7/S0.5 (Thrane and Thomsen, unpublished data). JNJ-7706631 was therefore chosen for validation in 
dose-response growth experiments. At all investigated concentrations, a preferential growth inhibition 
of the tamoxifen resistant T47D cells were found, while fulvestrant resistant T47D cells only were 
preferentially inhibited when treated with 1 µM JNJ-7706621 (Figure 16). However, the preferential 
growth inhibition of the fulvestrant resistant T47D cells at 1 µM was not a reprodusable finding. 
Therefore, treatment with JNJ-7706621 only seems to preferentially growth inhibit tamoxifen resistant 
cell lines, suggesting that mechanisms targeted by this inhibitor are especially important for tamoxifen 
resistant cell growth. Since JNJ-7706621 also preferentially inhibited growth of the tamoxifen resistant 
MFC-7 cells, the results also exemplifies, that similarities among the tamoxifen resistant model systems 
are present. 
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5.3.2 Fulvestrant Resistant T47D Cells Express High Levels of Active Aurora A and B and 
Inhibition of the Aurora B Kinase Induces Preferential Growth Inhibition 
The highly selective Aurora B inhibitor barasertib was identified as a hit in the kinase screen with the 
fulvestrant resistant T47D cell lines and the finding was confirmed in dose-response growth experiments 
(Figure 17). Treatment with barasertib resulted in dephosphorylation of Aurora B, but had no effect on 
the level of phosphorylation of Aurora A. The stability of the Aurora B protein was also affected by 
barasertib, since the Aurora B protein, upon 96 hours of treatment, was almost undetectable by western 
blot analysis (Figure 24B). This shows that barasertib is highly selective regarding inhibition of 
phosphorylated and thereby activation of the Aurora B protein and not Aurora A, and that the observed 
growth inhibition may be due to abolished Aurora B function. 
If fulvestrant resistant T47D cells depend on active Aurora B for growth, the protein should be present in 
the activated phosphorylated form in the resistant cell lines. This was confirmed by western blot 
analysis, which also showed that the expression of activated Aurora A and B was higher in both of the 
fulvestrant resistant T47D cell lines compared with parental T47D cells (Figure 24A). 
The amount of total Aurora A and B protein was similar in parental and fulvestrant resistant cell lines 
(Figure 25A and Figure 24A). Since Aurora A and B are activated by phosphorylation in a cell cycle phase 
specific manner, namely in the M phase of the cell cycle, the increased level of phosphorylated Aurora A 
and B could arise from an increased proportion of M phase cells, i.e. an increased proliferative index. 
However, the doubling time of the fulvestrant resistant T47D cells was similar in the resistant and 
parental cells (Figure 11), and cell cycle analysis showed no difference in proliferative index between the 
cell lines; 19%, 18% and 19% for T47D, 182R-1 and 182R-2 cells, respectively (Figure 26). Thus, the 
elevated levels of active Aurora proteins are not caused by a higher fraction of cells in M phase, 
suggesting that resistant cells express higher levels or activity of a kinase which activates the Aurora A 
and B proteins.  
The substantial and preferential growth inhibition of resistant cell lines treated with barasertib (around 
65% inhibition of resistant cell lines versus 30% inhibition of the parental cell line) suggest that 
activation of the multifunctinal Aurora B protein may be important for fulvestrant resistant cell growth. 
However, at present, we do not know the mechanisms whereby the activity of Aurora B is upregulated 
or how it is involved in resistant cell growth. 
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Resistant cell lines grown under standard conditions were found to have a greater proportion of 
multinucleated cells and a higher fraction of dead cells compared to the parental cell line (Figure 10, 
Figure 27 and Figure 30). This indicates that fulvestrant resistant T47D cells exhibit a reduced ability to 
correct errors during cell cycle progression and could explain why additional disturbance of the mitotic  
spindle-assembly checkpoint, induced by treatment with barasertib, results in a greater growth 
inhibition of the resistant cell lines compared to growth of parental cells. Overexpression of both Aurora 
A and B has been found to induce multinucleation either as a consequence of centrosome amplification, 
or disruption of chromatid cohesion or kinetochore-microtubule attachment (Ota et al, 2002;Zhou et al, 
1998;Katayama and Sen, 2010). The multinucleated cells could therefore be a consequence of the 
elevated levels of active Aurora proteins, since both overactivation and multinucleation is found in the 
resistant cell lines, but not in the parental T47D cells. An increased proportion of cell death under 
standard growth conditions could be caused by programmed cell death of multinucleated cells. 
5.3.3 Barasertib induces Chromosome Segregation Errors, Severe Multinucleation and Cell 
Death of Fulvestrant Resistant Cell Lines 
Aurora proteins are important for correct progression through mitosis and cytokinesis (Vader and Lens, 
2008). It was therefore investigated whether treatment with barasertib affected chromosome alignment 
and cell cycle phase distribution of parental and fulvestrant resistant T47D cells. 
Treatment with barasertib obstructed proper chromosome segregation, increased the proportion of 
multinucleated cells and induced G2/M phase arrest of the resistant cell lines (Figure 26 and Figure 27). 
The treatment thereby prevented progress through the cell cycle and lead to death of M phase cells, 
detected by an increase in the proportion of cells in Sub-G1. Parental T47D cells treated with barasertib 
also resulted in erroneous chromosome segregation and multinucleated cells. However, these cells did 
not arrest in G2/M, rather the cells reentered a new cell cycle in spite of failed cytokinesis resulting in 
polyploid cells. The proportion of dead cells upon treatment with barasertib was highly increased in 
resistant cells compared to parental cells (Figure 30). Western blot analysis detected PARP cleavage in 
the resistant cells (Figure 29), indicating that the cells, at least in part, died via activation of the 
apoptotic death pathway. 
Collectively, the results show that the fulvestrant resistant cells are more vulnerable to disruption of 
proper cell cycle progression. In contrast, parental cells treated with barasertib are able to survive, at 
least for a period, as polyploid cells. 
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5.3.4 Inhibition of Aurora B could benefit Patients with Advanced Breast Cancer 
Overexpression of Aurora B and the subsequent dysfunctional mitotic checkpoint could potentially 
cause genomic instability allowing for the accumulation of structural and numeral chromosomal 
abnormalities acquired for the cells to grow in the presence of fulvestrant. In fact, overexpression of 
Aurora B in chinese hamster embryonic diploid fibroblasts have been found to induces aneuploid cells 
capable of forming aggressive tumors in nude mice (Ota et al, 2002). However, an elevated level of 
Aurora proteins is not necessarily the driving factor for acquired resistant to fulvestrance in our T47D 
cell line model. The findings in this study suggest that the protein harbor key functions needed for the 
resistant cell lines to survive upon development of resistance, but it was not investigated whether 
overexpression of Aurora B caused the resistance or whether it was a result of the resistance. It has 
been shown that the level of Aurora B increases along with progression of prostate and thyroid cancer 
(Sorrentino et al, 2005;Chieffi et al, 2006). The same could be applicable for breast cancer, suggesting 
that as the cancer progresses; the tumor cells may become more dependent on functional Aurora B 
protein. Thus, patients with advanced breast cancer could be expected to have elevated expression of 
activated Aurora B protein. 
It has been found that Aurora B expression is more important for growth of a panel of cancer cell lines 
compared with the normal breast epithelial cell line MCF10A (Warner et al, 2006). In this study we 
found that all investigated breast cancer cell lines were growth inhibitied when treated with barasertib 
(Figure 17, Figure 22 and Figure 23). However, the growth inhibition of fulvestrant resistant T47D breast 
cancer cells was significantly greater compared to their parental cells, showing that these cells are more 
dependent on functional Aurora B.  
Collectively the findings from this study and others suggest that breast cancer patients resistant to 
fulvestrant treatment could benefit from treatment targeting the Aurora B kinase e.g. by the selective 
inhibitor barasertib. However, the anti-proliferative potential of the treatment seems to correlate with 
elevated levels of the activated form of the protein and only patients with high expression of actived 
Aurora B should therefore be offered this treatment.  
5.3.5 An Important Role of Aurora A for Fulvestrant Resistant Cell Growth Can Not Be Excluded 
Many of the inhibitors identified as hits in the kinase inhibitor screen with the fulvestrant resistant T47D 
cell lines targeted both Aurora A and B, but no additional growth inhibition was seen when both kinases 
were targeted compared to selective targeting of Aurora B. As described above, we have looked into the 
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importance of Aurora B for fulvestrant resistant cell growth, since treatment with the highly selective 
Aurora B inhibitor barasertib induced preferential growth inhibition, while the highly selective Aurora A 
inhibitor, Aurora A inhibitor I, did not exhibit a preferential growth inhibition of the fulvestrant resistant 
cell lines compared to parental T47D cells. However, it cannot be excluded that Aurora A is important 
for fulvestrant resistant cell growth, since we have only tested the growth inhibitory effect of Aurora A 
inhibitor I at 1 µM. Treatment with a lower concentration of the inhibitor may exhibit a preferential 
growth inhibition of the resistant cells. Moreover, siRNA-mediated knockdown of Aurora A was found to 
exert preferential growth inhibition of both fulvestrant resistant cell lines compared to parental cell line 
(Figure 25B). Aurora A has been found to be overexpressed in breast cancer (Tanaka et al, 1999) and the 
protein was highly active in the fulvestrant resistant cell line compared to the parental cell line (Figure 
24A). Thus, we cannot exclude that the Aurora A kinase is important for fulvestrant resistant cell growth 
and investigations into its importance for acquisition of fulvestrant resistance should not be excluded 
from future studies.  
5.4 Patients could benefit from Dual Targeting of the Estrogen Receptor and c-Src 
Several inhibitors targeting the SFK family or FAK, which is found in complex with c-Src, were identified 
as hits both the screen with fulvestrant and tamoxifen resistant T47D cell lines. These inhibitors were 
validated in dose-response growth experiments, which confirmed that inhibitors of SFKs can exhibit a 
preferential growth inhibition on both fulvestrant and tamoxifen resistant T47D cell lines (Appendix VIII  
and Figure 19). The inhibitors also targeted RTKs (VEGFR, FEGFR and PDGFR), c-Kit and Abl, however, 
none of the other inhibitors targeting VEGFR, FEGFR and PDGFR (except for the multi targeting ENMD-
2076) was found to induce a preferential growth inhibition of the resistant cell lines, suggesting that the 
inhibition could be due to selective inhibition of SFKs. Thus, to elucidate whether the preferential 
growth inhibition could be attributed to inhibition of SFKs, the growth inhibitory effect of treatment 
with the highly selective SFK inhibitor KX2-391 was also investigated. This inhibitor also induced a 
preferential growth inhibition of fulvestrant resistant cell lines compared to parental T47D (Figure 21A). 
However, the inhibitor was tested in concentrations ranging from 10-50 nM and already at 10 nM, 
maximum inhibition of resistant cells were observed (Figure 21A). Therefore, dose-response growth 
experiments with lower concentrations should be performed to unravel whether a more pronounced 
difference between the inhibition of resistant versus parental cells could be observed. The growth 
experiments collectively showed that SFKs are important for growth of anti-estrogen resistant cell lines.  
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If anti-estrogen resistant cells depend on active SFKs for growth, these proteins should be active in the 
resistant cell lines. Thus, western analysis was performed to measure the protein level of c-Src, the SFK 
which is most frequently is overexpressed in breast cancer (Elsberger et al, 2010). The level of 
phosphorylated c-Src was found to be higher in both fulvestrant and tamoxifen resistant cell lines 
compared to their parental cell lines (Figure 21B and Appendix VIII ), indicating that this kinase is more 
active in the anti-estrogen resistant cell lines. c-Src is important in a number of signal transduction 
pathways, where it regulates and relays intracellular signals (Parsons and Parsons, 2004). This suggests 
that the anti-estrogen resistant T47D cell lines upon development of resistance, utilize a broad range of 
pathways, which each contributes to the continued growth of the resistant cells. The level of total and 
active c-Src has been found to be elevated in breast cancer and expression of the active kinase is 
associated with reduced overall survival (Elsberger et al, 2010;Verbeek et al, 1996;Morgan et al, 2009). 
This suggests that c-Src could be used as a biomarker to identify patients with reduced response to anti-
estrogen treatment.  
Experiments presented in this study were all performed with anti-estrogen resistant cells grown in 
presence of the anti-estrogen. Other studies have shown that dual treatment with tamoxifen and a SFK 
inhibitor induced synergistic growth inhibition and completely prevented the progression to tamoxifen 
resistant cells (Hiscox et al, 2009;Anbalagan et al, 2012). Addinionally, a recent experiment in our 
laboratory have shown that the ER positive tamoxifen resistant T47D cell lines treated with both 
tamoxifen and the SFK inhibitor dasatinib were more growth inhibited compared to cells treated with 
dasatinib alone, indicating superiority of combined treatment regimes (Kirkegaard, unpublished data). 
Combined treatment is also supported by the finding that expression of dominant negative-Src in 
tamoxifen resistant MCF-7 cells resensitized the cells to treatment with tamoxifen and that 
overexpression of c-Src in MCF-7 cells significantly attenuated the growth inhibitory effects of tamoxifen 
(Morgan et al, 2009). Patients may therefore benefit from a treatment targeting both c-Src and ER upon 
relapse, if they exhibit an increased expression of active c-Src in their tumor. 
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6 Conclusion 
Comparative analyses of the estrogen and anti-estrogen responsive T47D breast cancer cell line with 
two newly established T47D derived breast cancer cell lines, which are resistant to treatment with the 
pure steroidal anti-estrogen fulvestrant, have unraveled several differences, some of which may be 
causally involved in the ability to grow in presence of fulvestrant. Compared to the parental T47D cells, 
the fulvestrant resistant T47D cell lines exhibited similar growth rate and proliferative index, decreased 
plating efficiency and increased cell death presumably due to programmed cell death of multinucleated 
cells.  
By using a kinase inhibitor library consisting of 195 different kinase inhibitors, we conclude that the 
Aurora family of protein kinases as well as other kinases involved in cell cycle control may play an 
important role for growth of the fulvestrant resistant cell lines. The importance of particularly the 
Aurora B protein was confirmed by the finding of increased expression level of the activated 
phosphorylated Aurora B protein in the two fulvestrant resistant cell lines compared to the parental cell 
line. Further support for the important function of the Aurora B protein was obtained in experiments 
showing that the highly specific Aurora B inhibitor barasertib inhibited phosphorylation of the Aurora B 
protein and exerted a substantial and preferential inhibition of growth of the fulvestrant resistant cell 
lines. The Aurora B protein is a cell cycle phase specific protein with multiple functions during mitosis 
and cytokinesis. At present, we do not know by which mechanisms the Aurora B protein may support 
growth of fulvestrant resistant T47D cell lines nor why the phosphorylated form of the protein is 
elevated in the resistant cell lines compared to parental cells. Additionally, based on our data we can not 
exclude that the Aurora A protein may also be involved in fulvestrant resistant cell growth as siRNA-
mediated knockdown of Aurora A expression reduced growth of fulvestrant resistant cell lines. We 
suggest that Aurora B inhibition, e.g. with the highly selective kinase inhibitor barasertib, could be a 
candidate treatment for breast cancer patients with tumors expressing the phosphorylated form of the 
Aurora B kinase.   
The Src Family Kinase (SFK) inhibitor dasatinib also displayed preferential growth inhibition of the 
fulvestrant resistant T47D cell lines as well as of two new tamoxifen resistant T47D cell lines.  Based on 
growth analysis and the finding of increased expression level of activated phosphorylated c-Src protein 
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in both fulvestrant and tamoxifen resistant T47D cell lines, we conclude that the c-Src protein is a 
potential candidate causally involved in fulvestrant resistant cell growth. We suggest that the activated 
form of c-Src may be used as a biomarker predicting resistance to treatment with anti-estrogens. 
The model system with anti-estrogen resistant T47D cell lines was established to elucidate whether it 
was a general phenomenon that ER positive breast cancer cells switch from ER driven cell growth to HER 
receptor driven cell growth upon acquisition of anti-estrogen resistance, as seen in our model system 
with the breast cancer cell line MCF-7. None of the kinases, which were identified as candidates causally 
involved in resistant cell growth of the T47D cell lines, belonged to the HER receptor family nor to down-
stream signaling molecules like Akt and ERK. Therefore, we conclude that the mechanisms rendering 
MCF-7 and T47D breast cancer cell lines resistant to anti-estrogen treatment are different. Our data 
emphasize the need for model systems to disclose the resistance mechanisms and to identify new 
biomarkers predicting resistance to anti-estrogen therapy.  
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7 Perspectives 
In this study we found that 9 of the 15 kinase inhibitors, which exterted a statistically significant and 
more than twofold higher growth inhibition of fulvestrant resistant T47D cell lines compared to the 
parental T47D cell line, targeted Aurora kinases. This finding strongly support that members of this 
family of kinases may be causally involved in the development of fulvestrant resistance and/or promote 
fulvestrant resistant cell growth. Specifically, the kinase activity of Aurora B may play an important role 
in fulvestrant resistance, but the exact mechanisms whereby Aurora B may confer fulvestrant resistance 
are still unclear. The Aurora B kinase has multiple functions and may thus be involved in both the ability 
of the resistant cells to survive fulvestrant treatment as well as in promoting growth in spite of 
treatment. To investigate whether expression of activated Aurora B is able to confer fulvestrant 
resistant cell growth, it could be determined whether expression of a constitutive active Aurora B 
mutant protein introduced into parental T47D rendered the cells resistant to fulvestrant treatment. 
Parental T47D cells expressing constitutive active Aurora B protein could also be used to investigate 
whether these cells would be more growth inhibited by treatment with barasertib compared to control 
T47D cells i.e. whether overexpression of the active kinase in the parental T47D cells would make the 
cells more sensitive to treatment with barasertib. If Aurora B expression correlates with cancer 
progression, we would expect tumors, which have acquired anti-estrogen resistance, to have a higher 
expression of active Aurora B protein at time of progression compared to the level in their primary 
tumor. Clinical material from primary tumors and corresponding metastases from breast cancer patients 
is available in the Breast Cancer Group, and the level of active Aurora B in these tissue samples could 
thereby be investigated by immunohistochemical analysis.   
Some of the experiments presented in this thesis should be performed again e.g. siRNA mediated 
knockdown of both Aurora A and B. It would also be interesting to further investigate the involvement 
of Aurora A in fulvestrant resistance. The importance of Aurora A could be investigated by selective 
inhibition of the protein by treatment with the Aurora A inhibitor I at concentrations lower than 1 µM.  
We proposed that c-Src is the most important SFK with respect to growth of anti-estrogen resistant cell 
lines, since c-Src has been shown to display the highest expression level in breast cancer compared to its 
family members (Elsberger et al, 2010). Additionally, we found an increased level of the active form of c-
Src in the anti-estrogen resistant cell lines. However, it was not investigated whether the preferential 
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inhibition induced by the SFK inhibitors could be caused by inhibition of other family members than c-
Src. Western blot analysis measuring the protein levels of other SFKs could be performed to investigate 
whether the levels of the activated forms of these proteins also are elevated in the resistant cell lines. 
Moreover, to verify that c-Src is the SFK responsible for anti-estrogen resistant cell growth, a knockdown 
experiment should be performed. Finally, to explore whether the expression of c-Src can be used as a 
biomarker to predict response to tamoxifen treatment, the level of c-Src expression and 
phosphorylation could be investigated by immunohistochemistry in primary tumors from tamoxifen 
treated breast cancer patients. Clinical material from such patiens has been collected and is available. 
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Appendix I  Abbrevations 
 
182R  T47D/182R (Fulvestrant resistant breast cancer cell lines) 
Abl  Abelson  
AF1  Activating function 1 
AF2  Activating function 2 
AI  Aromatase inhibitor 
AP-1  Activator protein 1 
APC/C  Anaphase-promoting complex/cyclosome 
ATP  Adenosintriphosphat  
Bcl-2  B-cell lymphoma 2 
BRACA1/2 Breast cancer genes ½ 
Caspases Cysteine aspartyl proteases 
CDK  Cyclin-dependent kinase 
Chk  Checkpoint kinase 
CK  Casein kinase 
CPC  Cromosomal Passenger Complex 
DBCG  Danish Breast Cancer Cooperative Group 
DBD  DNA-binding domain 
DMEM/F12 Dulbecco’s Modified Eagles Medium/Ham’s F12 
DMSO  Dimethyl sulfoxide 
DPBS  Dulbecco’s Phosphate-Buffered Saline  
DTT  Dithiothreitol 
EDTA  Ethylene diamine tetraacetic acid  
EGFR  Epidermal growth factor receptor 
ER  Estrogen receptor 
ERE  Estrogen-response element 
ERK 1/2 Extracellular-signal-regulated kinase 1/2 
FAK  Focal adhesion kinase 
FBS  Fetal bovine serum 
FDA  United States Food and Drug Administration 
FGFR  Fibroblast growth factor receptor 
Flt  Fms-like tyrosine kinase 
G1  Gab phase 1 
G2  Gab phase 2 
GDB  Guanosine diphosphate 
GRB  Growth factor receptor-bound protein 
GSK3  Glucogen synthase kinase 3 
GTB  Guanosine triphosphate  
HE  Hematoxylin and eosin 
HER  Human epidermal growth factor receptor 
HRP  Horse radish peroxidase 
HPG  Hypothalamic pituitary-gonadal 
INCENP   Inner centromere protein 
JAK  Janus kinase 
M phase Mitotic phase 
MAP  Mitogen activated protein 
MCC  Mitotic checkpoint complex 
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MCF-7/S0.05 MCF-7 subline 0.05 
MEK  Mitogen-activated protein kinase 
MOMP  Mitochondrial outer membrane permeabilizaion 
NFκB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NR  Nuclear receptor 
OD  Optic density 
ON  Over night 
p21  Cyclin dependent kinase inhibitor 1 
p53  Tumor protein 53 
P/S  Penicillin/Streptomycin 
PARP  Poly ADP ribose polymerase 
PMSF  Phenylmethylsulphonyl 
RIPA  Radioimmunoprecipitation 
RPMI  Roswell Park Memorial Institute 
PDC  Programmed cell death 
PDGFR  Platelet derived growth factor receptor 
PDK1  Phosphoinositide-dependent kinase 1 
PI3K  Phosphoinositide-3 kinase 
PIP2  Phosphatidylinositol-4,5-biphosphate 
PIP3  Phosphatidylinositol-3,4,5-triphosphate 
PKB  Protein kinase B (Akt) 
PTEN  Phosphatase and tensin homolog 
Pyk  Proline-rich tyrosine kinase 
Ras  Rat sarcoma 
Raf  Rapidly accelerated fibrosarcoma 
Rb  Retinoblastoma protein 
RT  Room temperature 
RTK  Receptor tyrosine kinase 
S phase  DNA synthesis phase 
SD  Standard deviation  
SDS  Sodium dodecyl sulphate 
SERD  Selective estrogen receptor downregulator 
SERM  Selective estrogen receptor modulator 
SFK  Src Family Kinase 
SH2  Src homology 2 
Shc  SH2 domain containing protein 
SOS  Son of sevenless 
Sp1  Specificity protein 1 
STAT  Signal transducer and activator of transcription 
T47D/S2 T47D Subline 2 
TBS  Tris-Buffered Saline  
TR  T47D/TR (tamoxifen resistant breast cancer cell lines) 
TF  Transcription Factor 
VEGFR  Vascular endothelial growth factor receptor 
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Appendix II  Establishment of Anti-Estrogen Resistant Cell Lines 
 
Establishment of Anti-Estrogen Resistant Cell Lines. A. Two fulvestrant resistant T47D cell lines were established from 
the parental estrogen receptor (ER) positive T47D breast cancer cell line. B. Two tamoxifen resistant T47D cell lines were 
established from the parental ER positive T47D breast cancer cell line, adapted to grow in 2% Fetal bovine serum (FBS) 
(T47D/S2). C. Four ICI 164,384 resistant MCF-7 cell lines were established from the parental ER positive MCF-7 cell line, 
adapted to grow in 1% FBS (MCF-7/S.05). MCF-7/S.05/164R cells are crossresistant to treatment with fulvestrant. D. 
Three fulvestrant resistant MCF-7 cell lines were established from the parental MCF-7/S0.05 cell line. C. and D are based 
on (Lykkesfeldt et al, 1995).  
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Appendix III  HER Signaling in Fulvestrant Resistant T47D Cell Lines 
 
 
Human Epidermal Growth Factor Receptor Expression and Effect on Cell Growth. A. Western blots showing total forms 
of EGFR (Dako, #M7298, 1:1000), HER2 (Dako, #A0485, 1:2000), HER3 (Dako, #M7297, 1:1000), HER4 (CST, #4795, 
1:500), Akt (CST, #9271, 1:2000) and ERK (CST, #9102, 1:2000), as well as phosphorylated form of Akt (Ser473) (CST, 
#9271, 1:500) and ERK (Thr202/Tyr204) (CST, #4377, 1:1000), in lysates from T47D, 182R-1 and 182R-2 grown under their 
standard conditions. Heat shock protein 70 (Hsp70) (Neomarkers, #MS-482-P0, 1:500,000) were used as loading control 
and 20 µg total protein was loaded in each well. The experiment was performed once. B. T47D, 182R-1 and 182R-2 cells 
were treated for 5 days with vehicle (0.1% DMSO) or 1.0 µM CI-1033 (Selleck) before cell number was measured by a 
crystal violet colorimetric assay and expressed as percentage of untreated control. The experiment was performed once 
with 4 sample replicates in 96-well plates, mean  SD is shown.  
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Appendix IV  Kinese Inhibitors 
The purchased 195 kinase inhibitors were provided in three 96-well plates and the setup of plate 1, 2, 
and 3 is shown below. 
 Plate 1 
            1 2 3 4 5 6 7 8 9 10 11 12 
a Control BMS-599626 
Erlotinib 
Hydrochlori
de 
Gefitinib 
(Iressa) 
Neratinib 
PD153035 
hydrochlorid
e 
Pelitinib Vande-tanib WZ3146 WZ4002 WZ8040 Empty 
b 
AV-951 
(Tivozanib) 
Axitinib 
BIBF1120 
(Nintedanib) 
BMS 
794833 
Control 
Cediranib 
(AZD2171) 
Control CYC116 Control 
Imatinib 
(STI571) 
Imatinib 
Mesylate 
Empty 
c Ki8751 KRN 633 
Masitinib 
(AB1010) 
MGCD-265 
Motesanib 
Diphosphat
e 
MP-470 OSI-930 
Pazopanib 
Hydrochloride 
Sorafenib 
Tosylate 
Sunitinib 
Malate 
TSU-68 Empty 
d Vatalanib 
XL880 
(GSK136308
9) 
PHA-739358 
(Danusertib) 
AT9283 
AZD0530 
(Saracatinib
) 
Bosutinib 
(SKI-606) 
Dasatinib Nilotinib 
Quercetin 
(Sophoretin) 
NVP-
ADW742 
AC-220 Empty 
e AP24534 
Tandutinib 
(MLN518) 
KW 2449 
CI-1033 
(Canertinib) 
CP-724714 
BAY 73-4506 
(Regorafenib
) 
JNJ-
38877605 
PF-04217903 PF-2341066 Control SGX-523 Empty 
f 
SU11274(P
KI-
SU11274) 
NVP-TAE684 SB 525334 R406 
R406(free 
base) 
XL184 BI 2536 GSK461364 HMN-214 ON-01910 AT7519 Empty 
g 
Flavopirid
ol 
(Alvocidib) 
BS-181 
hydrochlorid
e 
PD0332991 
PHA-
793887 
Roscovitine 
(CYC202) 
SNS-032 
(BMS-
387032) 
AZD7762 
Aurora A 
Inhibitor I 
AZD1152-
HQPA 
(Barasertib) 
CCT129202 ENMD-2076 Empty 
h 
Hesperadi
n 
MLN8237 Control 
PHA-
680632 
SNS-314 
Mesylate 
VX-680 
ZM-
447439 
AS703026 
AZD6244 
(Selumetinib
) 
AZD8330 BIX 02188 Empty 
 
Plate 2 
  1 2 3 4 5 6 7 8 9 10 11 12 
a BIX 02189 BMS 777607 
CI-1040 
(PD184352) 
PD318088 PD0325901 PD98059 
U0126-
EtOH 
LY2228820 BIRB 796 SB 202190 SB 203580 Empty 
b 
Vinorelbin
e(Navelbin
e) 
VX-702 VX-745 GDC-0879 Control PLX-4720 RAF265 SP600125 AZD6482 AS-605240 GDC-0941 Empty 
c IC-87114 LY294002 PIK-293 PIK-90 PIK-93 TG100-115 TGX-221 XL147 XL765 ZSTK474 AZD8055 Empty 
d 
Deforolim
us(MK-
8669) 
Everolimus 
(RAD001) 
KU-0063794 
Rapamycin 
(Sirolimus) 
Temsirolimus WYE-354 Control 
PIK-75 
Hydrochloride 
CHIR-99021 Indirubin SB 216763 Empty 
e KU-55933 KU-60019 MK-2206 Control AT7867 Control AZD1480 Control LY2784544 Control Enzastaurin Empty 
f Control Control SB 431542 ABT-869 (Linifanib) AEE788 
BIBW2992 
(Tovok) 
Lapatinib 
Ditosylate 
JNJ-7706621 Control BEZ235 GSK1059615 Empty 
g PI-103 AG-490 CP-690550 (Tofacitinib) 
Crenolanib 
(CP-868569) 
GSK1838705A KX2-391 
NVP-
BSK805 
PCI-32765 PF-562271 DCC-2036 LDN193189 Empty 
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Plate 3 
  1 2 3 4 5 6 7 8 9 10 11 12 
a AZD8931 Raf265 derivative 
NVP-
BHG712 
OSI-420 
R935788 
(Fostamatinib) 
AZ 960 
Mubritinib 
(TAK 165) 
PP242 Cyt387 Apatinib CAL-101 Empty 
b PIK-294 VX-765 
Telatinib  
(BAY 57-
9352) 
BI6727 
(Volasertib) 
WP1130 
BKM120 
(NVP-
BKM120) 
CX-4945 
Phenformin 
hydrochloride 
TAK-733 AZD5438 PP-121 Empty 
c OSI-027 
LY2603618 
(IC-83) 
PKI-587 CCT128930 A66 NU7441 
GSK21264
58 
WYE-125132 WYE-687 A-674563 AS-252424 Empty 
d 
GSK1120
212 
 (JTP-
74057) 
Flavopiridol 
hydrochlori
de 
AS-604850 WAY-600 TG101209 
GDC-0980 
(RG7422) 
A-769662 TAK-901 AMG900 ZM336372 Control Empty 
e PH-797804 
PF-
04691502 
Control Control Control Control Control Control Control Control Control Empty 
Setup of Plate 1-3 Containing Kinase Inhibitors. 96-well plates containing either kinase inhibitors, control (DMSO) or 
empty wells (Selleck Chemicals, 2012). 
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Appendix V  Funktional Kinase Inhibitor Screen Setup 
The 195 kinase inhibitors were distributed across three 96-well plates (blue) (named plate 1, plate 2, and 
plate 3) with additional DMSO controls (red). The screen is performed in triplicates and thus 9 plates 
were set up for each cell line. 
 
Kinase Inhibitor Screen Setup. Triplicate samples of each cell line (T47D, 182R-1, 182R-1, T47D/S2, TR-1 and TR-2) were 
treated for 5 days with vehicle (0.1% DMSO) (red wells) or 1.0 µM of 195 different kinase inhibitors (blue weels). 
Subsequently, cell number was determined by a cell viability assay. 
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Appendix VI  Data from Kinase Inhibitor Screen with Fulvestrant Resistant Cell Lines 
Results from the Kinase Inhibitor Screen with the Fulvestrant Resistant T47D Cell Lines. Triplicate samples of 
parental T47D and fulvestrant resistant 182
R
-1 and 182
R
-2 cells were treated with 1.0 µM of the indicated kinase 
inhibitors for 5 days. Cell number was determined by a cell viability assay. Inhibitory effect  standard deviation 
(SD) and targets of the kinase inhibitors are shown. 
 Inhibitory Effect ± SD (%) p-value  
Inhibitor 
T47D 182
R
-1 182
R
-2 
182R-1 
vs. 
T47D 
182R-2 
vs. 
T47D 
Target(s) 
BMS-599626 30.1 ± 6.4 17.5 ± 43.6 -2.8 ± 11.6 0.32 0.01 
EGFR,   
HER2 
Erlotinib 
Hydrochloride 
9.6 ± 7.8 35.8 ± 37.2 11.1 ± 3.6 0.15 0.39 EGFR 
Gefitinib(Iressa) 7.4 ± 6.3 20.2 ± 20.7 -5.0 ± 4.7 0.18 0.03 EGFR, Akt 
Neratinib 47.2 ± 2.4 55.8 ± 3.5 50.3 ± 3.9 0.01 0.15 HER2 
PD153035 
hydrochloride 
14.9 ± 12.7 5.0 ± 15.9 -17.1 ± 19.4 0.23 0.04 EGFR 
Pelitinib 43.9 ± 2.1 48.2 ± 1.0 36.2 ± 1.9 0.02 0.00 EGFR 
Vandetanib 6.5 ± 4.8 9.1 ± 8.5 11.7 ± 2.1 0.33 0.08 
VEGFR, 
EGFR, SFKs 
WZ3146 3.9 ± 4.1 6.2 ± 3.0 25.3 ± 0.8 0.24 0.00 EGFR 
WZ4002 -3.6 ± 9.5 10.8 ± 7.1 -7.5 ± 19.2 0.05 0.38 EGFR 
WZ8040 4.4 ± 6.3 16.2 ± 30.4 -17.3 ± 7.3 0.27 0.01 EGFR 
AV-951 
(Tivozanib) 
-7.0 ± 4.5 -2.7 ± 4.2 0.8 ± 6.3 0.15 0.08 
VEGFR, 
PDGFR 
Axitinib 8.6 ± 3.7 12.7 ± 1.4 19.1 ± 4.4 0.07 0.02 VEGFR 
BIBF1120 
(Nintedanib) 
11.8 ± 3.0 42.2 ± 3.5 33.9 ± 6.2 0.00 0.00 
SFKs,FGFR, 
VEGFR, 
PDGFR 
BMS 794833 7.9 ± 5.7 11.0 ± 4.9 6.2 ± 2.7 0.26 0.33 
VEGFR, c-
Met, Flt 
Cediranib 
(AZD2171) 
16.9 ± 9.9 17.5 ± 2.0 12.6 ± 8.7 0.46 0.30 VEGFR 
CYC116 28.8 ± 0.6 40.6 ± 3.9 41.1 ± 1.1 0.00 0.00 
Aurora, 
VEGFR 
Imatinib(STI571) 3.5 ± 7.3 2.0 ± 7.4 5.3 ± 5.4 0.41 0.38 
VEGFR, 
PDGFR 
Imatinib Mesylate 3.2 ± 5.7 -6.7 ± 5.3 -12.9 ± 2.9 0.05 0.01 
c-Kit, 
PDGFR 
Ki8751 0.3 ± 4.6 1.0 ± 3.1 3.5 ± 4.8 0.42 0.23 
c-Kit, 
VEGFR, 
PDGFR, 
KRN 633 10.0 ± 2.8 8.5 ± 1.0 9.4 ± 7.0 0.21 0.45 VEGFR 
Masitinib 19.2 ± 1.4 18.7 ± 6.5 16.7 ± 2.7 0.45 0.11 c-Kit, 
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(AB1010) PDGFR, 
FGFR 
MGCD-265 13.2 ± 3.2 17.5 ± 3.0 17.5 ± 4.7 0.08 0.13 
c-Met, 
VEGFR, 
Tie-2 
Motesanib 
Diphosphate 
8.7 ± 2.0 6.4 ± 0.9 10.4 ± 6.7 0.07 0.35 
VEGFR, 
PDGFR, 
SFKs 
MP-470 38.1 ± 4.3 35.6 ± 2.0 45.9 ± 6.4 0.21 0.08 
c-Kit, 
PDGFR, c-
Met 
OSI-930 9.8 ± 7.5 17.3 ± 2.9 24.1 ± 1.8 0.09 0.02 
c-Kit, 
VEGFR 
Pazopanib 
Hydrochloride 
12.3 ± 3.1 14.5 ± 4.7 21.7 ± 2.7 0.28 0.01 VEGFR 
Sorafenib Tosylate 12.4 ± 2.0 16.5 ± 10.0 26.5 ± 11.2 0.26 0.05 
VEGFR, 
PDGFR, 
RAF 
Sunitinib Malate -0.1 ± 10.4 5.9 ± 9.4 -0.5 ± 6.1 0.25 0.48 
FLT3, 
PDGFR, 
VEGFR 
TSU-68 -3.3 ± 6.4 -7.8 ± 9.7 -12.7 ± 1.7 0.27 0.03 
VEGFR, 
PDGFR, 
FGFR 
Vatalanib 9.5 ± 7.6 -3.7 ± 4.4 -3.3 ± 7.1 0.03 0.05 
VEGFR, c-
Kit, VEGFR, 
XL880 
(GSK1363089) 
41.3 ± 2.9 65.3 ± 1.9 65.9 ± 2.8 0.00 0.00 
c-Met, 
VEGFR 
PHA-739358 
(Danusertib) 
43.6 ± 3.9 72.1 ± 5.3 71.9 ± 2.5 0.00 0.00 
Aurora, 
Bcr-Abl 
AT9283 6.2 ± 3.6 46.4 ± 2.5 52.6 ± 2.1 0.00 0.00 
Aurora, 
JAK, Bcr-
Abl 
AZD0530 
(Saracatinib) 
32.0 ± 3.6 50.7 ± 1.2 42.3 ± 1.3 0.00 0.00 SFKs, Abl 
Bosutinib 
(SKI-606) 
28.5 ± 3.6 21.0 ± 1.7 31.7 ± 6.2 0.02 0.24 SFKs 
Dasatinib 18.0 ± 3.5 47.1 ± 2.7 37.0 ± 3.4 0.00 0.00 
SFKs, Abl, 
c-kit 
Nilotinib 13.3 ± 6.4 1.0 ± 0.8 4.2 ± 5.7 0.01 0.07 Bcr-Abl 
Quercetin 
(Sophoretin) 
10.0 ± 4.4 2.9 ± 0.2 2.9 ± 4.0 0.02 0.06 PI3K, PKC 
NVP-ADW742 31.5 ± 5.4 23.3 ± 4.3 23.7 ± 3.3 0.05 0.05 IGF-1R 
AC-220 30.5 ± 17.0 31.4 ± 19.1 43.8 ± 4.5 0.48 0.13 FLT-3 
AP24534 41.5 ± 1.7 40.5 ± 4.7 43.9 ± 1.6 0.37 0.07 
VEGFR, 
FGFR, 
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PDGFR 
Tandutinib 
(MLN518) 
4.2 ± 6.3 6.7 ± 1.6 5.8 ± 7.2 0.27 0.39 
FLT-3, 
PDGFR, KIT 
KW 2449 7.1 ± 4.1 23.7 ± 14.2 31.5 ± 3.3 0.06 0.00 
FLT-3, ABL, 
Aurora 
CI-1033 
(Canertinib) 
42.9 ± 3.7 40.8 ± 1.8 30.5 ± 2.3 0.21 0.00 
HER2, 
EGFR 
CP-724714 20.0 ± 0.4 14.6 ± 3.3 16.2 ± 0.9 0.02 0.00 HER2 
BAY 73-4506 
(Regorafenib) 
29.2 ± 7.2 15.1 ± 1.0 17.7 ± 5.3 0.01 0.04 
c-KIT, 
VEGFR, B-
Raf 
JNJ-38877605 10.3 ± 4.1 5.1 ± 7.6 7.9 ± 0.4 0.18 0.18 c-Met 
PF-04217903 13.5 ± 0.5 6.0 ± 1.8 5.7 ± 4.4 0.00 0.02 c-Met 
PF-2341066 12.4 ± 4.2 10.5 ± 3.9 13.4 ± 4.8 0.29 0.40 c-Met, ALK 
SGX-523 2.8 ± 11.3 -11.4 ± 7.5 -14.1 ± 1.6 0.07 0.03 c-Met 
SU11274 
(PKI-SU11274) 
8.1 ± 6.7 5.9 ± 5.9 7.1 ± 4.9 0.35 0.42 c-Met 
NVP-TAE684 45.1 ± 2.4 49.8 ± 2.8 47.8 ± 4.1 0.05 0.19 ALK 
SB 525334 12.3 ± 2.9 8.1 ± 9.4 3.9 ± 8.1 0.25 0.08 ALK, TGF-β 
R406 22.7 ± 9.0 29.9 ± 2.9 23.6 ± 3.3 0.13 0.44 Syk 
R406 (free base) 25.5 ± 2.7 28.0 ± 0.8 25.6 ± 1.4 0.10 0.48 Syk 
XL184 23.4 ± 4.8 16.5 ± 3.7 17.2 ± 3.7 0.06 0.08 
c-Met, FLT-
3, Tie2 
BI 2536 67.6 ± 0.9 76.8 ± 1.5 75.7 ± 1.7 0.00 0.00 PLK 
GSK461364 54.8 ± 3.3 84.4 ± 1.0 77.6 ± 1.6 0.00 0.00 PLK 
HMN-214 68.3 ± 7.8 80.7 ± 6.1 84.9 ± 2.3 0.05 0.01 PLK 
ON-01910 65.5 ± 3.6 92.5 ± 0.6 90.0 ± 0.8 0.00 0.00 PLK 
AT7519 32.6 ± 38.7 67.0 ± 17.7 79.9 ± 1.8 0.12 0.05 CDK 
Flavopiridol 
(Alvocidib) 
86.6 ± 1.7 82.9 ± 1.4 87.0 ± 1.0 0.02 0.38 CDK 
BS-181 
hydrochloride 
15.1 ± 7.7 11.3 ± 4.1 6.6 ± 2.4 0.24 0.07 CDK 
PD0332991 40.6 ± 3.1 33.7 ± 2.5 28.6 ± 3.9 0.02 0.01 CDK 
PHA-793887 34.0 ± 6.1 43.2 ± 5.7 40.6 ± 3.9 0.06 0.10 CDK 
Roscovitine 
(CYC202) 
10.3 ± 3.3 12.2 ± 1.1 11.6 ± 3.9 0.20 0.34 CDK 
SNS-032 
(BMS-387032) 
83.7 ± 0.2 79.3 ± 0.9 82.7 ± 1.5 0.00 0.17 CDK 
AZD7762 8.6 ± 10.3 30.3 ± 1.1 33.7 ± 2.8 0.01 0.01 Chk1/2 
Aurora A Inhibitor 
I 
42.9 ± 1.8 41.7 ± 3.2 49.2 ± 1.0 0.31 0.00 Aurora A 
AZD1152-HQPA 
(Barasertib) 
28.2 ± 1.7 58.9 ± 2.2 59.9 ± 2.1 0.00 0.00 Aurora B 
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CCT129202 20.1 ± 13.2 44.4 ± 4.8 48.8 ± 4.3 0.02 0.01 Aurora 
ENMD-2076 24.3 ± 16.5 61.8 ± 2.8 65.7 ± 1.5 0.01 0.01 
Aurora, 
Flt3/4, 
SFKs, 
VEGFR2 
Hesperadin 22.2 ± 9.9 44.3 ± 0.6 41.0 ± 6.0 0.01 0.02 Aurora B 
MLN8237 32.0 ± 4.3 34.8 ± 4.3 43.1 ± 5.2 0.24 0.02 Aurora 
PHA-680632 23.5 ± 7.4 62.8 ± 2.7 56.1 ± 5.0 0.00 0.00 Aurora 
SNS-314 Mesylate 19.4 ± 1.5 47.0 ± 2.6 52.8 ± 5.1 0.00 0.00 Aurora 
VX-680 27.6 ± 6.1 44.9 ± 1.7 46.5 ± 4.7 0.00 0.01 Aurora 
ZM-447439 24.2 ± 6.1 57.7 ± 1.7 65.6 ± 1.5 0.00 0.00 Aurora 
AS703026 20.2 ± 16.0 10.0 ± 2.9 5.4 ± 4.1 0.17 0.10 MEK 
AZD6244 
(Selumetinib) 
11.5 ± 3.5 -6.8 ± 5.4 -8.2 ± 6.0 0.00 0.00 MEK 
AZD8330 17.3 ± 5.8 -3.3 ± 13.4 -6.3 ± 10.7 0.04 0.01 MEK 
BIX 02188 4.7 ± 22.7 -23.9 ± 16.3 -26.5 ± 9.6 0.08 0.05 MEK 
BIX 02189 -21.6 ± 19.1 -8.3 ± 17.8 -13.6 ± 14.7 0.21 0.30 MEK 
BMS 777607 -10.5 ± 8.6 -1.9 ± 6.8 -4.0 ± 14.5 0.12 0.27 c-Met 
CI-1040 
(PD184352) 
10.3 ± 5.6 6.8 ± 3.8 1.2 ± 10.4 0.21 0.13 MEK 
PD318088 6.3 ± 12.9 3.8 ± 12.6 -3.2 ± 3.1 0.41 0.14 MEK 
PD0325901 7.3 ± 11.0 7.6 ± 0.8 0.8 ± 9.5 0.48 0.24 MEK 
PD98059 -13.8 ± 4.4 -10.9 ± 1.5 -1.7 ± 13.3 0.17 0.10 MEK 
U0126-EtOH 8.8 ± 2.5 2.7 ± 18.7 0.2 ± 7.1 0.30 0.06 MEK 
LY2228820 -5.9 ± 14.0 -2.8 ± 13.9 -4.8 ± 7.4 0.40 0.46 p38 MAPK 
BIRB 796 -17.4 ± 9.6 -2.1 ± 6.4 -10.4 ± 3.8 0.04 0.15 p38 MAPK 
SB 202190 -8.3 ± 10.9 -0.2 ± 6.9 -12.5 ± 6.7 0.17 0.30 p38 MAPK 
SB 203580 -25.9 ± 35.0 -8.6 ± 24.9 -17.2 ± 14.3 0.26 0.35 p38 MAPK 
Vinorelbine 
(Navelbine) 
52.2 ± 2.1 87.9 ± 1.3 82.4 ± 1.6 0.00 0.00 p38 MAPK 
VX-702 5.9 ± 6.6 2.4 ± 3.8 9.0 ± 3.8 0.24 0.26 p38 MAPK 
VX-745 8.2 ± 4.2 9.6 ± 3.7 5.3 ± 3.5 0.34 0.21 p38 MAPK 
GDC-0879 -4.0 ± 2.2 2.6 ± 9.7 0.8 ± 1.3 0.16 0.02 B-Raf 
PLX-4720 -6.0 ± 4.9 -2.6 ± 3.9 1.4 ± 3.0 0.20 0.04 B-Raf 
RAF265 23.4 ± 5.3 22.2 ± 5.0 25.2 ± 3.8 0.39 0.34 
RAF, 
VEGFR 
SP600125 -0.8 ± 5.1 6.4 ± 6.7 14.3 ± 13.6 0.11 0.07 JNK 
AZD6482 52.3 ± 3.7 55.1 ± 3.2 54.0 ± 4.3 0.19 0.32 PI3K 
AS-605240 21.9 ± 0.7 23.7 ± 2.5 12.7 ± 3.9 0.15 0.01 PI3K 
GDC-0941 72.0 ± 3.8 75.9 ± 4.6 75.1 ± 1.0 0.16 0.12 PI3K 
IC-87114 -11.6 ± 5.8 -4.6 ± 9.7 -3.9 ± 5.2 0.17 0.08 PI3K 
LY294002 13.8 ± 2.9 10.7 ± 7.6 10.7 ± 3.8 0.27 0.16 PI3K, 
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casein 
kinase II 
PIK-293 5.5 ± 3.4 5.3 ± 5.8 4.6 ± 5.4 0.48 0.41 PI3K 
PIK-90 72.3 ± 1.9 73.8 ± 0.5 78.3 ± 1.2 0.12 0.00 PI3K 
PIK-93 43.4 ± 3.3 41.3 ± 3.2 38.2 ± 3.5 0.27 0.10 PI3K 
TG100-115 5.0 ± 1.5 12.9 ± 2.3 13.2 ± 5.3 0.00 0.03 PI3K 
TGX-221 5.6 ± 3.7 0.5 ± 1.7 -1.6 ± 5.1 0.05 0.06 PI3K 
XL147 1.2 ± 2.2 -3.7 ± 8.4 -3.5 ± 13.2 0.19 0.29 PI3K 
XL765 4.0 ± 3.8 3.2 ± 1.8 4.5 ± 5.1 0.37 0.46 PI3K 
ZSTK474 74.1 ± 8.0 76.6 ± 1.3 75.5 ± 2.9 0.31 0.39 PI3K 
AZD8055 82.1 ± 1.5 80.0 ± 2.0 77.3 ± 3.6 0.10 0.05 mTOR 
Deforolimus(MK-
8669) 
51.0 ± 3.1 33.6 ± 4.9 26.5 ± 7.0 0.00 0.00 mTOR 
Everolimus(RAD00
1) 
56.9 ± 1.5 39.4 ± 1.0 35.0 ± 6.7 0.00 0.00 mTOR 
KU-0063794 84.9 ± 1.1 82.8 ± 2.8 79.8 ± 2.7 0.14 0.02 mTOR 
Rapamycin(Sirolim
us) 
61.3 ± 1.9 40.1 ± 5.3 30.9 ± 3.2 0.00 0.00 mTOR 
Temsirolimus 57.0 ± 0.7 42.8 ± 2.5 31.5 ± 2.3 0.00 0.00 mTOR 
WYE-354 80.4 ± 0.3 77.5 ± 0.7 74.0 ± 0.3 0.00 0.00 mTOR 
PIK-75 
Hydrochloride 
92.7 ± 0.6 90.1 ± 0.9 92.4 ± 0.5 0.01 0.27 PI3K 
CHIR-99021 -23.2 ± 3.1 -10.1 ± 2.4 -17.4 ± 2.4 0.00 0.03 GSK-3 
Indirubin 14.1 ± 4.5 5.4 ± 2.1 2.8 ± 4.6 0.02 0.02 GSK-3 
SB 216763 -11.8 ± 3.8 -12.4 ± 2.2 -12.9 ± 7.8 0.42 0.42 GSK-3 
KU-55933 1.5 ± 2.0 -1.1 ± 3.6 -5.7 ± 3.5 0.17 0.02 ATM 
KU-60019 7.5 ± 3.7 4.8 ± 0.7 6.1 ± 6.5 0.13 0.38 ATM 
MK-2206 (AKT inh) 78.2 ± 0.8 78.8 ± 1.0 75.5 ± 2.1 0.23 0.05 Akt 
AT7867 (AKT inh) 18.3 ± 2.7 11.3 ± 1.2 7.9 ± 3.9 0.01 0.01 
Akt, S6 
kinase 
AZD1480 2.7 ± 2.4 -1.6 ± 4.4 -2.1 ± 6.4 0.11 0.14 JAK 
LY2784544 25.5 ± 6.5 48.9 ± 5.2 57.3 ± 2.4 0.00 0.00 JAK 
Enzastaurin -18.6 ± 9.3 -22.4 ± 5.1 -28.9 ± 15.8 0.28 0.19 PKC 
SB 431542 33.1 ± 2.3 53.5 ± 3.1 54.6 ± 2.5 0.00 0.00 ALK 
ABT-869(Linifanib) 11.8 ± 2.4 16.7 ± 5.8 14.7 ± 2.2 0.12 0.10 
RTK, 
VEGFR, 
PDGFR 
AEE788 24.2 ± 1.9 34.5 ± 3.7 26.8 ± 1.7 0.01 0.07 
EGFR, 
HER2, 
VEGFR 
BIBW2992(Tovok) 27.3 ± 6.1 22.3 ± 6.6 21.1 ± 8.6 0.20 0.18 
EGFR, 
HER2 
Lapatinib 17.2 ± 1.9 14.8 ± 6.1 10.4 ± 5.1 0.28 0.05 EGFR, 
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Ditosylate HER2 
JNJ-7706621 1.7 ± 5.7 27.5 ± 4.9 33.4 ± 4.8 0.00 0.00 
Aurora, 
CDK 
BEZ235 81.7 ± 0.5 77.4 ± 2.3 75.1 ± 0.7 0.02 0.00 
PI3K, 
mTOR 
GSK1059615 85.8 ± 0.8 85.1 ± 0.2 84.0 ± 2.6 0.10 0.15 
PI3K, 
mTOR 
PI-103 74.0 ± 3.1 83.8 ± 1.1 82.6 ± 1.9 0.00 0.01 
PI3K, 
mTOR 
AG-490 4.3 ± 2.3 3.5 ± 6.7 11.9 ± 7.1 0.43 0.08 EGFR, JAK 
CP-690550 
(Tofacitinib) 
-3.2 ± 6.3 1.8 ± 3.3 1.3 ± 1.7 0.15 0.15 JAK 
Crenolanib (CP-
868569) 
-16.3 ± 7.1 9.4 ± 10.2 10.4 ± 4.2 0.01 0.00 PDGFR 
GSK1838705A 26.6 ± 1.6 11.0 ± 3.1 19.3 ± 2.3 0.00 0.01 IGF-1R 
KX2-391 54.3 ± 2.2 90.8 ± 0.9 85.1 ± 3.8 0.00 0.00 SFKS 
NVP-BSK805 0.9 ± 1.3 5.0 ± 5.6 0.0 ± 6.6 0.14 0.42 JAK 
PCI-32765 17.6 ± 3.9 21.1 ± 7.0 15.5 ± 11.0 0.24 0.38 SFKS 
PF-562271 1.4 ± 4.5 19.0 ± 3.5 14.8 ± 2.5 0.00 0.01 FAK, Pyk2 
DCC-2036 -6.9 ± 4.0 13.7 ± 5.3 20.9 ± 1.8 0.00 0.00 
SFKs, bcr-
Abl 
LDN193189 -1.0 ± 11.1 -2.6 ± 6.9 -7.9 ± 14.0 0.42 0.27 BMP 
AZD8931 18.8 ± 2.9 0.0 ± 22.5 7.9 ± 4.1 0.11 0.01 
EGFR, 
HER2 
Raf265 derivative -11.0 ± 5.5 -21.7 ± 6.7 -1.9 ± 9.0 0.05 0.11 Syk 
NVP-BHG712 -6.5 ± 3.0 -16.9 ± 24.8 1.7 ± 2.8 0.25 0.01 
VEGFR, 
SFKS, c-Abl 
OSI-420 3.0 ± 0.4 -8.7 ± 24.2 1.3 ± 5.1 0.28 0.35 EGFR 
R935788 
(Fostamatinib) 
-7.1 ± 3.9 -6.4 ± 10.3 6.7 ± 3.6 0.46 0.01 Syk 
AZ 960 56.4 ± 6.9 72.2 ± 1.2 76.7 ± 2.2 0.01 0.00 
JAK, 
Aurora 
Mubritinib (TAK 
165) 
47.5 ± 2.7 45.0 ± 2.9 54.9 ± 0.3 0.17 0.00 EGFR, CDK 
PP242 64.7 ± 5.2 68.2 ± 4.3 68.4 ± 2.5 0.21 0.16 mTOR 
Cyt387 -13.0 ± 3.2 -4.3 ± 7.0 -2.7 ± 5.6 0.06 0.03 JAK 
Apatinib -18.6 ± 4.4 -4.5 ± 6.2 -2.6 ± 4.3 0.02 0.01 EGFR 
CAL-101 -9.7 ± 7.0 -20.4 ± 7.1 -19.4 ± 7.6 0.07 0.09 PI3K 
PIK-294 -9.7 ± 10.4 -13.7 ± 17.5 -1.0 ± 6.4 0.38 0.14 PI3K 
VX-765 2.5 ± 0.6 -6.2 ± 17.6 3.3 ± 4.5 0.22 0.39 Caspase 
Telatinib  
(BAY 57-9352) 
4.4 ± 4.0 -1.5 ± 19.7 10.2 ± 1.4 0.32 0.04 
VEGFR,PD
GFR, c-Kit 
BI6727 (Volasertib) 69.7 ± 1.8 84.0 ± 1.5 77.8 ± 2.4 0.00 0.00 PLK 
APPENDIX VI 
 
114   
 
WP1130 12.6 ± 5.3 4.5 ± 8.5 19.3 ± 5.7 0.11 0.11 DUB 
BKM120  
(NVP-BKM120) 
53.3 ± 10.2 38.7 ± 1.1 48.2 ± 1.0 0.03 0.22 PI3K 
CX-4945 8.2 ± 2.1 27.9 ± 4.1 21.8 ± 1.7 0.00 0.00 CK2 
Phenformin hydro-
chloride 
3.7 ± 7.9 2.4 ± 1.8 8.5 ± 2.3 0.40 0.19 NULL 
TAK-733 9.9 ± 8.0 10.0 ± 7.2 3.7 ± 3.4 0.50 0.14 MEK 
AZD5438 -6.6 ± 0.9 25.6 ± 12.3 33.6 ± 4.2 0.01 0.00 CDK 
PP-121 70.9 ± 2.1 78.1 ± 1.1 75.5 ± 0.8 0.00 0.01 
DNA-PK, 
mTOR, 
PDGF 
OSI-027 74.7 ± 0.4 70.0 ± 6.1 73.1 ± 0.8 0.12 0.01 mTOR 
LY2603618 (IC-83) 5.2 ± 0.9 -0.1 ± 12.1 11.4 ± 4.6 0.25 0.04 CHK 
PKI-587 94.9 ± 0.3 91.1 ± 0.5 86.3 ± 1.1 0.00 0.00 
mTOR, 
PI3K 
CCT128930 37.4 ± 3.4 15.3 ± 7.7 14.9 ± 5.1 0.01 0.00 Akt 
A66 54.7 ± 3.3 40.1 ± 3.5 47.6 ± 2.0 0.00 0.02 PI3K 
NU7441 7.9 ± 4.2 7.3 ± 4.2 6.9 ± 4.0 0.43 0.39 
ATM, DNA-
PK, mTOR 
GSK2126458 88.7 ± 0.1 80.9 ± 0.4 78.4 ± 0.8 0.00 0.00 PI3K 
WYE-125132 84.2 ± 1.9 81.0 ± 0.2 77.3 ± 0.9 0.02 0.00 mTOR 
WYE-687 75.8 ± 0.9 72.0 ± 1.8 68.8 ± 1.2 0.02 0.00 mTOR 
A-674563 45.5 ± 2.8 40.7 ± 0.7 54.7 ± 2.5 0.02 0.01 Akt 
AS-252424 -11.2 ± 2.7 -6.5 ± 4.4 -9.3 ± 4.3 0.09 0.27 PI3K 
GSK1120212 (JTP-
74057) 
6.7 ± 8.5 3.3 ± 2.6 1.3 ± 3.4 0.27 0.18 MEK 
Flavopiridol 
hydrochloride 
86.5 ± 0.8 83.8 ± 1.0 85.8 ± 1.0 0.01 0.20 CDK 
AS-604850 1.8 ± 1.4 9.2 ± 2.1 4.8 ± 2.7 0.00 0.08 PI3K 
WAY-600 54.3 ± 0.8 56.2 ± 5.6 54.6 ± 2.0 0.30 0.41 mTOR 
TG101209 27.3 ± 3.6 29.3 ± 1.3 30.3 ± 2.3 0.21 0.15 FLT-3, JAK 
GDC-0980 
(RG7422) 
89.1 ± 0.7 86.2 ± 0.6 84.4 ± 0.9 0.00 0.00 
mTOR, 
PI3K 
A-769662 5.1 ± 3.5 1.7 ± 6.6 0.7 ± 5.9 0.24 0.17 AMPK 
TAK-901 56.5 ± 2.0 72.5 ± 1.4 75.3 ± 0.7 0.00 0.00 Aurora 
AMG900 25.3 ± 3.0 55.8 ± 4.5 55.5 ± 0.6 0.00 0.00 Aurora 
ZM336372 -2.8 ± 1.5 -2.7 ± 4.1 -0.6 ± 2.2 0.48 0.11 B-Raf 
PH-797804 4.0 ± 4.1 7.4 ± 3.4 6.0 ± 6.1 0.17 0.33 p38 MAPK 
PF-04691502 89.5 ± 0.8 86.7 ± 1.8 85.8 ± 0.5 0.03 0.00 
mTOR, 
PI3K 
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Appendix VII  Data from Kinase Inhibitor Screen with Tamoxifen Resistant Cell Lines 
Results from the Kinase Inhibitor Screen with the Tamoxifen Resistant T47D Cell Lines. Triplicate samples of 
parental T47D/S2 and tamoxifen resistant TR-1 and TR-2 cells were treated with 1.0 µM of the indicated kinase 
inhibitors for 5 days. Cell number was determined by a cell viability assay. Inhibitory effect  standard deviation 
(SD) and targets of the kinase inhibitors are shown. 
 Inhibitory Effect ± SD (%) p-value  
 
Inhibitor 
T47D/S2 TR-1 TR-2 
TR-1 
vs. 
T47D/
S2 
TR-2 
vs. 
T47D
/S2 
 
Target(s) 
BMS-599626 45.1 ± 6.9 19.8 ± 12.0 12.7 ± 2.3 0.32 0.01 
EGFR,   
HER2 
Erlotinib 
Hydrochloride 
17.0 ± 7.4 12.0 ± 29.8 -6.5 ± 4.6 0.15 0.39 EGFR 
Gefitinib (Iressa) 18.7 ± 6.3 11.8 ± 29.6 -3.0 ± 4.3 0.18 0.03 EGFR, Akt 
Neratinib 36.9 ± 7.2 26.0 ± 5.8 25.0 ± 11.1 0.01 0.15 HER2 
PD153035 
hydrochloride 
8.8 ± 3.9 0.8 ± 17.1 -10.8 ± 9.0 0.23 0.04 EGFR 
Pelitinib 37.0 ± 1.3 33.7 ± 12.3 29.2 ± 11.2 0.02 0.00 EGFR 
Vandetanib 16.8 ± 1.9 2.4 ± 20.5 -1.5 ± 5.6 0.33 0.08 
VEGFR, 
EGFR, SFKs 
WZ3146 19.5 ± 1.8 3.8 ± 3.8 2.3 ± 21.3 0.24 0.00 EGFR 
WZ4002 6.5 ± 3.0 -8.2 ± 17.5 -14.3 ± 11.0 0.05 0.38 EGFR 
WZ8040 -9.6 ± 4.4 12.2 ± 60.2 -16.4 ± 12.7 0.27 0.01 EGFR 
AV-951 
(Tivozanib) 
4.0 ± 5.4 -1.0 ± 6.4 -6.3 ± 5.0 0.15 0.08 
VEGFR, 
PDGFR 
Axitinib 19.4 ± 8.0 10.7 ± 4.5 10.4 ± 1.4 0.07 0.02 VEGFR 
BIBF1120 
(Nintedanib) 
17.1 ± 1.2 18.8 ± 1.7 17.7 ± 7.4 0.00 0.00 
SFKs,FGFR, 
VEGFR, 
PDGFR 
BMS 794833 19.5 ± 6.2 9.3 ± 3.8 7.9 ± 3.9 0.26 0.33 
VEGFR, c-
Met, Flt 
Cediranib 
(AZD2171) 
20.3 ± 1.2 3.3 ± 1.8 4.9 ± 1.6 0.46 0.30 VEGFR 
CYC116 33.7 ± 5.8 21.7 ± 3.0 16.8 ± 4.8 0.00 0.00 
Aurora, 
VEGFR 
Imatinib(STI571) 12.2 ± 3.2 1.5 ± 3.1 -0.3 ± 5.6 0.41 0.38 
VEGFR, 
PDGFR 
Imatinib Mesylate 2.1 ± 6.5 -6.8 ± 5.0 -6.3 ± 5.0 0.05 0.01 
c-Kit, 
PDGFR 
Ki8751 7.4 ± 2.8 2.3 ± 16.1 -1.2 ± 9.7 0.42 0.23 
c-Kit, 
VEGFR, 
PDGFR 
KRN 633 28.7 ± 25. 4.3 ± 11.7 -2.0 ± 6.2 0.21 0.45 VEGFR 
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5 
Masitinib 
(AB1010) 
34.2 ± 7.4 16.0 ± 2.6 9.9 ± 7.3 0.45 0.11 
c-Kit, 
PDGFR, 
FGFR 
MGCD-265 40.7 ± 3.5 22.9 ± 4.6 24.3 ± 4.2 0.08 0.13 
c-Met, 
VEGFR, 
Tie-2 
Motesanib 
Diphosphate 
16.3 ± 3.7 7.5 ± 3.5 9.5 ± 1.7 0.07 0.35 
VEGFR, 
PDGFR, 
SFKs 
MP-470 43.6 ± 4.1 31.4 ± 1.0 32.9 ± 2.1 0.21 0.08 
c-Kit, 
PDGFR, c-
Met 
OSI-930 28.0 ± 1.9 33.6 ± 13.0 24.3 ± 6.6 0.09 0.02 
c-Kit, 
VEGFR 
Pazopanib 
Hydrochloride 
26.8 ± 6.4 15.2 ± 0.8 14.0 ± 4.3 0.28 0.01 VEGFR 
Sorafenib Tosylate 66.1 ± 
23.
9 
57.8 ± 15.1 46.1 ± 23.5 0.26 0.05 
VEGFR, 
PDGFR, 
RAF 
Sunitinib Malate 6.7 ± 5.1 -1.8 ± 6.0 -3.2 ± 1.0 0.25 0.48 
FLT3, 
PDGFR, 
VEGFR, 
TSU-68 -7.7 ± 8.5 -10.9 ± 9.9 -9.7 ± 5.0 0.27 0.03 
VEGFR, 
PDGFR, 
FGFR 
Vatalanib 11.5 ± 
24.
6 
-7.1 ± 8.2 0.7 ± 4.5 0.03 0.05 
VEGFR,   c-
Kit, VEGFR 
XL880 
(GSK1363089) 
40.7 ± 3.4 31.8 ± 1.7 25.5 ± 6.9 0.00 0.00 
c-Met, 
VEGFR 
PHA-739358 
(Danusertib) 
34.1 ± 2.5 44.3 ± 2.3 43.3 ± 4.7 0.00 0.00 
Aurora, 
Bcr-Abl 
AT9283 29.3 ± 
22.
0 
45.3 ± 1.6 40.2 ± 6.6 0.00 0.00 
Aurora, 
JAK,     Bcr-
Abl 
AZD0530 
(Saracatinib) 
37.4 ± 2.8 31.2 ± 1.4 29.9 ± 2.8 0.00 0.00 SFKs, Abl 
Bosutinib 
(SKI-606) 
33.2 ± 1.2 17.3 ± 3.7 14.8 ± 1.6 0.02 0.24 SFKs 
Dasatinib 23.3 ± 0.9 49.6 ± 1.7 51.5 ± 2.8 0.00 0.00 
SFKs, Abl, 
c-kit 
Nilotinib 36.1 ± 2.5 26.0 ± 4.0 23.0 ± 5.7 0.01 0.07 Bcr-Abl 
Quercetin 
(Sophoretin) 
4.0 ± 4.4 9.9 ± 19.0 3.0 ± 3.3 0.02 0.06 PI3K, PKC 
NVP-ADW742 40.6 ± 1.3 7.3 ± 4.4 9.6 ± 1.4 0.05 0.05 IGF-1R 
AC-220 85.2 ± 2.2 77.4 ± 3.4 77.8 ± 3.1 0.48 0.13 FLT-3 
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AP24534 41.3 ± 2.1 34.8 ± 5.0 19.3 ± 8.5 0.37 0.07 
VEGFR, 
FGFR, 
PDGFR 
Tandutinib 
(MLN518) 
12.9 ± 4.9 5.3 ± 1.8 5.1 ± 3.6 0.27 0.39 
FLT-3, 
PDGFR, KIT 
KW 2449 17.5 ± 6.7 9.7 ± 1.9 -0.7 ± 10.6 0.06 0.00 
FLT-3, ABL, 
Aurora 
CI-1033 
(Canertinib) 
50.3 ± 0.5 31.8 ± 1.1 29.7 ± 6.6 0.21 0.00 
HER2, 
EGFR 
CP-724714 34.2 ± 5.3 18.8 ± 2.6 19.5 ± 4.3 0.02 0.00 HER2 
BAY 73-4506 
(Regorafenib) 
38.3 ± 2.4 25.3 ± 2.5 26.2 ± 3.7 0.01 0.04 
c-KIT, 
VEGFR,  
B-Raf 
JNJ-38877605 14.5 ± 7.2 5.3 ± 1.2 7.7 ± 2.4 0.18 0.18 c-Met 
PF-04217903 18.6 ± 4.9 4.8 ± 2.8 6.7 ± 4.6 0.00 0.02 c-Met 
PF-2341066 23.0 ± 3.3 7.1 ± 1.7 12.5 ± 7.9 0.29 0.40 c-Met, ALK 
SGX-523 -4.4 ± 3.8 -13.7 ± 1.9 -7.7 ± 6.6 0.07 0.03 c-Met 
SU11274 
(PKI-SU11274) 
15.7 ± 4.3 11.0 ± 5.5 6.9 ± 4.2 0.35 0.42 c-Met 
NVP-TAE684 50.3 ± 1.8 34.7 ± 0.2 30.6 ± 2.4 0.05 0.19 ALK 
SB 525334 23.8 ± 3.8 7.4 ± 1.1 3.0 ± 5.0 0.25 0.08 ALK, TGF-β 
R406 40.6 ± 1.3 29.8 ± 5.2 27.0 ± 5.1 0.13 0.44 Syk 
R406 (free base) 35.4 ± 8.7 24.6 ± 2.2 23.9 ± 4.7 0.10 0.48 Syk 
XL184 30.0 ± 3.1 13.4 ± 0.5 9.9 ± 3.2 0.06 0.08 
c-Met, 
FLT-3, Tie2 
BI 2536 65.8 ± 1.6 63.0 ± 0.0 63.9 ± 0.9 0.00 0.00 PLK 
GSK461364 52.5 ± 3.1 61.7 ± 2.0 64.7 ± 2.9 0.00 0.00 PLK 
HMN-214 52.6 ± 2.3 49.6 ± 0.5 55.5 ± 1.3 0.05 0.01 PLK 
ON-01910 48.6 ± 1.2 53.2 ± 3.5 59.1 ± 1.7 0.00 0.00 PLK 
AT7519 54.0 ± 7.3 24.0 ± 6.3 31.5 ± 16.2 0.12 0.05 CDK 
Flavopiridol 
(Alvocidib) 
78.6 ± 1.8 81.2 ± 1.0 81.6 ± 0.8 0.02 0.38 CDK 
BS-181 
hydrochloride 
25.3 ± 
11.
5 
14.6 ± 4.6 13.0 ± 6.6 0.24 0.07 CDK 
PD0332991 31.6 ± 3.0 23.4 ± 1.9 25.0 ± 4.9 0.02 0.01 CDK 
PHA-793887 31.3 ± 3.0 34.0 ± 4.0 32.8 ± 3.5 0.06 0.10 CDK 
Roscovitine 
(CYC202) 
11.1 ± 0.8 5.3 ± 1.8 6.5 ± 4.9 0.20 0.34 CDK 
SNS-032 
(BMS-387032) 
74.8 ± 0.7 76.3 ± 0.7 74.8 ± 0.6 0.00 0.17 CDK 
AZD7762 37.2 ± 3.2 28.7 ± 1.4 27.5 ± 11.6 0.01 0.01 Chk1/2 
Aurora A  
Inhibitor I 
52.5 ± 4.0 42.6 ± 3.6 37.4 ± 9.0 0.31 0.00 Aurora A 
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AZD1152-HQPA 
(Barasertib) 
21.0 ± 1.1 20.0 ± 1.8 23.0 ± 2.4 0.00 0.00 Aurora B 
CCT129202 33.5 ± 0.8 18.7 ± 0.9 18.3 ± 4.5 0.02 0.01 Aurora 
ENMD-2076 26.6 ± 6.3 11.0 ± 3.0 6.9 ± 7.1 0.01 0.01 
Aurora, 
Flt3/4, 
SFKs, 
VEGFR2 
Hesperadin 28.8 ± 5.2 38.6 ± 5.1 38.9 ± 4.6 0.01 0.02 Aurora 
MLN8237 39.2 ± 
14.
1 
34.9 ± 3.2 30.1 ± 5.9 0.24 0.02 Aurora 
PHA-680632 22.7 ± 3.5 33.7 ± 4.4 31.6 ± 1.0 0.00 0.00 Aurora 
SNS-314 Mesylate 18.4 ± 5.6 32.8 ± 3.3 31.1 ± 4.1 0.00 0.00 Aurora 
VX-680 17.2 ± 9.5 22.7 ± 4.3 22.8 ± 1.9 0.00 0.01 Aurora 
ZM-447439 20.5 ± 2.5 23.7 ± 5.5 21.5 ± 7.7 0.00 0.00 Aurora 
AS703026 30.5 ± 4.1 24.4 ± 7.7 21.2 ± 6.9 0.17 0.10 MEK 
AZD6244 
(Selumetinib) 
16.6 ± 4.6 6.3 ± 2.7 12.2 ± 7.1 0.00 0.00 MEK 
AZD8330 9.2 ± 2.3 1.0 ± 4.0 2.2 ± 8.9 0.04 0.01 MEK 
BIX 02188 -13.4 ± 4.4 -15.0 ± 2.5 -8.3 ± 5.0 0.08 0.05 MEK 
BIX 02189 -29.4 ± 
11.
7 
-19.6 ± 0.4 -11.6 ± 5.0 0.21 0.30 MEK 
BMS 777607 -20.0 ± 2.3 -14.2 ± 0.5 -9.1 ± 5.0 0.12 0.27 c-Met 
CI-1040 
(PD184352) 
19.4 ± 2.9 5.4 ± 3.4 7.3 ± 1.9 0.21 0.13 MEK 
PD318088 7.1 ± 9.4 1.3 ± 1.1 6.7 ± 1.7 0.41 0.14 MEK 
PD0325901 5.3 ± 2.4 -3.0 ± 2.4 1.8 ± 6.6 0.48 0.24 MEK 
PD98059 -20.6 ± 9.2 -16.8 ± 2.9 -5.7 ± 6.8 0.17 0.10 MEK 
U0126-EtOH -2.0 ± 
10.
6 
0.9 ± 3.6 4.6 ± 1.6 0.30 0.06 MEK 
LY2228820 -10.6 ± 7.2 -13.6 ± 8.4 -6.0 ± 4.8 0.40 0.46 p38 MAPK 
BIRB 796 -32.8 ± 
10.
8 
-29.2 ± 4.8 -13.7 ± 5.3 0.04 0.15 p38 MAPK 
SB 202190 -23.2 ± 6.5 -15.8 ± 5.1 -21.0 ± 3.1 0.17 0.30 p38 MAPK 
SB 203580 -60.6 ± 
21.
3 
-35.7 ± 9.1 -24.5 ± 15.3 0.26 0.35 p38 MAPK 
Vinorelbine 
(Navelbine) 
37.1 ± 6.5 41.7 ± 1.1 46.4 ± 1.8 0.00 0.00 p38 MAPK 
VX-702 5.8 ± 5.2 -2.9 ± 3.7 2.7 ± 2.9 0.24 0.26 p38 MAPK 
VX-745 7.7 ± 1.7 3.7 ± 4.3 9.9 ± 3.3 0.34 0.21 p38 MAPK 
GDC-0879 -3.4 ± 3.7 5.1 ± 0.3 10.4 ± 7.0 0.16 0.02 B-Raf 
PLX-4720 -12.6 ± 9.4 0.4 ± 6.2 3.8 ± 1.5 0.20 0.04 B-Raf 
RAF265 50.6 ± 2.8 27.5 ± 4.2 28.6 ± 6.9 0.39 0.34 
RAF, 
VEGFR 
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SP600125 -3.3 ± 2.8 -5.7 ± 4.7 0.6 ± 2.2 0.11 0.07 JNK 
AZD6482 49.7 ± 3.3 39.3 ± 2.2 42.2 ± 9.0 0.19 0.32 PI3K 
AS-605240 58.3 ± 5.3 26.7 ± 3.3 26.9 ± 10.5 0.15 0.01 PI3K 
GDC-0941 68.5 ± 5.1 57.0 ± 2.5 57.3 ± 3.6 0.16 0.12 PI3K 
IC-87114 -7.2 ± 5.5 -0.4 ± 5.7 -2.6 ± 8.0 0.17 0.08 PI3K 
LY294002 22.8 ± 9.0 6.0 ± 1.7 10.3 ± 3.4 0.27 0.16 
PI3K, 
casein 
kinase II 
PIK-293 14.6 ± 
26.
2 
-1.1 ± 7.1 8.5 ± 1.6 0.48 0.41 PI3K 
PIK-90 66.5 ± 1.6 58.5 ± 1.4 54.4 ± 6.4 0.12 0.00 PI3K 
PIK-93 44.5 ± 5.4 35.5 ± 3.2 33.6 ± 7.7 0.27 0.10 PI3K 
TG100-115 0.9 ± 2.2 0.6 ± 0.6 8.7 ± 3.9 0.00 0.03 PI3K 
TGX-221 -3.0 ± 4.0 1.6 ± 3.2 2.6 ± 2.1 0.05 0.06 PI3K 
XL147 12.3 ± 1.6 16.0 ± 4.3 13.4 ± 5.7 0.19 0.29 PI3K 
XL765 2.4 ± 3.8 -1.0 ± 2.9 -1.5 ± 6.1 0.37 0.46 PI3K 
ZSTK474 75.2 ± 2.1 62.0 ± 2.2 60.6 ± 7.1 0.31 0.39 PI3K 
AZD8055 72.5 ± 2.7 63.4 ± 1.8 67.6 ± 2.5 0.10 0.05 mTOR 
Deforolimus(MK-
8669) 
43.6 ± 3.8 19.4 ± 4.2 27.3 ± 2.1 0.00 0.00 mTOR 
Everolimus(RAD00
1) 
49.0 ± 3.0 20.9 ± 5.0 26.5 ± 2.6 0.00 0.00 mTOR 
KU-0063794 77.8 ± 2.7 74.9 ± 0.6 73.8 ± 3.3 0.14 0.02 mTOR 
Rapamycin(Sirolim
us) 
47.2 ± 3.9 22.7 ± 3.4 27.9 ± 2.0 0.00 0.00 mTOR 
Temsirolimus 49.9 ± 5.0 24.3 ± 0.7 26.5 ± 3.8 0.00 0.00 mTOR 
WYE-354 72.4 ± 0.3 64.9 ± 0.9 64.3 ± 3.1 0.00 0.00 mTOR 
PIK-75 
Hydrochloride 
89.6 ± 0.5 96.4 ± 0.5 94.7 ± 0.4 0.01 0.27 PI3K 
CHIR-99021 -24.9 ± 3.2 4.2 ± 5.7 0.8 ± 5.3 0.00 0.03 GSK-3 
Indirubin 11.0 ± 7.8 3.1 ± 0.8 5.8 ± 4.0 0.02 0.02 GSK-3 
SB 216763 -12.1 ± 
39.
6 
-8.3 ± 6.0 -1.0 ± 2.0 0.42 0.42 GSK-3 
KU-55933 14.6 ± 4.6 1.6 ± 1.8 4.4 ± 6.6 0.17 0.02 ATM 
KU-60019 18.1 ± 6.4 9.6 ± 1.3 6.4 ± 5.3 0.13 0.38 ATM 
MK-2206 (AKT inh) 73.3 ± 1.3 57.1 ± 1.7 60.6 ± 4.6 0.23 0.05 Akt 
AT7867 (AKT inh) 9.1 ± 2.2 2.0 ± 2.2 3.8 ± 6.9 0.01 0.01 
Akt,  
S6 kinase 
AZD1480 2.2 ± 3.8 7.7 ± 1.8 4.6 ± 1.6 0.11 0.14 JAK 
LY2784544 41.4 ± 
13.
0 
36.3 ± 1.5 28.8 ± 9.0 0.00 0.00 JAK 
Enzastaurin -14.5 ± 
26.
5 
5.0 ± 2.3 0.7 ± 10.5 0.28 0.19 PKC 
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SB 431542 25.4 ± 7.5 46.6 ± 2.1 39.5 ± 6.5 0.00 0.00 ALK 
ABT-869(Linifanib) 24.3 ± 6.5 20.7 ± 4.0 9.7 ± 9.7 0.12 0.10 
RTK, 
VEGFR, 
PDGFR 
AEE788 28.6 ± 3.2 16.0 ± 2.2 13.7 ± 5.2 0.01 0.07 
EGFR, 
HER2, 
VEGFR 
BIBW2992(Tovok) 34.8 ± 3.6 21.0 ± 5.5 14.7 ± 7.0 0.20 0.18 
EGFR, 
HER2 
Lapatinib 
Ditosylate 
33.4 ± 2.9 16.5 ± 1.2 17.0 ± 2.1 0.28 0.05 
EGFR, 
HER2 
JNJ-7706621 0.6 ± 1.7 20.2 ± 2.1 17.2 ± 2.7 0.00 0.00 
Aurora, 
CDK 
BEZ235 74.0 ± 1.0 65.9 ± 2.2 65.9 ± 2.8 0.02 0.00 
PI3K, 
mTOR 
GSK1059615 83.9 ± 1.6 93.8 ± 0.7 93.4 ± 3.0 0.10 0.15 
PI3K, 
mTOR 
PI-103 78.0 ± 1.5 17.2 ± 3.0 27.2 ± 9.7 0.00 0.01 
PI3K, 
mTOR 
AG-490 5.2 ± 5.3 -2.2 ± 4.2 3.2 ± 4.1 0.43 0.08 EGFR, JAK 
CP-
690550(Tofacitinib
) 
-2.3 ± 7.2 2.8 ± 2.8 10.1 ± 2.1 0.15 0.15 JAK 
Crenolanib (CP-
868569) 
-15.8 ± 5.8 -4.1 ± 1.8 -1.5 ± 4.8 0.01 0.00 PDGFR 
GSK1838705A 26.4 ± 3.4 8.2 ± 3.7 8.0 ± 4.8 0.00 0.01 IGF-1R 
KX2-391 36.5 ± 4.2 43.8 ± 1.0 45.6 ± 1.9 0.00 0.00 SFKS 
NVP-BSK805 0.8 ± 3.0 3.2 ± 1.4 3.7 ± 0.8 0.14 0.42 JAK 
PCI-32765 19.3 ± 4.5 10.7 ± 1.6 9.4 ± 2.8 0.24 0.38 SFKS 
PF-562271 -13.1 ± 4.1 5.7 ± 2.6 10.1 ± 3.2 0.00 0.01 FAK, Pyk2 
DCC-2036 14.4 ± 7.5 38.1 ± 1.1 26.9 ± 14.6 0.00 0.00 
SFKs,  
Bcr-Abl 
LDN193189 -2.6 ± 7.4 -21.9 ± 5.0 -14.2 ± 9.6 0.42 0.27 BMP 
AZD8931 0.3 ± 2.9 -9.6 ± 8.5 -29.0 ± 24.6 0.11 0.01 
EGFR, 
HER2 
Raf265 derivative -1.7 ± 2.8 3.8 ± 5.6 -12.0 ± 2.9 0.05 0.11 Syk 
NVP-BHG712 14.6 ± 6.5 10.5 ± 5.4 -7.6 ± 13.0 0.25 0.01 
VEGFR, 
SFKS, c-Abl 
OSI-420 14.6 ± 5.4 4.0 ± 3.5 -8.5 ± 7.7 0.28 0.35 EGFR 
R935788 
(Fostamatinib) 
18.7 ± 9.8 18.7 ± 4.8 11.1 ± 7.0 0.46 0.01 Syk 
AZ 960 40.4 ± 3.7 51.6 ± 1.7 47.3 ± 3.0 0.01 0.00 
JAK, 
Aurora  
Mubritinib (TAK 
165) 
34.3 ± 1.4 27.9 ± 5.7 28.7 ± 3.2 0.17 0.00 EGFR, CDK 
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PP242 66.6 ± 4.2 62.3 ± 0.4 57.0 ± 4.2 0.21 0.16 mTOR 
Cyt387 -14.9 ± 8.0 -14.0 ± 4.5 -16.9 ± 6.6 0.06 0.03 JAK 
Apatinib -7.5 ± 7.1 4.4 ± 14.4 -4.3 ± 6.2 0.02 0.01 EGFR 
CAL-101 -31.3 ± 
22.
1 
-37.2 ± 11.1 -43.8 ± 7.7 0.07 0.09 PI3K 
PIK-294 -4.6 ± 4.3 -7.2 ± 3.8 -13.4 ± 11.6 0.38 0.14 PI3K 
VX-765 3.6 ± 6.1 5.0 ± 7.2 3.4 ± 0.7 0.22 0.39 Caspase 
Telatinib (BAY 57-
9352) 
17.8 ± 7.0 7.6 ± 6.0 5.7 ± 5.6 0.32 0.04 
VEGFR, 
PDGFR, 
c-Kit 
BI6727 (Volasertib) 67.6 ± 1.8 62.0 ± 1.9 64.3 ± 1.3 0.00 0.00 PLK 
WP1130 25.2 ± 9.1 25.5 ± 8.2 10.8 ± 13.7 0.11 0.11 DUB 
BKM120 (NVP-
BKM120) 
67.8 ± 3.8 50.9 ± 4.5 46.4 ± 11.6 0.03 0.22 PI3K 
CX-4945 29.7 ± 5.3 37.3 ± 2.2 36.1 ± 8.3 0.00 0.00 CK2 
Phenformin 
hydrochloride 
-1.9 ± 5.1 -4.0 ± 1.4 0.8 ± 3.6 0.40 0.19 NULL 
TAK-733 24.6 ± 5.4 12.3 ± 3.2 9.4 ± 3.1 0.50 0.14 MEK 
AZD5438 3.6 ± 4.9 14.5 ± 1.9 10.1 ± 1.4 0.01 0.00 CDK 
PP-121 68.1 ± 4.3 65.1 ± 1.4 62.4 ± 9.4 0.00 0.01 
DNA-PK, 
mTOR, 
PDGF 
OSI-027 73.6 ± 1.5 61.0 ± 0.6 58.5 ± 5.7 0.12 0.01 mTOR 
LY2603618 (IC-83) 16.2 ± 1.8 8.5 ± 7.1 10.8 ± 7.1 0.25 0.04 CHK 
PKI-587 91.1 ± 0.6 98.1 ± 0.1 98.5 ± 0.2 0.00 0.00 
mTOR, 
PI3K 
CCT128930 38.8 ± 3.3 13.3 ± 4.6 16.4 ± 4.1 0.01 0.00 Akt 
A66 54.3 ± 1.4 29.3 ± 5.7 31.8 ± 3.0 0.00 0.02 PI3K 
NU7441 39.8 ± 2.5 23.2 ± 4.0 21.4 ± 6.7 0.43 0.39 
ATM, 
DNA-PK, 
mTOR 
GSK2126458 83.3 ± 1.4 93.6 ± 0.7 94.4 ± 0.4 0.00 0.00 PI3K 
WYE-125132 77.7 ± 0.4 69.7 ± 0.4 70.3 ± 1.0 0.02 0.00 mTOR 
WYE-687 71.2 ± 1.1 57.8 ± 0.3 54.0 ± 3.3 0.02 0.00 mTOR 
A-674563 53.5 ± 4.9 40.6 ± 12.2 32.5 ± 3.0 0.02 0.01 Akt 
AS-252424 -2.0 ± 
14.
2 
-10.0 ± 3.7 -11.4 ± 15.7 0.09 0.27 PI3K 
GSK1120212 (JTP-
74057) 
26.8 ± 2.9 10.3 ± 3.6 4.0 ± 8.2 0.27 0.18 MEK 
Flavopiridol 
hydrochloride 
83.2 ± 1.0 88.4 ± 0.6 87.0 ± 1.3 0.01 0.20 CDK 
AS-604850 8.0 ± 6.6 3.4 ± 0.5 3.1 ± 2.4 0.00 0.08 PI3K 
WAY-600 61.5 ± 3.6 51.3 ± 4.9 42.4 ± 7.7 0.30 0.41 mTOR 
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TG101209 38.3 ± 0.8 32.2 ± 1.6 31.9 ± 1.4 0.21 0.15 FLT-3, JAK 
GDC-0980 
(RG7422) 
85.2 ± 0.4 87.9 ± 1.3 85.4 ± 6.2 0.00 0.00 
mTOR, 
PI3K 
A-769662 17.7 ± 5.1 4.5 ± 3.0 5.3 ± 3.4 0.24 0.17 AMPK 
TAK-901 55.4 ± 4.3 66.1 ± 0.8 62.6 ± 3.3 0.00 0.00 Aurora 
AMG900 24.5 ± 2.5 30.8 ± 1.5 27.9 ± 1.8 0.00 0.00 Aurora 
ZM336372 -1.4 ± 0.3 -8.7 ± 3.9 -5.4 ± 9.2 0.48 0.11 B-Raf 
PH-797804 12.4 ± 2.6 17.0 ± 17.1 1.3 ± 10.4 0.17 0.33 p38 MAPK 
PF-04691502 86.0 ± 1.0 89.1 ± 3.0 88.9 ± 0.8 0.03 0.00 
mTOR, 
PI3K 
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Appendix VIII  Validation of Dasatinib and Protein Expression of c-Src 
 
Growth Effect of Treatment with the SFK Inhibitor Dasatinib and Expression of c-Src Detected by Western Analysis. 
A. Dose-response growth experiment with dasatinib. Cells were seeded in 96-well plates. Experimental medium 
containing vehicle (0.1 % DMSO) or dasatinib in the indicated concentrations were added on day 2 and renewed on day 
5. Cell number was determined by a crystal violet colometric assay on day 7. Mean cell numbers in percentage of vehicle 
treated control  SD are shown. The experiment was performed with 6 sample replicates and asterisks (*) indicate 
statistically significant difference from the parental cell line at the investigated concentration (p<0.05). A. T47D, 182R-1 
and 182R-2 B. T47D/S2, TR-1 and TR-2. C. Western blots showing total and phosphorylated (p) form of c-Src (Tyr416) in 
lysates from T47D/S2, TR-1 and TR-2 grown in standard growth medium. Cells were seeded in 6-well plates and medium 
was renewed on day 2 and day 5. Cells were harvested for western analysis on day 6. 20 µg total protein were loaded in 
each lane and heat shock protein 70 (Hsp70) was used as loading control. Antigens: pTyr416-c-Src (Cell Signaling 
Tecknology, # 2101, 1:1000), c-Src (Cell Signaling Tecknology, # 2109, 1:1000) and Hsp (Neomarkers, #MS-482-PO, 
1:500,000). 
